PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
Edited by
Edward C. L...
123 downloads
1922 Views
2MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
Edited by
Edward C. Lauterbach, M.D.
Washington, DC London, England
Note: The authors have worked to ensure that all information in this book concerning drug dosages, schedules, and routes of administration is accurate as of the time of publication and consistent with standards set by the U.S. Food and Drug Administration and the general medical community. As medical research and practice advance, however, therapeutic standards may change. For this reason and because human and mechanical errors sometimes occur, we recommend that readers follow the advice of a physician who is directly involved in their care or the care of a member of their family. Books published by the American Psychiatric Press, Inc., represent the views and opinions of the individual authors and do not necessarily represent the policies and opinions of the Press or the American Psychiatric Association. Copyright © 2000 American Psychiatric Press, Inc. ALL RIGHTS RESERVED Manufactured in the United States of America on acid-free paper First Edition 03 02 01 00 4 3 2 1 American Psychiatric Press, Inc. 1400 K Street, N.W. Washington, DC 20005 www.appi.org Library of Congress Cataloging-in-Publication Data A CIP record is on file with the Library of Congress. British Library Cataloguing in Publication Data A CIP record is available from the British Library.
Dedicated to the Creator, my parents, and clinicians who take care of patients with neuropsychiatric illnesses
This page intentionally left blank
Contents Contributors
ix
Introduction to the Clinical Practice Series Judith H. Gold, M.D., F.R.C.P.C.
xi
Preface
xiii
1
Psychiatric Management Principles in Neurological Disease Edward C. Lauterbach, M.D.
1
2
Parkinson’s Disease Morgan L. Levy, M.D. Jeffrey L. Cummings, M.D.
41
3
Huntington’s Disease Neal G. Ranen, M.D.
71
4
Wilson’s Disease (Progressive Hepatolenticular Degeneration) Edward C. Lauterbach, M.D.
93
5
Fahr’s Syndrome Edward C. Lauterbach, M.D.
137
6
Dystonia Edward C. Lauterbach, M.D.
179
7
Stroke Robert G. Robinson, M.D.
219
8
Multiple Sclerosis Steven R. Schwid, M.D. Amy Weinstein, Ph.D. Heather A. Wishart, Ph.D. Randolph B. Schiffer, M.D.
249
9
Acquired Immunodeficiency Syndrome Jorge Luis Maldonado, M.D. Francisco Fernandez, M.D. Joel K. Levy, Ph.D.
271
10
Family Management Issues Edward C. Lauterbach, M.D.
297
Index
305
Contributors Jeffrey L. Cummings, M.D. Augustus S. Rose Professor of Neurology; Professor of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, California Francisco Fernandez, M.D. Professor and Chairman, Department of Psychiatry and Behavioral Neurosciences, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois Edward C. Lauterbach, M.D. Chief, Division of Adult and Geriatric Psychiatry; Professor of Psychiatry and Internal Medicine (Neurology), Department of Psychiatry and Behavioral Sciences and the Department of Internal Medicine (Neurology Section), Mercer University School of Medicine, Macon, Georgia Joel K. Levy, Ph.D. Assistant Professor of Neurology and Physical Medicine/Rehabilitation, Departments of Neurology and Physical Medicine/Rehabilitation, Baylor College of Medicine, Houston, Texas Morgan L. Levy, M.D. Assistant Professor of Psychiatry, Department of Psychiatry, Wake Forest University School of Medicine, Winston-Salem, North Carolina Jorge Luis Maldonado, M.D. Staff Psychiatrist, The Kneibert Clinic, Doctor’s Regional Medical Center, Poplar Bluff, Missouri
ix
x
Psychiatric Management in Neurological Disease
Neal G. Ranen, M.D. Medical Director, Health Pathways Geriatric and Neuropsychiatric Assessment Program, Albright Care Services Inc., York, Pennsylvania; and Clinical Associate Professor of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania Robert G. Robinson, M.D. Paul W. Penningroth Professor and Head, Department of Psychiatry, University of Iowa School of Medicine, Iowa City, Iowa Randolph B. Schiffer, M.D. The Vernon and Elizabeth Haggerton Chair in Neurology, and Chair, Department of Neuropsychiatry and Behavioral Sciences, Texas Tech University Health Sciences Center, Lubbock, Texas Steven R. Schwid, M.D. Assistant Professor of Neurology, University of Rochester Medical Center, Rochester, New York Amy Weinstein, Ph.D. Assistant Professor of Neurology and Psychiatry, University of Rochester Medical Center, Rochester, New York Heather A. Wishart, Ph.D. Assistant Professor of Psychiatry, Neuropsychology Program, Dartmouth Medical School, Lebanon, New Hampshire
Introduction
to the Clinical Practice Series
T
he Clinical Practice Series is dedicated to the support of continuing education and enrichment for the practicing clinician. Books in this series address topics of concern and importance to psychiatrists and other mental health clinicians. Each volume provides up-todate literature reviews and emphasizes the most recent treatment approaches to psychiatric illnesses. Theoretical and scientific data are applied to clinical situations, and case illustrations are used extensively to increase the relevance of the material for the practitioner. Each year the series publishes a number of books dealing with all aspects of clinical practice. From time to time some of these publications may be revised and updated. Some books in the series are written by a single clinician widely acknowledged to be an authority on the topic area; other series books are edited volumes in which knowledgeable practitioners contribute chapters in their areas of expertise. Still other series books have their origins in presentations for an American Psychiatric Association Annual Meeting. All contain the newest research and clinical information available on the subjects discussed. The Clinical Practice Series provides enrichment reading in a compact format specially designed to meet the continuing-education needs of the busy mental health clinician. Judith H. Gold, C.M., M.D., F.R.C.P.C., F.R.A.N.Z.C.P. Series Editor
xi
This page intentionally left blank
Preface Edward C. Lauterbach, M.D.
T
he focus of this volume is on managing psychiatric problems in neurological brain disorders. These illnesses are prevalent in clinical psychiatric practices and impose great morbid and economic burdens. Unique treatment complications inherent to these illnesses can challenge clinical skills. Although books on the psychiatry of Alzheimer’s disease and epilepsy exist, there seems to be no single concise work addressing the clinical psychiatric management of other neurological disorders. Therefore, we have synthesized management principles for these other neurological conditions for which suitable clinical information exists. We have selected key representative neurological disorders. These provide clinical principles useful in managing brain diseases of all types. These illnesses, and brain diseases in general, affect limbic connections with the rest of the nervous system. Each illness presents a distinct psychiatric profile requiring a select management approach tailored to the nature of the illness and the level of the nervous system affected. Management principles set forth in Chapter 1 apply to neurological diseases in general. Ensuing chapters detail techniques valuable for treating specific illnesses. These techniques can be further cross-applied to other neurological illnesses not explicitly addressed here. The disorders surveyed in this volume range from basal ganglia diseases (e.g., Parkinson’s, Huntington’s, and Wilson’s diseases) to illnesses affecting white-matter basal ganglia–cortical circuit projections (e.g., acquired immunodeficiency syndrome [AIDS], multiple xiii
xiv
Psychiatric Management in Neurological Disease
sclerosis). Major movement disorders are covered, including idiopathic dystonia. Diseases with characteristic lesion sites as well as diseases with diffuse or multifocal pathology are discussed. Diseases of the substantia nigra (Parkinson’s), striatum (Huntington’s), putamen (Wilson’s), globus pallidus (Fahr’s), subcortical white matter (AIDS, multiple sclerosis, stroke), and cortex (stroke) are detailed. Physiological disorders (e.g., dystonia), systemic illness (e.g., Wilson’s disease, Fahr’s syndrome, secondary dystonias), and immunological diseases (e.g., AIDS, multiple sclerosis) are considered. Thus, the disorders covered in this volume constitute a representative cross-section of conditions affecting the brain at various levels. We have organized the book for ease of use for the practicing clinician. The first chapter considers important clinical features, psychotherapeutic principles, and pharmacological issues that are critical to successful psychiatric treatment of patients with neurological illnesses. Each subsequent chapter begins with a basic overview of the disorder, followed by a profile of psychiatric disorders occurring in the illness, including drug-induced psychiatric disorders. Each chapter ends with a discussion of specific treatment approaches, including neurological and psychiatric management. In particular, specific pharmacological and psychotherapeutic approaches to treatment of the disease are detailed when available, along with caveats unique to these patients. Explicit information is provided on how to contact and refer patients to support groups. Because these illnesses also dramatically affect family members, the book’s final chapter addresses the family. It is our sincere intent that this book will serve as a time-saving reference that will yield significant clinical dividends in quality of care exceeding many times the initial investment of its purchase. We have summarized and integrated the most recent data in an attempt to formulate a user-friendly approach to comprehensive psychiatric management of patients with neurological illness. The editor’s own private practice experience has convinced him of the need for efficient learning: “so many patients, so little time to read.” Managed care compels outpatient treatment of ever more seriously ill patients with multiple physical illnesses. Knowing these diseases and predicting what may go wrong between outpatient visits is therefore of increasing importance. Recognizing this need, we
Preface
xv
seek to provide a wealth of practical information on a diversity of disorders to assist the busy clinician. We also endeavor to provide a more explicit detailing of management principles than is available elsewhere.
This page intentionally left blank
C H A P T E R
1
Psychiatric Management Principles in Neurological Disease Edward C. Lauterbach, M.D.
T
he focus of this book is on psychiatric conditions in key, representative neurological disorders. These disorders impose great disability and cost on both the patient and the nation (Table 1–1). They also impose substantial complexity of care because of unique treatment considerations. General considerations in neurological disease are offered here and specific aspects of particular conditions are reviewed in the chapters that follow. Neurological disorders disrupt basal ganglia–cortical circuits at various levels. The basal ganglia (Figure 1–1), composed of the striatum and the globus pallidus, are functionally and structurally interposed between the limbic system and the cortex. Basal ganglia–cortical circuits are vital to psychiatry, connecting certain limbic structures to the cerebral cortex and other important brain regions. In addition to limbic inputs, important influences on these circuits include major monoamine projections and other connections. Basal ganglia–cortical circuits constitute essential pathways that integrate and mediate mood, cognition, movement, behavior, and other functions critical to psychiatric disorders (Cummings 1993). The disorders considered in this book have variable causations, presentations, pathologies, and treatments. An equally diverse array of psychopathology in these disorders can variably respond to 1
2
Table 1–1.
Annual incidence, prevalence, and annual cost of neurological disorders
Disorder
Prevalence
Annual cost, $
16,000 50,000 1,500 15,000 35,000
80,000 500,000 25,000 100,000 >1,300,000
>1,000,000,000 6,000,000,000 >250,000,000 >250,000,000 >3,000,000,000
500,000 <10,000
3,000,000 <350,000
>30,000,000,000 5,000,000,000
Note. Annual incidence is provided in terms of new U.S. cases per year; prevalence is U.S. cases; annual cost is total cost to the nation. AIDS = acquired immunodeficiency syndrome. Source. 1995 data obtained from the Office of Scientific and Health Reports, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health.
Psychiatric Management in Neurological Disease
Neurological AIDS Parkinson’s disease Huntington’s disease Dystonias Other motor disorders (including Wilson’s disease and Fahr’s syndrome) Stroke/cerebrovascular Multiple sclerosis
Annual incidence
Psychiatric Management Principles in Neurological Disease
3
Striatum Caudate nucleus Putamen
Lenticular nucleus Putamen Globus pallidus External segment Internal segment
Thalamus
Figure 1–1. Horizontal (axial) image depicting basal ganglia structures and thalamus.
conventional psychiatric treatment and, at times, to treatment of the underlying disorder (e.g., Wilson’s disease). This chapter therefore considers specific diagnostic and treatment principles for managing patients with neurological diseases in general. More detailed considerations of these principles are elaborated elsewhere (see Ovsiew 1992 and Sultzer 1994 for reviews of the neuropsychiatric evaluation).
Approach to Neurological Illnesses: Clinical Recognition, Mental Status, and Neurological Exam Basal ganglia–cortical circuits flow from the cerebral cortex to the striatum (caudate and putamen), to the globus pallidus (internal, ex-
4
Psychiatric Management in Neurological Disease
ternal, and ventral segments), and on to the thalamus, which then projects back to the cerebral cortex (Figure 1–2). An alternative route courses through the reticular portion of the substantia nigra instead of the globus pallidus. These circuits are modulated by inputs from the nigra pars compacta and subthalamic nucleus. Five parallel, functionally segregated circuits between the basal ganglia and the cerebral cortex have been identified, each with its own important clinical consequences (Cummings 1993). These circuits project to anterior cingulate, dorsolateral prefrontal, orbitofrontal, sensorimotor, and oculomotor cortical areas.
Frontal Circuit Signs Certain findings can help localize pathology to dorsolateral prefrontal, orbitofrontal, and anterior cingulate frontal lobe circuits (Table 1–2). Findings consistent with dorsolateral prefrontal circuit disease include reduced verbal fluency, psychomotor slowing, dysexecution, perseveration, stimulus-bound behavior, apathy, and impaired abstraction. Dysexecution refers to difficulty in planning, organizing, and sequencing activities that involve complex problem solving. Dysexecution can be detected by excessive perseverative errors and other abnormalities on neuropsychological testing. Stimulus-bound phenomena are manifest in utilization behavior, wherein a patient will pick up an object in the environment and continuously manipulate it until it is taken away. Orbitofrontal circuit involvement can be signaled by emotional lability, behavioral disinhibition (e.g., manic-like behavior), impulsivity, and impaired insight, judgment, and abstraction. Medial frontal circuit involvement can manifest in sparse verbal output, akinesia or paucity of movement, and apathy. Oculomotor circuit involvement is suggested by jerky ocular pursuit (when the patient is asked to follow a moving target) or saccadic intrusions (wherein the patient’s eyes quickly and involuntarily dart away from and then later return to the target). Jerky pursuit occurs in the parkinsonisms and with nigral and cerebellar lesions; saccadic intrusions can be seen in choreic conditions and caudate nucleus lesions, such as in Huntington’s disease. Sensorimotor circuit findings are usually those of a movement disorder or bizarre paresthesia sensations.
Psychiatric Management Principles in Neurological Disease
5
Figure 1–2. Basal ganglia pathways and their physiology in the normal (nondiseased) state and in Parkinson’s disease (PD), Huntington’s disease (HD), primary dystonia (DT), and hemiballismus (HB). GPe = globus pallidus externa; GPi = globus pallidus interna; SNc = substantia nigra pars compacta; SNr = substantia nigra pars reticulata; STN = subthalamic nucleus; STR = striatum (caudate nucleus and putamen); VL = ventrolateral nucleus of the thalamus. Connections ending in arrowheads indicate excitatory connections; connections ending in a bar signify inhibitory connections. For simplicity, excitatory glutamatergic projections from the cortex to the striatum are not depicted. With the exception of dopaminergic projections from the SNc (D2 receptors are inhibitory and D1 receptors are excitatory), all other inhibitory connections are GABAergic and all other excitatory connections are glutamatergic. In PD, thalamic stimulation of the cortex is reduced due to excessive GPi activity, presumably leading to hypokinesia. In HD, this physiology is reversed, presumably leading to hyperkinetic chorea. In DT, a hyperkinetic physiological state results, distinguished by excessive directpathway (STR-GPi connection) activity predominating over increases in indirect-pathway (STR-GPe) and STN activity. This may, however, be true only for certain DTs. In HB, the extreme movements are consistent with a hyperkinetic physiological state induced by the loss of GPi stimulation by the STN. Source. Adapted from Vitek et al. 1999.
6
Table 1–2.
Psychiatric Management in Neurological Disease
Frontal lobe syndromes
Dorsolateral
Orbitofrontal
Reduced verbal fluency
Medial Sparse verbal output
Psychomotor slowing
Lability
Dysexecution (planning, organizing, sequencing)
Disinhibition
Akinesia
Perseveration Stimulus-bound phenomena (utilization behavior) Apathy
Impulsivity
Impaired abstraction
Impaired judgment, insight, and abstraction
Apathy (occasional)
Signs Localizing to Certain Brain Structures Certain clinical findings sometimes assist in localizing brain pathology. Localization can help in understanding the nature of the illness, predicting disabilities, and planning treatment. Frontal release signs suggest frontal lobe disease and include primitive reflexes (glabellar tap [Meyerson’s sign], grasp, suck, root, palmomental). Decreased verbal fluency and utilization behavior also suggest frontal lobe disease (see “Frontal Circuit Signs” subsection above). Depression is associated with frontal lesions, especially of the left frontal lobe. Mania is often observed in lesions of the right temporal cortex and orbitofrontal regions as well as of the caudate, thalamus, subthalamic nucleus, and cerebellum (see Chapter 7 in this volume). Left cerebellar disturbances can affect caudate and thalamic connections with the right temporal and orbitofrontal cortex (Lauterbach 1996). Obsessions or compulsions may point to frontal lobe disturbance or striatal disease. Right parietal lesions are associated with constructional apraxia (difficulty drawing a complex two- or three-dimensional figure) and neglect (sometimes manifest in a patient’s dressing only the right half of his or her body, or drawing only the right half of a figure). Apraxia can reflect left frontal, left parietal, or callosal lesions. Other neurobehavioral signs that can assist in localizing brain lesions are listed in Table 1–3.
Psychiatric Management Principles in Neurological Disease
Table 1–3.
7
Behavioral findings potentially helpful in localizing neuropathology
Left frontal lobe Broca’s expressive aphasia (can usually comprehend spoken or written language but cannot speak, name, or repeat fluently) Transcortical motor aphasia (like Broca’s, but can repeat fluently) Apraxia (inability to perform complex movements despite intact motor system) Right frontal lobe Reduced social awareness Left temporal lobe Wernicke’s receptive aphasia (comprehension difficulty on reading and listening, repeating, and naming) Verbal amnesia Change in personality Right temporal lobe Amusia (reduced ability to appreciate content of music) Aprosodia (reduced ability to modulate or appreciate the emotional content of speech) Prosopagnosia (reduced ability to recognize familiar faces) Visual amnesia Change in personality Left parietal lobe Angular gyrus syndrome—includes anomia (deficit in naming), alexia with agraphia (deficits in reading and writing), or Gerstmann syndrome—includes apraxia, right–left confusion, finger agnosia (inability to discriminate between fingers), and dyscalculia (difficulty calculating) Right parietal lobe Neglect (inattention to the left hemispace, including left visual field) Constructional apraxia Spatial disorientation and agnosia Left occipital lobe Alexia without agraphia Color agnosia Right occipital lobe Cortical blindness with denial (Anton’s syndrome) (continued)
8
Psychiatric Management in Neurological Disease
Table 1–3.
Behavioral findings potentially helpful in localizing neuropathology (continued)
Right occipital lobe (continued) Topographic spatial disorientation Corpus callosum Apraxia of the left hand Anomia for objects in the left hand Alien hand syndrome (unconsciously motivated wandering hand) Source.
Adapted from Mendez 1996.
Cortical and Subcortical Signs It is possible to distinguish between cortical and subcortical disruptions of basal ganglia–cortical circuits (Table 1–4). Certain features can assist in determining whether cortical or subcortical pathology is present. This distinction is best seen in the comparison between cortical and subcortical dementias. Patients with cortical dementias generally exhibit an inability to learn new material, variably accompanied by aphasia, upper motor neuron signs (see below), and normal psychomotor speed and complex attention (e.g., normal execution of a three-stage command). Dysexecution may or may not be present. Patients with subcortical dementias generally manifest an inability to retrieve learned information (retrieval deficits) but may be capable of learning new information that can be retrieved with memory cues, in contrast to cortical dementia. Speech may be dysarthric, but aphasia is usually absent. Other contrasts with cortical dementia include the presence of extrapyramidal movement disorders, psychomotor slowing, abnormal complex attention, and dysexecution. As with cortical disease, the specific findings in subcortical disease depend on the location of the lesion. Movement disorders are recognized by their form and suggest subcortical pathology. They are often best seen by casually observing the patient without the patient’s awareness, such as in the waiting room and on walking from the waiting room to the office. The finding of a movement disorder with minimal other neurological findings can suggest a basal ganglia disease (e.g., Wilson’s disease, Huntington’s disease, Fahr’s syndrome), whereas diverse, distributed
Psychiatric Management Principles in Neurological Disease
Table 1–4.
9
Cortical versus subcortical dementias
Function Psychomotor speed Complex attention (3-stage command) Executive function Memory
Cortical Normal Normal
Frontal–Subcortical Slow Abnormal
Normal or abnormal Amnesic
Speech
Aphasic
Motor disorder
Pyramidal
Abnormal Retrieval errors (can be cued) Dysarthric (aphasia rarely) Extrapyramidal
neurological findings on exam can suggest a multifocal disease (e.g., multiple sclerosis, acquired immunodeficiency syndrome [AIDS], stroke). Upper motor neuron signs and sensory deficits can result from cortical, subcortical, or noncortical lesions. Upper motor neuron signs—including hemiparesis, hemiplegia, hyperreflexia, spasticity, rigidity, clonus, and Babinski sign (upgoing toe when the plantar surface of the foot is stroked)—point to the motor system (Table 1–5). Sensory deficits point to the sensory system.
Movement Disorders as Localizing Signs The form of the movement disorder can sometimes reveal the location of the pathology (see Table 1–5). Hyperkinetic disorders— wherein the patient exhibits excessive, unwanted, involuntary movements—occur with lesions of the caudate (chorea), putamen (dystonia), subthalamic nucleus (ballismus, chorea), thalamus (chorea, dystonia, ballismus, myoclonus), and cerebellum (myoclonus, tremor). Hypokinetic disorders (the parkinsonisms) usually suggest lesions of the substantia nigra or the globus pallidus. This is not to say that other disorders cannot occur with these lesions, or that such disorders always occur with lesions in these areas. Distinguishing features of parkinsonism, chorea, and dystonia are discussed in the chapters on Parkinson’s disease, Huntington’s disease, and idiopathic dystonia (Chapters 2, 3, and 6, respectively). Ballismus is a ballistic movement that is often of extreme amplitude,
10
Table 1–5.
Psychiatric Management in Neurological Disease
Localizing neurological signs and symptoms
Sign Upper motor neuron signs Sensory deficit Parkinsonism Chorea Dystonia Ballismus Striatal toe, striatal dishing Cerebellar signs, intention tremor Rubral tremor Alien hand syndrome Pathological affect
Potential localizations Motor cortex, internal capsule, pons, pyramidal tracts, corticospinal tracts Parietal cortex, thalamus, brain stem, spinothalamic tracts, dorsal columns Substantia nigra, globus pallidus Caudate, subthalamic nucleus, thalamus Putamen, thalamus, globus pallidus Subthalamic nucleus, thalamus Striatum Cerebellum, cerebellar outflow tracts Red nucleus Thalamus, corpus callosum Corticobulbar tracts, basal ganglia, thalamus, brain stem
especially when affecting the proximal joints such as the shoulder. It is quite striking in severity, usually involving one or both limbs on one side of the body after a subthalamic vascular lesion. Other signs of basal ganglia dysfunction include striatal dishing (hyperextension of the metacarpophalangeal joints) and striatal toe (the great toe spontaneously extends).
Cerebellar Signs The cerebellum influences basal ganglia–cortical circuit physiology (Figure 1–3) and can also be affected in certain basal ganglia diseases (e.g., Wilson’s disease, Fahr’s syndrome). Cerebellar features evident on the neurological exam include cerebellar rebound, ataxia, dysmetria, dysdiadochokinesia, cerebellar speech, and terminal kinetic tremor. Rebound in an upper extremity can be tested for by asking the patient to flex the biceps muscle while the examiner pulls down on the forearm and then suddenly lets go. Patients with cerebellar disease may be unable to quickly adjust their muscle tone to stop flexing and may strike themselves in the face. Therefore, the examiner must
Psychiatric Management Principles in Neurological Disease
11
Figure 1–3. Cerebellar connections. The direction of projection is symbolized from neuronal soma to axonal bouton (e.g., from cerebellum to septum). Amyg = amygdala, CB = cerebellum, DPFC = dorsal prefrontal cortex, Forn = fornix, GP = globus pallidus, HC = hippocampus, LC = locus coeruleus, NA = nucleus accumbens, OBFC = orbitofrontal cortex, PPN = pedunculopontine nucleus, Sept = septum, SN = substantia nigra, Thal = thalamus, TL = temporal lobe, VTA = ventral tegmental area.
interpose his or her other arm between the patient’s forearm and face to protect against this result. Ataxia is seen in side-to-side wandering deviations from the correct path of the limb on finger-to-nose (FTN) testing, heel-to-shin (HTS) exam, or tandem gait (“drunk driving test”). Dysmetria is evident on FTN or HTS tests by stopping before (“undershooting”) or after (“overshooting”) the target. Some patients mask dysmetria by performing the FTN test with excessive slowness, but dysmetria becomes apparent when the patient is required to perform the test more rapidly. Dysdiadochokinesia is elicited by having the patient perform rapid alternating movements, such as repetitive alternating tapping of the dorsal, then ventral hand against the thigh simultaneously with both hands. Dysdiadocho-
12
Psychiatric Management in Neurological Disease
kinesia is manifest in a dyscoordinated, dysrhythmic performance, either unilaterally or bilaterally. Cerebellar speech involves inability to properly control the rate and volume of speech. Thus, speech rate, volume, and tone fluctuate during the course of a sentence, conveying the impression that the patient is intoxicated when, in fact, he or she is not.
Tremors Cerebellar terminal kinetic tremor (i.e., tremor at the end of movement) becomes apparent as the patient approaches the target (e.g., on FTN exam). This type of tremor has also been called “intention tremor” and is distinguishable from action-postural tremor (consistently present throughout the range of movement) and resting tremor (evident at rest and attenuating with movement). Rubral tremor combines elements of all of these other tremors and suggests disease involving the red nucleus in the midbrain.
Psychogenic Findings Despite the tendency to misdiagnose movement disorders as psychogenic (see Chapter 6 in this volume), certain clinical findings can signal the presence of psychogenic movement disorders. In one study of 131 patients with such disorders (Williams et al. 1995), clinical tip-offs to a psychogenic origin included abrupt onset after inciting events; multiple coexisting forms of movement disorders; variable and inconsistent motor manifestations fluctuating during the exam; motor signs incongruous with organic origin; increases in movement severity or complexity on examination of the affected body part; diminished movement severity with distraction or when not under direct scrutiny; excessive startle; incongruous or false neurological signs; response to placebo, suggestion, or psychotherapy; and presence of associated psychiatric symptoms. Of course, none of these findings can be considered pathognomonic (see Chapter 6 in this volume for further diagnostic tip-offs and caveats). Moreover, organic movement disorders are also associated with psychiatric disorders. In addition to the clinical tip-offs listed above, the form of the movement disorder can serve to raise the clinician’s index of suspicion. Some movement disorders are more common than others. In
Psychiatric Management Principles in Neurological Disease
13
the study of Williams et al. (1995), psychogenic dystonia was the most common psychogenic movement disorder, occurring in 82 (62.6%) of 131 patients with psychogenic movement disorders. The next most common psychogenic movement disorder was tremor (in 21 patients [16%]), followed by gait disorder (14 patients [10.7%]), undifferentiated dyskinesias (14 patients [10.7%]), myoclonus (11 patients [8.4%]), parkinsonism (3 patients [2.3%]), tics (2 patients [1.5%]), and stiff man syndrome (1 patient [0.8%]). Some patients had more than one condition. Obviously, the underlying psychopathology must be addressed in order to successfully treat psychogenic conditions. Certain psychiatric disorders have been observed more frequently than others. Among 24 patients with psychogenic movement disorders undergoing psychiatric treatment in the study of Williams et al. (1995), psychiatric diagnoses included conversion disorder (18 patients [75%]), somatization disorder (3 patients [12.5%]), factitious disorder (2 patients [8.3%]), and malingering (1 patient [4.2%]). Nearly all patients (except 1 with oppositional defiant disorder) had associated mood, anxiety, or adjustment disorders. The most common associated diagnosis was dysthymia. DSM Cluster B and C personality disorders were also common, especially dependent personality disorder. Several patients had learning disabilities. Although 3 patients with psychogenic movement disorders did not experience remission and 1 committed suicide, most were quite improved. The most successful treatment was hypnosis, followed by family therapy and then physical therapy. Most of these patients were also on psychotropics. The use of placebo was helpful in 3 cases.
General Principles of Psychiatric Management in Neurological Illnesses Some of the most germane psychiatric treatment considerations in treating neurological patients are summarized below. For a more comprehensive discussion, the reader may wish to supplement this material with other texts, including comprehensive psychotherapy (Forrest 1992) and psychopharmacology (Stoudemire et al. 1995) treatment reviews.
14
Psychiatric Management in Neurological Disease
General Nonpharmacological Treatment Concerns Psychiatrists should be vigilant for disabilities imposed by cognitive deficits, neurobehavioral syndromes, personality changes, affective lability, and more traditional psychiatric diagnoses. DSM-IV (American Psychiatric Association 1994) diagnoses of concern include delirium, dementia, amnestic and other cognitive disorders, and mental disorders due to a general medical condition. Each of these disorders has specific management implications. Special neuropsychiatric treatment concerns. Detection of aphasia, apraxia, agnosia, and other conditions can aid in understanding the nature of the patient’s disability and its psychosocial impact. Elucidating deficits can promote acceptance of limitations and planning of compensatory strategies. Parietal anosognosia, right-hemisphere denial, and organic repression (Weinstein and Friedland 1977) can interfere with treatment. Considerable empathy is needed in dealing with these patients. Patients with orbitofrontal lesions, disinhibition, aggression, hypersexuality, or episodic dyscontrol—including DSM-IV personality change due to a general medical condition (disinhibited, aggressive, and labile types)—may require a quiet environment to prevent overstimulation. Hemineglect can interfere with providing instructions to the patient, and information must be delivered to the correct hemispace in such instances (e.g., stand on the right side of the bed for patients with neglect of the left hemispace). The classical presentation of hemineglect is left-hemispace neglect, which occurs after right parietal lobe lesions; however, neglect can also occur after left-sided lesions. Patients with dementia, cognitive impairment, or amnestic disorders require instructions to be conveyed in a simple, straightforward manner. Patients with dysfunction of subcortical or medial frontal circuits or depression may suffer from amotivation. Communication disorders requiring special effort on the part of both the patient and the psychiatrist include the various aphasias, dysarthria, parkinsonian speech hesitancy, pallilalia, hypophonia, vocal cord dystonia, cerebellar speech, other speech disorders, and thought disorders. Depression is extraordinarily common among people with neu-
Psychiatric Management Principles in Neurological Disease
15
rological disorders. Depression, substance abuse, and suicidality may complicate the treatment course as the patient reacts to disability. Sleep disorders (especially in patients with brain-stem lesions) and sexual disturbances may be caused by the underlying neurological illness (e.g., Huntington’s disease) or its treatment (e.g., Parkinson’s disease). The psychiatrist should monitor the grief process as the patient and family mourn the disease or its functional disabilities. The patient or family may experience guilt, shame, or anger (e.g., parents may engage in self-blame for passing a genetic disease on to their children). Genetic counseling for the patient or family members may be indicated for familial disorders. Neuropsychiatric diagnostic dilemmas. The distinction of apathy from depression chiefly relies on a thorough evaluation of depressive signs and symptoms. The DSM-IV analogue of this behavioral change (apathy) is personality change due to a general medical condition, apathetic type. If depressive cognitions (especially feelings of hopelessness, worthlessness, or pathological guilt), mood, and depressed affect are present, the patient should be treated with antidepressants. If they are absent but reduced affect is apparent, antiapathy agents (bromocriptine, amantadine) may be useful. Limitedsymptom, partially expressed (forme fruste) depression and alexithymia can complicate the diagnosis of apathy. Another problem is the distinction of flat affect from facial akinesia, and of catatonia from parkinsonism. The clinical features of these conditions overlap. Generally, the more symptoms of either disorder are present, the easier the distinction. When the conditions are indiscriminable, the presence of psychosis and response to benzodiazepines may imply flat affect or catatonia, and the absence of psychosis and benzodiazepine nonresponse may imply facial akinesia or parkinsonism. Major depression is associated with both catatonia and parkinsonism; mania is associated with both catatonia and antiparkinsonian medications. Novel neuropsychiatric presentations. Psychiatric disorders may evolve or remit during the course of the illness and must be considered on an ongoing basis. Clinical rating scales are of value to monitor clinical change between visits, reviewed elsewhere (Coffey et al.
16
Psychiatric Management in Neurological Disease
1995). Limited-symptom partial expressions (formes frustes) of psychiatric disorders may sometimes be present, requiring heightened clinical suspicion and necessitating thorough evaluation to determine the diagnosis. Tactile hallucinosis or paresthesias may attend disease of the parietal or temporal lobes, sensory system, thalamus, and basal ganglia and does not necessarily signify primary psychosis or somatization. Certain behaviors should be distinguished from the signs of mania. The childish, impish humor of witzelsucht can be seen in patients with dementia and frontal lobe disease. Disturbed social behavior may attend frontal lobe disease before other symptoms (e.g., cognitive decline) become evident. A wandering, mischievous hand that performs actions that the patient denies intent to perform may signal alien hand syndrome. Pseudobulbar affect with pathological laughter can be distinguished from manic elation or euphoria. The patient with pseudobulbar affect is generally euthymic and may complain of selective loss of control over emotions. Pathological crying or laughter can be triggered by events of mood-incongruent emotional significance. For example, a patient with pathological laughter may laugh uncontrollably after being informed of some terrible tragedy with personal significance. Certain neurological disorders have specific characteristic personality features. For example, patients with epilepsy tend to be moralistic, with intensified religiosity, a sense of urgency and mission, and a tendency toward anger and remorse. (Refer to chapters on specific diseases in this volume for details on the personality traits characteristically seen in these illnesses.) Special neuropsychiatric treatment modalities. Self-help books regarding the disease (e.g., Duvoisin 1984; Mace and Rabins 1991) can be useful to patients and caregivers. Information about the disease often reduces fear of the unknown and fosters acceptance. Both patients and family members can benefit. Support groups exist for some disorders and can provide therapeutic benefits, including socialization, support, education, a sense of control over the illness, and the chance to keep active. Better outcome is associated with attending support groups, although it is not clear whether this improved outcome is cause or effect (Montgom-
Psychiatric Management Principles in Neurological Disease
17
ery et al. 1994). Support group exercise programs can enhance mobility and reduce flexion contractures. Patients can run for office, encouraging preservation of an active, functional lifestyle. Support groups are available for a variety of specific disorders. For guidance on referrals to organizations offering information and resources, contact the Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services, P.O. Box 1133, Washington, DC 20013-1133 (phone 1-800-336-4797 or 301-565-4167; fax 301-984-4256). For information about uncommon illnesses, contact the National Organization for Rare Disorders, P.O. Box 8923, New Fairfield, CT 06812-8923 (phone 1-800-999-6673 or 203-746-6518; fax 203-746-6481). Names of support groups and informational resources for spouses of patients can be obtained by contacting the Well Spouse Foundation, 610 Lexington Avenue, Suite 208, New York, NY 10022-6005 (phone 1-800-838-0879 or 212-644-1241; fax 212-644-1338). (See Chapter 10 in this volume for family treatment considerations.) Rehabilitation programs can assist in practical recovery and disability management. Pet therapy may be useful for loneliness and isolation, but the patient’s degree of disability may contraindicate this (e.g., a big dog may knock the patient off his feet; a small animal might lead to problems in a patient who is unable to bend down). Special neuropsychiatric treatment techniques. Management of movement disorders is detailed in the chapters that follow. Gait disturbances in neurological disorders are an important and frustrating source of disability. Impaired sensory, visual, vestibular, and motor systems contribute to gait disturbance, as can frontal apraxia and cerebellar ataxia. Learning to attend more to input from unimpaired systems can improve gait (e.g., attending with greater vigilance to visual input). Patients with visuospatial perceptual problems may require planning and positional mapping to overcome this disability. Running a finger along the wall while walking can provide compensatory sensory information for those with loss of lower-extremity propioception. Apraxia can sometimes be improved with a cane or walker. Parkinsonian freezing can be reduced by avoiding narrow, confined passageways. Gait hesitancy (difficulty initiating gait) can be assisted with the use of mental counting techniques (e.g.,
18
Psychiatric Management in Neurological Disease
“1-2-1-2-1-2 . . . ”). Another technique involves having the spouse rock the patient from foot-to-foot, thereby initiating gait. Any existing foot conditions (e.g., improperly fitting shoes, painful toenails) or other physical impediments should be addressed. Optimizing treatment of the underlying condition may also be helpful (e.g., dopaminergic therapy in Parkinson’s disease, neuroleptics in Huntington’s disease). Orthostatic hypotension caused by underlying diseases (e.g., Shy-Drager parkinsonian syndrome) or treatments (e.g., dopamine agonists) can lead to falls and immobility. Replacement of offending medications, use of support hose, or administration of salt tablets or mineralocorticoids may be useful. Vitamin status should be considered, because treatable gait disorders caused by vitamin deficiency may be present (thiamin, B12 cobalamin, or folate), especially in patients with poor nutritional status. Some patients become phobic of falling and therefore of ambulating (particularly on stairs). Behavior therapy with physical therapists or a personal trainer can often help in these instances. In addition, benzodiazepines, neuroleptics, and sedating agents can sometimes destabilize gait.
General Pharmacological Concerns Double-blind, placebo-controlled studies of psychotropics for psychosis, depression, anxiety, and agitation in neurological diseases have been reviewed recently (Rummans et al. 1999). In general, the choice of psychotropics is initially the same as in traditional treatment, except for the caveats detailed in this book. In particular, clinicians should remain alert for drug interactions with neurological agents. Further, delayed development of compound psychiatric syndromes with differentially responsive components or atypical responsivity can occur with neurological disease (Lauterbach et al. 1994). Strategies to manage noncompliance attributable to attendant neurobehavioral syndromes, amotivation, apathy, cognitive disorders, or depression should be considered. Many patients with neurological illness are elderly, debilitated, or afflicted with disease of other organs. Therefore, the usual rules applying to geriatric psychiatry should be followed. These include considerations of increased drug availability at receptor sites be-
Psychiatric Management Principles in Neurological Disease
19
cause of reduced serum protein, the need for lower initial dosages and slower advances of dosage, functionally prolonged half-lives that result in dose accumulation, reduced metabolism, reduced clearance, and the possibility of therapeutic levels on lower-thancustomary dosages. Patients with neurological disease may also be taking multiple medications, which exponentially increases the possibility of drug interactions. In anticipation of future additions to the regimen by other physicians, drugs with short half-lives are preferred to avoid prolonged clearances in the event of the need for discontinuation (e.g., fluoxetine’s metabolite norfluoxetine can linger for many weeks before eventual clearance). The atypical antipsychotics and the newer antidepressants represent important therapeutic advances. These agents have more favorable side-effect profiles than their predecessors. Theoretically, the lesser proclivity of the atypical antipsychotics (e.g., clozapine, quetiapine, olanzapine, risperidone) to induce extrapyramidal movement disorders is of value in patients with neurological disease who are predisposed to these side effects. However, review of the literature of atypical antipsychotics in these neurological diseases indicates that well-controlled data are scant (Rummans et al. 1999). The few data available suggest mixed results in Parkinson’s disease, with some patients becoming more parkinsonian or delirious on clozapine. As of this writing, a single study (Singh et al. 1997) suggests that risperidone may be the treatment of choice for psychosis in human immunodeficiency virus infection, especially for patients with mania. Although experience is limited and it is too early to declare the superiority of these agents in patients with the neurological diseases considered in this book, it is clear that patients deserve intensive monitoring while on either these agents or conventional neuroleptics, especially those patients with parkinsonian features. The relative absence of anticholinergic effects of the newer antidepressants is a clear theoretical advantage in neurological patients who are predisposed to anticholinergic delirium. Some of the major potential psychotropic–disease and drug– drug interactions are detailed in Tables 1–6 and 1–7, respectively. These and other interactions are elaborated on in greater detail elsewhere (Stoudemire et al. 1995). Furthermore, cytochrome P450 enzyme inhibition by selective serotonin reuptake inhibitors (SSRIs)
Major potential interactions between diseases and psychotropics
Congestive heart failure Cardiac conduction defects
Orthostatic hypotension Dysautonomia
Seizure disorders
Cognitive disorders
Psychiatric Management in Neurological Disease
Hypertension Coronary artery disease
Reduced first-pass effect through liver, increasing plasma drug levels Clozapine can produce hypotension, tachycardia, and dizziness LPNs, TCAs, and carbamazepine prolong conduction times (avoid) Trazodone occasionally produces heart block and ventricular arrhythmias Psychostimulants and venlafaxine can increase blood pressure LPNs, TCAs, MAOIs, and trazodone can produce hypotension, reducing coronary artery perfusion LPNs, clozapine, TCAs, trazodone, MAOIs, carbamazepine, and antihistamines can worsen orthostatic hypotension See orthostatic hypotension LPNs, clozapine, TCAs, paroxetine, MAOIs, carbamazepine, and antihistamines are anticholinergic Bladder outlet obstruction has been reported with trazodone SSRIs are associated with sexual side effects Clozapine, chlorpromazine, lithium, maprotiline, clomipramine, and bupropion are relatively contraindicated Barbiturates, phenytoin, and carbamazepine can lower neuroleptic and TCA levels Valproate can increase neuroleptic and TCA levels Valproate can increase carbamazepine toxicity Anticholinergics, LPNs, clozapine, tertiary-amine TCAs, trazodone, carbamazepine, lithium, antihistamines, and benzodiazepines can lead to delirium, increase cognitive impairment, and impair alertness Neuroleptics may increase sedative effects of barbiturates, and vice versa
20
Table 1–6.
Movement disorders
Hepatic disease
Renal disease
21
(continued)
Psychiatric Management Principles in Neurological Disease
Gait disorders
Lithium can lead to confusion and sedation at low or normal lithium levels Benzodiazepines can lead to behavioral disinhibition USABs (e.g., triazolam) especially likely to produce confusion, dissociation, and anterograde amnesis See orthostatic hypotension, cognitive disorders, and movement disorders (agents that worsen these conditions can lead to impairment of gait) Lithium, valproate, benzodiazepines, beta-blockers, and sedating agents can induce ataxia Antipsychotics can aggravate parkinsonism, dystonia, and akathisia Neuroleptic malignant syndrome is more likely in neurological disease Clozapine can sometimes worsen Parkinson’s disease signs Anticonvulsants, lithium, SSRIs, and antihistamines can worsen action-postural tremors SSRIs can lead to serotonin syndrome SSRIs can produce or worsen akathisia, dystonia, myoclonus, dyskinesias, and, rarely, parkinsonism Buspirone can produce tremor and persistent dystonia Avoid long-half-life drugs Anticonvulsants and many other drugs can further impair liver function Hydrazide MAOIs can be hepatotoxic Avoid benzodiazepines that are oxidized before glucuronidation Avoid LABs (dose accumulation can occur) Quazepam can accumulate Avoid long-half-life drugs Avoid lithium for mood stabilization if possible
Major potential interactions between diseases and psychotropics (continued)
Pulmonary disease
Blood dyscrasias
Note. LAB = long-acting benzodiazepine; LPN = low-potency neuroleptic; MAOI = monoamine oxidase inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; USAB = ultra-short-acting benzodizepine. Source. Charney et al. 1995; DePaulo 1984; Koczerginski et al. 1989; Lauterbach 1993, 1995; Lauterbach and Shillcutt 1997; Ray et al. 1989; Stoudemire and Fogel 1987; Stoudemire et al. 1995.
Psychiatric Management in Neurological Disease
Avoid MAOIs (hypertensive crises with respiratory agents) Benzodiazepines (especially LABs), barbiturates, and beta-blockers can compromise respiration LPNs, clozapine, carbamazepine, and valproate can suppress bone marrow Avoid clozapine
22
Table 1–6.
Potential drug–drug interactions
Aspirin Type 1A antiarrhythmics Propafenone Warfarin, digitoxin, digoxin
Can increase valproate level LPNs and TCAs prolong conduction times (avoid these agents) Can elevate TCA levels SSRIs, TCAs, and MAOIs can increase anticoagulant effect Increased risk for hypertensive hemorrhagic stroke in MAOI hypertensive crisis Lithium may increase digitalis toxicity Carbamazepine increases warfarin metabolism (decreases anticoagulant effect) Psychostimulants can increase prothrombin times Clonidine Neuroleptics can reduce the efficacy on blood pressure control Beta-blockers Increase psychotropic hypotension Increase neuroleptic levels Thiazide diuretics, spironolactone, Increase lithium levels triamterene Calcium channel blockers Variable effects on lithium levels Diltiazem increases carbamazepine to toxic levels Verapamil Bradycardia with lithium Increases carbamazepine to toxic levels ACE inhibitors (e.g., enalapril) Occasional elevated lithium levels Carbamazepine Carbamazepine levels can be lowered by quinidine, phenytoin, warfarin, clozapine, and propranolol Carbamazepine toxicity increased by diltiazem and verapamil
23
(continued)
Psychiatric Management Principles in Neurological Disease
Table 1–7.
Potential drug–drug interactions (continued)
Carbamazepine (continued)
Phenytoin Barbiturates
Benzodiazepines Sympathomimetics
Psychiatric Management in Neurological Disease
Valproate
Carbamazepine induces cytochrome P450 (CYP) 3A3/4/5 Increases the metabolism of anticoagulants Can increase prothrombin times Can lower TCAs, neuroleptic, clozapine, valproate, and benzodiazepine levels SSRIs can increase carbamazepine levels Can increase prothrombin times Can inhibit platelet aggregation Aspirin can increase valproate levels Can increase TCAs, carbamazepine 10-11 epoxide, benzodiazepine (except lorazepam), and phenobarbital levels Can be increased by chlorpromazine Can be decreased by carbamazepine, phenytoin, and phenobarbital Can displace protein-bound phenytoin and carbamazepine Can lower TCAs, neuroleptics, and carbamazepine levels SSRIs, psychostimulants, and carbamazepine can increase phenytoin levels Can lower TCAs, neuroleptics, and carbamazepine levels Can increase carbamazepine 10-11 epoxide levels SSRIs and psychostimulants can increase barbiturate levels Can be potentiated by MAOIs SSRIs can increase benzodiazepine levels Can be potentiated by MAOIs Hypertensive crisis with MAO-A inhibitors
24
Table 1–7.
Fatality, dystonia, and other movement disorders with antipsychotics Hypertensive crisis with MAO-A inhibitors Discontinue before starting antidepressants Serotonin syndrome can result with serotonergic psychotropics Can lower lithium and benzodiazepine levels MAO-A inhibitors contraindicated
Note. ACE = angiotensin-converting enzyme; LPN = low-potency neuroleptic; MAOI = monoamine oxidase inhibitor; MAO-A = monoamine oxidase type A; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant. Source. Charney et al. 1995; DePaulo 1984; Stoudemire and Fogel 1987; Stoudemire et al. 1995.
Psychiatric Management Principles in Neurological Disease
Metoclopramide L-dopa Selegiline Serotonin agonists Theophylline and aminophylline
25
26
Psychiatric Management of Neurological Diseases
may lead to drug–drug interactions with cardiac or other medications the patient may be taking (Table 1–8). These interactions occur with a wide variety of antiarrhythmics, calcium channel blockers, beta-blockers, and warfarin (Nemeroff et al. 1996). The list of interactions of SSRIs with these other drugs seems to be continually growing, and caution is therefore indicated when prescribing these antidepressants. Among the SSRIs, citalopram may be the least likely to produce P450 interactions. Venlafaxine may produce P450 inhibition less frequently than SSRIs. Nevertheless, it is wise to monitor blood levels of cardiac and other drugs during treatment to ensure that such interactions are not occurring, given that new interactions are still being reported. Additional considerations in certain types of patients follow. Heart disease. The treating psychiatrist should consider obtaining an electrocardiogram prior to treating depressed neurological patients, because heart disease may be present (for example, in stroke, Wilson’s disease). Bupropion or one of the SSRIs may be a better choice than tricyclic antidepressants (TCAs) if conduction problems are present. In a study of 36 patients with severe heart disease and DSM-III (American Psychiatric Association 1980) major depression, bupropion was found to be free of effects on myocardial contractility and conduction, although blood pressure was increased (Roose et al. 1991). In an open-label trial, sertraline did not significantly change heart rate, blood pressure, cardiac conduction, or ejection fraction in post–myocardial infarction patients (Shapiro et al. 1999). In contrast to the findings for sertraline, a study of fluoxetine in cardiac patients revealed a 6% decrease in heart rate, a 2% increase in supine blood pressure, and a 7% increase in ejection fraction, although conduction, arrhythmias, and orthostatic blood pressure were unaffected (Roose et al. 1998). Four percent of the patients suffered an adverse cardiovascular event. However, these and newer agents have not been adequately investigated in patients with arrhythmias or heart failure. Moreover, P450 interactions of SSRIs with cardiovascular drugs warrant careful attention to patient selection. Beta-blockers are useful for action-postural tremors and akathisia. Major concerns regarding psychotropic administration in cardiovascular and other diseases are listed in Table 1–6.
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs)
Drug Analgesics Acetaminophen Codeine Dextromethorphan Phenacetin Cardiovascular agents Anticoagulants Warfarin Beta-blockers Metoprolol Propranolol Antiarrhythmics Amiodarone Encainide Flecainide Mexiletine Propafenone
CYP 1A2 (fluvoxamine)
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone)
+
+ + +
+
+
+
+
+
+
+ + + + + + + +
+
27
(continued)
Psychiatric Management Principles in Neurological Disease
Table 1–8.
CYP 1A2 (fluvoxamine)
Antiarrhythmics (continued) Quinidine Lidocaine Calcium channel blockers Verapamil Diltiazem Nifedipine Lipid-lowering agents Lovastatin Gastrointestinal agents Omeprazole Cisapride Phosphodiesterase inhibitors Caffeine Theophylline
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone) +
+ +
+ +
+ + + +
+ +
+ +
+
Psychiatric Management in Neurological Disease
Drug
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs) (continued)
28
Table 1–8.
Psychiatric Management Principles in Neurological Disease
+ + + + + + + + + +
+
+ +
+
+ + + +
29
Hypoglycemics Tolbutamide Oncologic agents Vincristine Vinblastine Immunosuppressants Cyclosporine Steroids Dexamethasone Estrogen Testosterone Antibiotics Erythromycin Clarithromycin Antifungals Ketoconazole Protease inhibitors Indinavir Nelfinavir Ritonavir Saquinavir Cognitive enhancers Tacrine Donepezil
+ (continued)
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs) (continued)
Antipsychotics Haloperidol Perphenazine Thioridazine Risperidone Clozapine Remoxipride Pimozide Olanzapine Quetiapine Anticonvulsants Carbamazepine Ethosuximide Hexobarbital Mephobarbital Phenytoin
CYP 1A2 (fluvoxamine) +
+ + + + + +
+
+ +
+
+ + + + + + +
Psychiatric Management in Neurological Disease
Drug
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone)
30
Table 1–8.
Psychiatric Management Principles in Neurological Disease
Antidepressants Tetracyclics Maprotiline Tricyclics Amitriptyline Nortriptyline Imipramine Desipramine Clomipramine Others Bupropion Mirtazapine Mianserin Trazodone Venlafaxine Nefazodone Monoamine oxidase inhibitors Moclobemide Anxiolytics Alprazolam Diazepam Midazolam
+ +
+
+
+
+
+
+
+ + + + +
+ + + +
+ + + + +
+
+
+
+ + +
31
(continued)
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs) (continued)
Anxiolytics (continued) Triazolam Clonazepam Antihistamines Astemizole Terfenadine Loratadine
CYP 1A2 (fluvoxamine)
+ + + + +
Note. Partial listing of some of the more important potential drug interactions in neurological patients. The strongest inhibitors of cytochrome P450 2D6 are paroxetine, followed by fluoxetine. The weakest 2D6 inhibitors are citalopram and fluvoxamine. Although venlafaxine is considered a weaker inhibitor than the antidepressants listed, it can also inhibit 2D6.
Psychiatric Management in Neurological Disease
Drug
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone)
32
Table 1–8.
Psychiatric Management Principles in Neurological Disease
33
Dysautonomia and orthostatic hypotension. Sympathomimetics used to treat neurological patients with dysautonomia or hypoventilation can lead to anxiety and hypertensive reactions with monoamine oxidase inhibitors (MAOIs). Psychotropics with anticholinergic actions (Table 1–6) and anticholinergics used to treat dystonia and parkinsonism may worsen dysautonomia and produce gastroparesis, tachycardia, dry mouth, blurred vision, and urinary retention. Coadministration of antipsychotics and metoclopramide can lead to severe dystonia that can sometimes prove fatal (Lauterbach 1992). Many drugs can worsen orthostatic hypotension and induce sexual dysfunction, usually through alpha1 receptor blockade. Many of these agents (see Table 1–6) can also be quite anticholinergic. Highpotency neuroleptics, bupropion, and SSRIs might be preferred, although SSRIs have also been associated with sexual side effects, potentially compounding the sexual dysfunctions seen in some dysautonomias. Bupropion may improve erectile failure, and bupropion and desipramine may be useful for anorgasmia (Charney et al. 1995). Bladder outlet obstruction has been reported with trazodone, and paroxetine has sometimes been reported to exhibit clinically significant anticholinergic effects. Seizure disorders. Among antipsychotics, molindone, fluphenazine, thioridazine, and mesoridazine may cause the least reduction in seizure threshold (Edwards et al. 1986; Luchins et al. 1984). Among antidepressants, desipramine, MAOIs, and SSRIs reduce the seizure threshold the least and thus are preferred in treating depressed patients with seizures (Charney et al. 1995). Clozapine, lithium, maprotiline, clomipramine, and bupropion are best avoided in patients at risk for seizures (Charney et al. 1995). The risk of seizures with clozapine is dose related: 1%–2% at doses up to 300 mg/day, 3%–4% at between 300 mg/day and 600 mg/day, and 5% at 600–900 mg/day (Stoudemire et al. 1995). Blood levels for anticonvulsants should be followed, since many psychotropics interact with these agents (Tables 1–7 and 1–8). When valproate is coadministered with carbamazepine, it may displace carbamazepine from protein binding sites and raise the concentration of carbamazepine’s 10-11 epoxide, thereby increasing carbamazepine bioavailability and, potentially, toxicity without increasing clinically detectable blood levels (Stoudemire et al. 1995).
34
Psychiatric Management in Neurological Disease
Cognitive disorders. Many agents (Table 1–7) can further impair cognition in patients with cognitive disorders. High-potency neuroleptics, risperidone, the newer antidepressants, and buspirone carry the least risk for cognitive impairment. Among TCAs, the secondary amines (e.g., nortriptyline, desipramine) have the least potential for causing impairment. SSRI treatment has been associated with several forms of myoclonus, some producing significant distress to the patient (Bharucha and Sethi 1996; Lauterbach 1994). Patients with central nervous system disease may show confusion and sedation on lower levels of lithium than those causing such effects in the general population (DePaulo 1984). Although trazodone and the benzodiazepines can calm agitation in the cognitively impaired, they can sometimes also produce behavioral disinhibition. Ultra-short-acting benzodiazepines (e.g., triazolam) are more likely than long-acting agents to produce acute confusion, dissociation, and anterograde amnesis (Stoudemire et al. 1995), but long-acting benzodiazepines (e.g., clonazepam, flurazepam) can accumulate over several weeks to toxic levels in patients with reduced clearance (e.g., Wilson’s disease with liver complications). Despite having benzodiazepine-1 receptor affinity, quazepam can also accumulate to toxic levels (Stoudemire et al. 1995). Buspirone is less likely than the benzodiazepines to impair cognition and thus is a logical alternative in patients with cognitive impairment attributable to benzodiazepines. Pathological affect. Pathological affect can respond to SSRIs, antidepressants, lithium, L-dopa, amantadine, and methylphenidate (Lauterbach and Schweri 1991; also see Chapter 7 in this volume). Gait disorders. Agents that impair cognition, reduce arousal, or lead to hypotension, parkinsonism, or ataxia can also impair gait. Lithium and valproate can induce or amplify gait ataxia. Carbamazepine can cause dose-related ataxia, diplopia, and sedation, each of which can destabilize gait. Benzodiazepines are associated with hip fractures in the elderly. In a study of 4,501 elderly people taking benzodiazepines compared with 24,041 control subjects, the relative risk for hip fracture was increased 70% by long half-life and 10% by short half-life benzodiazepines (Ray et al. 1989). This increase in risk was observed after controlling for demographic and other clinical factors. Shorter-acting benzodiazepines include alprazolam, triazo-
Psychiatric Management Principles in Neurological Disease
35
lam, lorazepam, and oxazepam. Clonazepam added to therapeutic levels of lithium has led to ataxia and dysarthria (Koczerginski et al. 1989). Movement disorders. Clozapine, quetiapine, olanzapine, risperidone, and low-potency neuroleptics are less apt to aggravate parkinsonism than are high-potency neuroleptics. Nevertheless, these agents can certainly elicit parkinsonism and other movement disorders, and patients should be closely monitored. Neuroleptic malignant syndrome is a possibility in patients taking antipsychotics, given that this condition tends to evolve in patients with neurological impairment and debilitation, especially if dehydration is also present (Stoudemire et al. 1995). In contrast to their ability to precipitate acute neuroleptic-induced dystonia, neuroleptics can either improve or worsen other dystonias (see Chapter 6 in this volume). The heterocyclic antidepressant amoxapine can metabolize to variable concentrations of the neuroleptic loxapine. Clozapine has many side effects, including cognitive impairment, but it can reduce L-dopa dyskinesia, as can the SSRIs and buspirone. Improvement in dystonia and parkinsonism has been reported with clozapine, although double-blind trials in Parkinson’s disease patients have disclosed worsened parkinsonism and precipitation of delirium with clozapine (Rummans et al. 1999). Psychosis may be induced by neurological medications (e.g., dopamine agonists) and can sometimes remit with dosage reduction. In Parkinson’s disease patients, the drug selegiline should be discontinued at least 14 days prior to commencing treatment with antidepressant agents (5 weeks before fluoxetine) because of reported fatalities due to drug interactions. Vigilance for the serotonin syndrome (ataxia, nystagmus, confusion, fever, tremor, and myoclonus) is necessary when combining serotonergic agents with MAOIs or SSRIs. Although probably rare, visual hallucinations and illusions have occurred when SSRIs were administered to Parkinson’s disease patients being treated with L-dopa (Lauterbach 1993). SSRIs can induce a wide variety of movement disorders (Leo 1996). Although SSRIs usually have no effect on parkinsonism and dystonia, they variably improve or worsen different forms of myoclonus and dystonia (Lauterbach 1994, 1995). SSRIs can sometimes improve L-dopa dyskinesia in Parkinson’s disease. Coadministra-
36
Psychiatric Management in Neurological Disease
tion of MAOIs and L-dopa can trigger hypertensive crises, although each of these agents individually can cause hypotension. Electroconvulsive therapy may be useful in some cases of Parkinson’s disease as well as some cases of dystonia (Lauterbach and Moore 1990). Lithium and valproate can amplify ataxia. Benzodiazepines and beta-blockers improve action-postural tremors. Buspirone has led to tremor and persistent dystonia (LeWitt et al. 1993). Hepatic and renal disease. Portal hypertension reduces first-pass effects, and patients with liver disease should be started on one-third to one-half the usual dose of antidepressants until blood levels have been determined or tolerance to side effects occurs. Short-acting agents (e.g., paroxetine instead of fluoxetine) are used because of extended-half-life considerations. Among anxiolytics, oxazepam, temazepam, and lorazepam are directly glucuronidated without first being oxidized and thus are the preferred agents in this class. The tyramine diet required with MAOIs may make these agents an unpalatable option in a patient already on a renal or hepatic diet. Nonhydrazide MAOIs have less hepatotoxic potential than do hydrazide MAOIs. Anticonvulsants should be avoided in liver disease, as should lithium in patients with renal disease. Drug plasma levels should be frequently monitored when possible, especially in patients on dialysis. Pulmonary disease and blood dyscrasias. Hypoventilation can attend neurological diseases, particularly Parkinson’s disease. Concerns regarding sympathomimetics have already been detailed (see “Dysautonomia and orthostatic hypotension,” above). Anticholinergic agents can reduce tracheobronchial secretions in asthma and chronic obstructive pulmonary disease. Steroids carry their own psychiatric risks. Benzodiazepines can impair ventilatory status; buspirone is a logical alternative. Blood dyscrasia can attend Wilson’s disease. Interactions of concern in pulmonary disease and blood dyscrasias are listed in Tables 1–6 and 1–7.
Summary Diseases affecting basal ganglia–cortical circuits are devastating in terms of functional impairment and economic costs. A panoply of
Psychiatric Management Principles in Neurological Disease
37
psychiatric, behavioral, and neurological conditions can occur in these diseases. Certain features can help to localize pathology. Movement disorders are particularly common in basal ganglia–cortical diseases. Psychiatric management involves determining deficits and helping the patient adjust to them, employing specific treatment approaches. Principles of pharmacotherapy involve consideration of drug effects on the underlying illness, associated conditions, other drugs in the regimen, and special proclivities to side effects unique to the condition. A cautious, conservative approach is warranted. Self-help books, support groups, family education and therapy, and, at times, genetic counseling can represent important treatment options in these disorders.
References American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Bharucha KJ, Sethi KD: Complex movement disorders induced by fluoxetine. Mov Disord 11:324–326, 1996 Charney DS, Miller HL, Licinio J, et al: Treatment of depression, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 575–601 Coffey CE, Cummings JL, Duffy JD, et al: Assessment of treatment outcomes in neuropsychiatry: a report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 7:287–289, 1995 Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurol 50:873–880, 1993 DePaulo JR Jr: Lithium. Psychiatr Clin North Am 7:587–599, 1984 Duvoisin RC: Parkinson’s Disease: A Guide for Patient and Family, 2nd Edition. New York, Raven, 1984 Edwards JG, Long SK, Sedgwick EM, et al: Antidepressants and convulsive seizures: clinical, electroencephalographic, and pharmacological aspects. Clin Neuropharmacol 9:329–360, 1986
38
Psychiatric Management in Neurological Disease
Forrest DV: Psychotherapy of patients with neuropsychiatric disorders, in The American Psychiatric Press Textbook of Neuropsychiatry, 2nd Edition. Edited by Yudofsky SC, Hales RE. Washington, DC, American Psychiatric Press, 1992, pp 703–739 Koczerginski D, Kennedy SH, Swinson RP: Clonazepam and lithium—a toxic combination in the treatment of mania? Int Clin Psychopharmacol 4:195–199, 1989 Lauterbach EC: Haloperidol-induced dystonia and parkinsonism on discontinuing metoclopramide: implications for differential thalamocortical activity. J Clin Psychopharmacol 12:442–443, 1992 Lauterbach EC: Dopaminergic hallucinosis with fluoxetine in Parkinson’s disease (letter). Am J Psychiatry 150:1750, 1993 Lauterbach EC: Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick’s disease. Mov Disord 9:343–346, 1994 Lauterbach EC: Fluoxetine, buspirone, myoclonus, and dystonia (letter). Am J Psychiatry 152:1697, 1995 Lauterbach EC: Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Biol Psychiatry 40:726–730, 1996 Lauterbach EC, Moore NC: Parkinsonism-dystonia syndrome and ECT (letter). Am J Psychiatry 147:1249–1250, 1990 Lauterbach EC, Schweri MM: Amelioration of pseudobulbar affect by fluoxetine: possible alteration of dopamine-related pathophysiology by a selective serotonin reuptake blocker. J Clin Psychopharmacol 11: 392–393, 1991 Lauterbach EC, Shillcutt SD: Dyskinesia with fluoxetine: tardive or lateonset persistent acute norfluoxetine dyskinesia? (letter). J Clin Psychiatry 58:85–86, 1997 Lauterbach EC, Price ST, Spears TE, et al: Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm. Biol Psychiatry 35:488–490, 1994 Leo RJ: Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449–454, 1996 LeWitt PA, Walters A, Hening W, et al: Persistent movement disorders induced by buspirone. Mov Disord 8:331–334, 1993 Luchins DJ, Oliver AP, Wyatt RJ: Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 25:25–32, 1984
Psychiatric Management Principles in Neurological Disease
39
Mace NL, Rabins PV: The 36-Hour Day: A Family Guide to Caring for Persons With Alzheimer’s Disease, Related Dementing Illnesses, and Memory Loss in Later Life. Baltimore, MD, Johns Hopkins University Press, 1991 Mendez MF: The neuroanatomy of neurobehavioral syndromes. Lecture presented at The American Association for Geriatric Psychiatry 1996 Board Review Course for the Examination for Added Qualifications in Geriatric Psychiatry, Los Angeles, CA, October 1996 Montgomery EB Jr, Lieberman A, Singh G, et al: Patient education and health promotion can be effective in Parkinson’s disease: a randomized controlled trial (PROPATH Advisory Board). Am J Med 97:429–435, 1994 Nemeroff CB, De Vane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311–320, 1996 Ovsiew F: Bedside neuropsychiatry: eliciting the clinical phenomena of neuropsychiatric illness, in The American Psychiatric Press Textbook of Neuropsychiatry, 2nd Edition. Edited by Yudofsky SC, Hales RE. Washington, DC, American Psychiatric Press, 1992, pp 703–739 Ray WA, Griffin MR, Downey W: Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 262:3303–3307, 1989 Roose SP, Dalack GW, Glassman AH, et al: Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 148: 512–516, 1991 Roose SP, Glassman AH, Attia E, et al: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 155:660–665, 1998 Rummans TA, Lauterbach EC, Coffey CE, et al: Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 11:176–189, 1999 Shapiro PA, Lesperance F, Frasure-Smith N, et al: An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J 137:1100–1106, 1999 Singh AN, Golledge H, Catalan J: Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res 42:489–493, 1997 Stoudemire A, Fogel BS: Psychopharmacology in the medically ill, in Principles of Medical Psychiatry. Edited by Stoudemire A, Fogel BS. Orlando, FL, Grune & Stratton, 1987, pp 79–112
40
Psychiatric Management in Neurological Disease
Stoudemire A, Moran MG, Fogel BS: Psychopharmacology in the medically ill patient, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 783–801 Sultzer DL: Mental status examination, in The American Psychiatric Press Textbook of Geriatric Neuropsychiatry. Edited by Coffey CE, Cummings JL. Washington, DC, American Psychiatric Press, 1994, pp 99–104 Vitek JL, Chockkan V, Zhang JY, et al: Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 46:22–35, 1999 Weinstein EA, Friedland RP: Behavioral disorders associated with hemiattention. Adv Neurol 18:51–62, 1977 Williams DT, Ford B, Fahn S: Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 65:231–257, 1995
C H A P T E R
2
Parkinson’s Disease Morgan L. Levy, M.D. Jeffrey L. Cummings, M.D.
P
arkinson’s disease (PD) is a common degenerative disease of unknown etiology that primarily affects subcortical brain structures. It produces motor, cognitive and psychiatric abnormalities. Motor symptoms include bradykinesia (slowness of movement), cogwheel rigidity, tremor, and gait dysfunction. Cognitive symptoms include bradyphrenia (slowness of thinking) and executive dysfunction, which involves deficits in problem solving, word list generation, abstracting ability, set shifting, and memory retrieval. More severe dementia syndromes may occur in about 40% of patients. Psychiatric symptoms include depression, anxiety, and reduced motivation. Several psychiatric symptoms may be associated with anti-PD therapy; these include hallucinations, delusions, confusional states, mania, increased libido, and sleep disturbances. In this chapter our focus is primarily on cognitive and psychiatric abnormalities in PD.
Prevalence The prevalence of PD varies widely by geographic location, ranging from 31 per 100,000 in Libya to 328 per 100,000 in India. Most Western countries report prevalence rates of approximately 110 per 100,000. This project was supported by a Department of Veterans Affairs Neuroscience Fellowship, a National Institute on Aging Alzheimer’s Disease Center grant (AG10123), and the Sidell-Kagan Research Fund.
41
42
Psychiatric Management in Neurological Disease
The mean age at onset is 58–62 years (range: 40–70 years) (Martilla 1987). The average time to death in untreated PD is 8 years (range: 1–30 years). Contemporary therapeutic interventions have extended the life expectancy of patients so that 50% are alive 16 years after disease onset (Di Rocco et al. 1996). Most cases are sporadic, and twins generally lack concordance. However, a family history of either PD or essential tremor is a risk factor for the disease. Increasing age is the only unequivocal risk factor; postulated risks include being exposed to pesticides or heavy metals (Fe, Mn, Al), drinking well water, and living in rural communities. Cigarette smoking and diets rich in vitamin E have been associated with reduced risk of PD (Tanner and Goldman 1996).
Clinical Recognition and Neurological Presentation Motor disturbances in PD include tremor, rigidity, bradykinesia, and loss of righting reflexes. Autonomic abnormalities and oculomotor dysfunction are found in most patients, although these are more subtle than the deficits found in progressive supranuclear palsy or Shy-Drager syndrome (see below). The typical PD tremor is a lowfrequency (4–5 cycles per second), large-amplitude rest tremor. Cogwheel rigidity results from the superposition of the tremor on increased muscle tone when the forearm or another joint is being moved through a full range of motion, whereas plastic rigidity is more common in the lower extremities, where there may be an increase in muscle tone and resistance to movement without apparent jerking or tremor. Bradykinesia is defined as slowness of movement and is one of the most pervasive elements of PD. Patients with bradykinesia have hesitation in initiating movements, impaired repetitive movements, freezing episodes, diminished arm swing, micrographia, facial masking, and sialorrhea. “En bloc” movements can be seen when patients attempt to turn while walking, a maneuver that may require multiple steps. PD patients often have a stooped posture with flexion of the trunk, knees, elbows, and neck, and their gait is characterized by short steps with diminished step height (“marche en petit pas”). Balance is impaired, and patients may lean and step backward (retropulsion) or forward (propulsion) and may fail to
Parkinson’s Disease
43
make the appropriate postural adjustments. Impotence, constipation, postural hypotension, and seborrheic dermatitis that is generally evident on the forehead are among the signs of autonomic dysfunction in PD; impaired convergence, limited up-gaze, and lid retraction are the most common neuro-ophthalmological abnormalities (Barbeau 1986). In addition to idiopathic PD, many disorders manifest parkinsonism (Table 2–1). These “Parkinson-plus” syndromes generally present with features of PD but manifest additional symptoms. Progressive supranuclear palsy is a syndrome that is similar to PD but that may produce impaired vertical gaze (up-gaze as well as downgaze), axial rather than distal rigidity, and hypererect rather than stooped posture. Shy-Drager syndrome is associated with severe autonomic dysfunction early in its course, and cerebellar or pyramidal symptoms suggest the presence of olivopontocerebellar atrophy or some other Parkinson-plus syndrome. A Parkinson-plus syndrome should be suspected when tremor is absent, atypical features are present, or a patient fails to respond to dopaminergic therapy (Koller and Megaffin 1994).
Gender and Pregnancy Gender does not appreciably affect PD expression. Although men predominated in two U.S. studies of PD (Hubble et al. 1993; Marder et al. 1996), the incidence of PD was slightly more common in women than in men in the Netherlands (Hofman et al. 1989). In pregnancy, exacerbations of parkinsonism have been observed in rare cases. PD poses no increased risk to the fetus except when amantadine has been administered to the mother.
Pathological Features Increased muscle tone results from an imbalance between competing inhibitory and disinhibitory neural pathways within the subcortical motor circuit, which projects from the sensorimotor cortex through the putamen, pallidum, thalamus, and back to the cortex (Figure 2–1). Between the striatum and thalamus are dynamically balanced circuits that both decrease and increase thalamic inhibition
44
Table 2–1.
Psychiatric Management in Neurological Disease
Differential diagnosis of parkinsonism
Degenerative disorders Idiopathic Parkinson’s disease
Metabolic causes of parkinsonism Hypothyroidism
Progressive supranuclear palsy Huntington’s disease (rigid variant)
Hypoparathyroidism
Striatonigral degeneration Shy-Drager syndrome Idiopathic basal ganglia calcification Guamanian parkinsonism– dementia complex Machado-Joseph disease
Wilson’s disease
Neuroacanthocytosis Lewy body dementia Hallervorden-Spatz disease Olivopontocerebellar atrophy Spinocerebellar degenerations Pallidal degeneration syndromes Ceroid lipofuscinosis Mitochondrial encephalopathy Type III (adult) GM1 gangliosidosis Vascular parkinsonism Lacunar state (a syndrome of punctate lesions in subcortical structures) Binswanger’s disease Infection-related parkinsonism Postencephalitic parkinsonism after epidemic encephalitis Transient parkinsonism after acute viral encephalitis Jakob-Creutzfeldt disease Human immunodeficiency virus encephalopathy Neurosyphilis
Non-Wilsonian hepatocerebral degeneration Drug-induced and toxic parkinsonism Neuroleptics Reserpine Alphamethyldopa Selective serotonin reuptake inhibitors Lithium Diazepam (high doses) Monoamine oxidase inhibitors Calcium channel–blocking agents Cytosine arabinoside Cyanide Organophosphates Manganese Carbon monoxide 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) Miscellaneous disorders Hydrocephalus Brain tumors Subdural hematomas Syringomesencephalia Trauma
Parkinson’s Disease
45
Figure 2–1. Frontal–subcortical circuits. *The indirect path includes the external segment of the globus pallidus and the subthalamic nucleus (DeLong 1990), although recent anatomic evidence suggests that this circuit may be more extensive (Parent and Hazrati 1995). + = excitation; − = inhibition.
(DeLong 1990; Parent and Hazrati 1995). Dopaminergic projections from the substantia nigra to the striatum appear to regulate or stabilize this inhibitory/disinhibitory balance (Saint-Cyr et al. 1995), and loss of dopamine results in unopposed thalamic inhibition and parkinsonism. Bradyphrenia and executive dysfunction are mediated by frontal–subcortical circuits that are parallel to but separate from the motor circuit. These originate in the frontal association cortex and project to the striatum at the caudate, whereas the “motor loop” originates in the supplementary motor cortex and connects to the putamen. Dopamine-mediated stabilization of the inhibitory/disinhibitory balance between direct and indirect pathways probably occurs in this circuit in the same fashion as described for the motor
46
Psychiatric Management in Neurological Disease
circuit (Saint-Cyr et al. 1995), and serotonergic and cholinergic projections also influence these loops. The principal neuropathological changes in PD are depigmentation and loss of dopamine-containing neurons in the substantia nigra, with protein- and sphingomyelin-containing cytoplasmic inclusions known as Lewy bodies developing in many of the remaining neurons. Similar but less severe changes also occur in the locus coeruleus (origin of norepinephrine projections), nucleus basalis (source of acetylcholine connections), and other subcortical nuclei. Deficiency of dopamine is the main neurotransmitter alteration; less-marked deficits of norepinephrine, acetylcholine, serotonin, glutamate, gamma-aminobutyric acid (GABA), and enkephalin also occur.
Neuroimaging Structural imaging has limited diagnostic utility in PD and most parkinsonian syndromes, but functional imaging, such as positron-emission tomography (PET), using [18F]fluorodopa as a tracer, can directly assess neurotransmitter activity in the nigrostriatal dopaminergic system. In contrast with normal aging or other causes of dementia, most causes of parkinsonism, including PD, are associated with reduced striatal [18F]fluorodopa. PD can be further differentiated from other causes of parkinsonism by its particularly low levels of putaminal [18F]fluorodopa. Fluorodopa PET is also useful for detecting preclinical PD and for following disease progression over time (Snow 1996) (Figure 2–2). [18F]fluorodeoxyglucose PET is used to measure cerebral metabolic rate; findings may be normal or may demonstrate global reduction in cerebral metabolism, reduced metabolism in the frontal lobes, or reduced parietal lobe activity.
Psychiatric Manifestations Dementias Cognitive dysfunction exists in a majority of PD patients, and 25%–40% have overt dementia (Aarsland et al. 1996). Bradyphrenia (slow thinking) and executive function impairment are the most
Parkinson’s Disease
A
47
B
Figure 2–2. [18F]Fluorodopa positron-emission tomography (PET) scans showing (A) dopamine uptake in the striatum (dark areas) in a normal control subject and (B) reduction in dopamine uptake in a patient with Parkinson’s disease. Source. Courtesy of Gary Small, M.D.
common aspects of cognitive dysfunction in nondemented PD patients. Bradyphrenia is usually apparent in the form of slowed response time. Executive dysfunction may be evidenced by impaired insight, judgment, planning, and abstracting ability and may be directly assessed by testing verbal and design fluency, delayed recall, alternating programs, multiple loops, and serial hand sequences (a detailed description of these and other executive function tests can be found in Cummings and Trimble 1995). Memory retrieval, visual constructions, verbal fluency, and naming may be mildly impaired, and the pattern of deficits in these domains also suggests frontal–subcortical system abnormalities or executive dysfunction. Cortical features of dementia, such as aphasia, amnesia, agnosia, and apraxia, can occur and likely signify the presence of cortical Lewy bodies, Alzheimer’s-type pathology, or both (Cummings and Benson 1992; Growdon et al. 1990). Lewy body dementia frequently presents with psychiatric symp-
48
Psychiatric Management in Neurological Disease
toms such as depression, agitation, delusions, and hallucinations early in the course (Beck 1995). Cognitive symptoms can progress rapidly and relentlessly but often fluctuate, and relatively lucid intervals may occur. Patients may have mild extrapyramidal symptoms, vivid visual hallucinations, gait disturbances, orthostatic hypotension, unexplained falls, and transient clouding and/or loss of consciousness. Most PD patients have at least a few cortical Lewy bodies, and most Lewy body dementia patients have brain-stem and diencephalic Lewy bodies in the same distribution as previously described for PD (Olichney et al. 1995).
Apathy and Bradyphrenia Apathy (lack of interest or motivation) and bradyphrenia (cognitive slowing) share many phenomenological and, possibly, physiological features. These symptoms occur frequently in PD and are associated with both cognitive impairment and depression; however, an association with bradykinesia (motor slowing) has not been demonstrated (Mayeux et al. 1987; Rogers et al. 1987). Apathy also occurs in a significant number of nondepressed PD patients and these patients have reduced cognitive speed (Starkstein et al. 1992b). One mechanism suggested to explain these symptoms focuses on forebrain dopaminergic systems, which are involved in motivation and reward and are damaged in PD (Rogers et al. 1987). Mayeux et al. (1987) proposed a role for noradrenergic dysfunction in producing bradyphrenia.
Mood Disorders Thirty percent to 50% of PD patients will develop symptoms of depression at some point during the course of their illness. Bipolar disorder is infrequent unless associated with drug treatment. Crosssectional studies of clinical samples report major depression in approximately 20% and minor depression in another 20% (Starkstein et al. 1990a). In contrast, epidemiological studies report lower rates of depression; in one study of 245 patients, 12 (5.1%) had moderateto-severe depressive symptoms, 19 (7.7%) had major depression, and 106 (45.5%) had mild depressive symptoms (Tandberg et al. 1996). Risk factors for depression in PD include female gender, personal but not family history of depression, early age at onset of PD,
Parkinson’s Disease
49
greater right-sided symptoms (i.e., left-hemisphere dysfunction), and prominence of bradykinesia and gait instability as opposed to tremor- dominant syndromes (Jankovic et al. 1990; Starkstein et al. 1990a). Depression can be reliably diagnosed in PD based on DSM-IV (American Psychiatric Association 1994) criteria, although anergia, motor retardation, and early awakening may be equally severe in PD patients with and without depression (Starkstein et al. 1990b). Depression may appear before the onset of motor symptoms (Mayeux et al. 1981), may be relatively stable over time (Brown et al. 1988; Mayeux et al. 1988), and may be associated with faster progression of the illness and a more rapid decline in ability to perform activities of daily living (Starkstein et al. 1992a). Distinguishing characteristics of the parkinsonian depressive syndrome include sadness without guilt or self-reproach, high levels of anxiety, a relative lack of psychotic features, and frequent suicidal ideation (albeit with a low suicide rate) (Cummings 1992). Cognitive performance is more severe in depressed than in nondepressed PD patients but involves similar deficits, with impairment affecting executive function, memory, and language (Mayeux et al. 1981; Starkstein et al. 1989, 1990a, 1990b; Troster et al. 1995b). However, PD patients with overt dementia have no greater frequency of depression than those without dementia (Huber et al. 1986). Serotonin and norepinephrine are regulatory neurotransmitters that are produced in the brain stem and project diffusely throughout the cerebral cortex. Abnormal mood likely results from a disruption in circuits that depend on these neurotransmitters. Predisposing factors include genetic loading and psychosocial stress. Patients with PD may be predisposed to the development of depression as a result of reduced dopaminergic stimulation of the orbitofrontal cortex, which is the primary source of cortical input to brain-stem serotonergic nuclei (Mayberg and Soloman 1995). The increased frequency of depression in PD may also be related to neuronal cell loss in noradrenergic and serotonergic nuclei (Perry et al. 1991). Psychological factors also appear to play a crucial role in protecting some individuals from depression while making others more susceptible to it. Overall disability, rather than stage of illness, accounts for more of the variance in depression (MacCarthy and
50
Psychiatric Management in Neurological Disease
Brown 1989). Other factors that have been identified include the availability and quality of social support, the types of strategies the individual uses to cope with stress, the explanatory cognitions and perceptions of control, and attitudes and beliefs about the self (Brown and Jahanshahi 1995). Depression may also fluctuate over the course of the illness in response to psychological factors. The initial discovery that one has a chronic disabling disease may result in intense depressive symptoms that abate as acceptance occurs but that may re-ignite in response to acute episodes of increased disability.
Anxiety Disorders In studies of anxiety disorders in PD patients, anxiety symptoms have been reported in 40% of PD patients and anxiety disorders in 29%–38%, with the most frequent diagnoses being simple phobia (34%–41%), panic disorder (8%–28%), social phobia (3%–17%), generalized anxiety disorder (4%–5%), and obsessive-compulsive disorder (0%–17%) (Menza et al. 1993; Stein et al. 1990). Anxiety in PD is more frequent and severe than in elderly patients with other chronic illnesses, and it is highly comorbid with depression (Henderson et al. 1992; Menza et al. 1993; Schiffer et al. 1988). In some patients, the onset of the motor arrests known as “freezing” attenuates the course of preexisting panic disorder, whereas other patients develop limited-symptom panic attacks with the onset of freezing (Lauterbach and Duvoisin 1991, 1993). Deficits in noradrenergic and possibly serotonergic function are theorized to mediate increased susceptibility to anxiety in PD patients (Henderson et al. 1992; Menza et al. 1993). Psychological factors also contribute to a heightened state of anxiety, and problems in social interaction are the most frequently cited as the reason for seeking counseling. The problems reported by more than 80% of PD patients in one study included reduced manual skills, reduced gestures and body language, slowness, reduced motivation and drive, anxiety about helplessness, increase of symptoms under minimal stress, disabling insecurity in social interactions, and fewer activities with partners and family (Ellgring et al. 1993).
Parkinson’s Disease
51
Sexual Disorders In a study by Brown et al. (1990) of PD patients, premature ejaculation and impotence occurred in 13 (65%) and 12 (60%), respectively, of the 20 male patients assessed; among the 11 female patients, 4 (36%) had anorgasmia and 3 (27%) had vaginismus. Nearly all of the patients in this study were taking antiparkinsonian medications. High levels of sexual dysfunction were documented in the spouses of PD patients as well as in the patients themselves, but couples in which the husband was the patient were the most severely affected. A diversity of biopsychosocial factors were important in explaining sexual dysfunction in this study. In another study, however, Lipe et al. (1990) found no difference in sexual desire, arousal, orgasm, and satisfaction between male patients with PD and male patients with arthritis. Sexual dysfunction was associated with increased age, illness severity, and depression in that study. A study of 50 patients with PD found that autonomic dysfunction was common, more common than depression, in those suffering from reduced sexual interest and functioning (Koller et al. 1990).
Medication-Induced Psychiatric Disorders Therapy with dopaminergic agents may be associated with formed visual hallucinations, persecutory delusions, anxiety, depression, mania, hypersexuality, and sleep disturbance; anticholinergic therapy may produce delirium with or without psychotic features (Cummings 1991; Factor et al. 1995; Koller and Megaffin 1994; Saint-Cyr et al. 1993) (Table 2–2). Psychosis is rare in untreated PD and usually indicates an adverse treatment response. Visual hallucinations are the most common neuropsychiatric side effect of PD treatment, occurring in approximately 30% of patients (Cummings 1991; Factor et al. 1995). Dopaminergic agents typically produce silent, nonthreatening visual hallucinations of fully formed human or animal figures in a clear sensorium, although frightening visions, altered sensoria, and hallucinations in other sensory modalities can be experienced. Hallucinations frequently occur at night and are more common in patients with sleep disturbance (Koller and Megaffin 1994). Predicting which patients are at risk for hallucinatory experiences is difficult;
52
Table 2–2.
Psychiatric side effects of antiparkinson medications Bromocriptine
Pergolide
Anticholinergics
Amantadine
Selegiline
+++ +++ + + ++ ++ ++
++++ ++ ++ + + + +
+++ ++ ++ + + + +
++ ++ ++++ − − + −
+ ++ + − − + +
+ + + − + + +
++
−
+
+
−
−
Note. + = weak association; ++ = moderate association; +++ = strong association; − = no association. Source. Cummings 1991; Factor 1995; Koller and Megaffin 1994; Saint-Cyr et al. 1993.
Psychiatric Management in Neurological Disease
Hallucinations Delusions Confusional state Depression Mania Anxiety Increased libido Sleep disturbance
L-dopa
Parkinson’s Disease
53
the only factors that have been identified are increasing age, premorbid history of psychiatric illness, more marked cognitive impairment, and longer duration of concomitant treatment with anticholinergic agents and amantadine (Glantz et al. 1987). Hallucinatory symptoms caused primarily by anticholinergic toxicity are usually associated with delirium and tend to be threatening, less well formed, and accompanied by hallucinations in other sensory modalities (Goetz et al. 1982). Delusions occur in approximately 10% of patients treated with dopaminergic agents but can be caused by any of the anti-PD medications (Cummings 1992). L-dopa/carbidopa (Sinemet) generally does not produce delusions before 2 years of continuous therapy (Klawans 1978), and delusions are more common among patients treated with higher doses of drugs. Other risk factors include older age and preexisting dementia (Fischer et al. 1990). Delusions often involve well-formed, complex belief systems and are frequently preceded by hallucinations. Although delusions are usually persecutory or paranoid in nature, misidentification syndromes and delusions of grandeur have also been reported (Cummings 1992). Confusional states, or “delirium,” with fluctuating arousal, impaired attention, and incoherent verbal output occur in 5%–25% of patients treated with anti-PD agents. Overt dementia and anticholinergic therapy are major risk factors and, when combined, may cause delirium in 93% of PD patients (de Smet et al. 1982). L-dopa may also produce confusion, but the higher-potency ergot derivatives such as bromocriptine (Parlodel) and pergolide (Permax) appear to cause it more frequently (Cummings 1992). Selegiline (Eldepryl) rarely produces psychiatric symptoms when used alone but can cause confusional states and/or psychosis when added to L-dopa. Depression is no more frequent in treated than in untreated PD patients when measured prospectively (Celesia and Wanamaker 1972), and it should be regarded as a comorbid condition rather than a drug-induced side effect (Factor et al. 1995). Mania, hypomania, and euphoria do not occur in untreated PD but are infrequent side effects of dopaminergic agents and, occasionally, selegiline. Patients with a history of bipolar disorder frequently experience an acute exacerbation when treated with these medications (Goodwin 1971).
54
Psychiatric Management in Neurological Disease
Symptoms may range from mild euphoria to an intense manic episode and typically subside when the offending agent is reduced or removed. Anxiety is frequent in untreated PD patients, and L-dopa does not appear to account for the extent of anxiety symptoms in treated patients. Nevertheless, symptoms ranging from mild jitteriness to panic attacks have been reported to occur in patients without anxiety prior to treatment, and panic attacks may not necessarily correlate with general levels of anxiety during treatment (Vazquez et al. 1993). Dopaminergic agents are the most frequent anxiety-inducing agents and may directly cause or worsen anxiety. Anxiety is common during “off” periods, when blood dopamine levels are rapidly decreasing. Finally, patients with PD may experience akathisia, a symptom that should be differentiated from drug-induced anxiety. Increased libido regularly occurs in patients treated with dopaminergic agents. In a small minority of patients, hypersexuality occurs and can result in increased masturbation, extramarital affairs, and paraphilic behavior such as sadomasochism, pedophilia, voyeurism, exhibitionism, scatological letter writing, and pederastic and rape fantasies. This complication occurs in 0.9%–3.0% of patients receiving L-dopa (Goodwin 1971; Lesser et al. 1979) and is more common in men with early-onset PD. Diminished prolactin levels are associated with dopaminergic therapy and may be involved in increased libido. Sleep disturbance is more common in patients with drug-related hallucinosis, delusions, confusional states, or depression than in those without these conditions. Vivid dreams and nightmares may be associated with dopaminergic agents, as may sleep architecture disturbances, including diminished stage III and stage IV with multiple arousals and awakenings (Emser et al. 1988).
Neurological Management Dopamine Agents The principal therapeutic modalities useful in the treatment of idiopathic PD and other parkinsonian syndromes caused by structural brain changes are dopamine precursor therapy and administration
Parkinson’s Disease
55
of dopamine receptor agonists. Dopamine does not cross the blood– brain barrier, but L-dopa, the biochemical precursor of dopamine, readily enters the brain through active-transport mechanisms. Coadministration of L-dopa/carbidopa results in higher brain levels of dopamine and limits the side effects produced by peripheral L-dopa catabolism. Potential central nervous system side effects of L-dopa therapy include chorea, tics, vivid dreams and nightmares, hallucinations, delusions, and confusional states. Early responses to dopamine therapy are often dramatic, with many PD patients having nearly complete resolution of symptoms. In contrast, people with non-PD causes of parkinsonism may respond poorly or not at all. Response failure and motor fluctuations may become apparent with prolonged therapy. For this reason, L-dopa therapy should be delayed until the disability begins to interfere with daily function. Precursor therapy depends on the integrity of at least a portion of the normal neuronal population of the substantia nigra to metabolize L-dopa to dopamine and transport the product to the synaptic terminals in the striatum. When the functioning cell population is too small, precursor therapy is ineffective, and other means of stimulating striatal receptors must be found. Bromocriptine (Parlodel), an ergot derivative, is a direct dopamine receptor agonist that is used in conjunction with L-dopa and may continue to provide relief of parkinsonism after the beneficial effects of L-dopa have been exhausted. Pergolide (Permax), a semisynthetic ergoline dopamine agonist, is 10 times more potent than bromocriptine. Ergots may also be effective for non-PD causes of parkinsonism. Dopamine agonist therapy may also be used early in the course of PD in order to delay introduction of L-dopa. Two recently approved D2-specific receptor agonists, ropinirole (Requip) and pramipexole (Mirapex), have fewer side effects than the nonspecific dopamine agonists bromocriptine and pergolide. These newer agents are effective in early (Adler et al. 1997; Shannon et al. 1997) and late PD, and they may be more effective than bromocriptine (Guttman 1997; Korczyn et al. 1998). Pramipexole may also have antidepressant properties (Maj et al. 1997).
56
Psychiatric Management in Neurological Disease
Monoamine Oxidase Type B Inhibitors Selegiline (L-deprenyl, Eldepryl) selectively inhibits monoamine oxidase type B (MAO-B) at low doses and may slow deterioration, reduce the amount of L-dopa required for symptomatic relief, and delay the need for L-dopa by 6–9 months (Olanow et al. 1995; Parkinson’s Study Group 1993). Selegiline’s effect may be due to catecholamine-mediated symptomatic relief, or it could confer neuroprotection through its antioxidant effect. It is recommended that all newly diagnosed PD patients be treated with 5 mg of selegiline twice daily (morning and noon) and that L-dopa be added when symptoms become more pronounced. The major side effect of selegiline is insomnia; for this reason, it is often given in the morning (5 mg) and at noon (5 mg). The 10-mg daily dose should not be exceeded, because selegiline loses its selectivity for MAO-B at higher doses.
Catechol-O-Methyltransferase Inhibitor Tolcapone (Tasmar) is a recently approved catechol-O-methyltransferase (COMT)–inhibiting medication for the treatment of PD that works by slowing the peripheral metabolism of L-dopa and reducing the wide fluctuations in blood level. The “wearing-off” phenomenon, which occurs in 50% of patients after 2–5 years of L-dopa therapy, is reduced by this medication. Also, less L-dopa is needed, and there is significant improvement in motor function and performance of activities of daily living (Waters et al. 1997).
Anticholinergic Agents and Amantadine Anticholinergic agents such as trihexyphenidyl (Artane) and benztropine (Cogentin) improve tremor, rigidity, and L-dopa–induced dystonia but have little effect on akinesia. They must be started at low doses and increased slowly to minimize dry mouth, urinary hesitancy, constipation, blurred vision, memory loss, confusion, disorientation, insomnia, and sedation. Amantadine has both dopaminergic and anticholinergic properties and can improve all symptoms of PD, although the effect may decline in 1–3 months.
Parkinson’s Disease
57
Anticholinergics and amantadine may be useful as adjunctive agents in the treatment of PD, but they are rarely sufficiently efficacious to be used alone (Gancher 1992).
Surgical Therapy Four surgical procedures may play increasingly larger roles in the therapy of PD. Pallidotomy (ventroposterolateral globus pallidus lesion) improves most PD symptoms, including bradykinesia, tremor, and L-dopa–induced dyskinesias. Thalamotomy (ventrolateral thalamic nucleus lesion) is effective primarily in reducing tremor. Both pallidotomy and thalamotomy carry a risk of damage to descending motor fibers, which currently restricts their bilateral use (Burchiel 1995). Electrical stimulation of the thalamus is most effective for tremor (Benabid et al. 1996); stimulation of the pallidum (Siegfried and Lippitz 1994) or of the subthalamic nucleus (Pollak et al. 1996) is effective for bradykinesia and rigidity. Neural grafts of fetal mesencephalic dopamine-producing cells into denervated striatum has proven successful in reducing akinesia but currently is still an experimental treatment (Barinaga 1995; Olanow et al. 1994).
Psychiatric Management The American Parkinson’s Disease Association (APDA; 60 Bay Street, Suite 401, Staten Island, NY 10301, 718-981-8001, 1-800-223-2732) has 47 Information and Referral Centers, 80 chapters, and more than 350 support groups located throughout the United States. They can help with referrals to neurologists, therapists, social workers, lawyers, and financial consultants, and many of the local groups offer patient education and peer support.
Treatment of Dementia Cognitive symptoms in PD may be partially improved early in the course of the illness by L-dopa therapy or by treatment of depression. L-dopa produces nonspecific arousal and may improve the performance of cognitive tasks that require effort. Depression in PD is associated with memory, visuospatial (Troster et al. 1995a), and executive function impairment (Cummings 1992). Later in the course of PD,
58
Psychiatric Management in Neurological Disease
Lewy body dementia or Alzheimer’s disease may emerge, and new treatments for the cognitive symptoms in Alzheimer’s disease— including cholinesterase inhibitors (tacrine and donepezil), antiinflammatory agents, estrogen replacement therapy, and vitamin E—may be effective. Patients with Lewy body dementia have been shown to have lower neocortical choline acetyltransferase levels than patients with Alzheimer’s disease, and these patients may respond particularly well to cholinomimetic therapy (Perry et al. 1994). Tacrine (Cognex) requires a liver function test every other week while doses are increasing. The starting dose is 10 mg qid for 6 weeks with an increase of 40 mg/day every 6 weeks up to a maximum dose of 160 mg/day. Donepezil (Aricept) does not require monitoring of liver functions. Patients may be started on 5 mg/day with an increase to 10 mg/day after 4 weeks; no further increase is required. The various cholinesterase inhibitors appear to have approximately equal efficacy, and all produce gastrointestinal side effects.
Treatment of Apathy Apathy is a common neuropsychiatric syndrome in PD. Although a variety of empirical treatment options are available, there have been no controlled trials that target apathy (Marin et al. 1995). The first step is to diagnose and treat depression or systemic illnesses such as hypothyroidism, if present. Next, if neuroleptics are in use, the dosages should be reduced or the patient should be switched to clozapine (Clozaril) or olanzapine (Zyprexa). Apathy is theorized to result from dysfunction in the basal forebrain mesolimbic and mesocortical dopaminergic system; therefore, any medication that improves dopaminergic activity may improve apathy. If severe apathy persists after motor symptoms have resolved, it may be reasonable to cautiously increase dopaminergic agents, taking care to avoid precipitating psychotic symptoms. L-dopa, bromocriptine, pergolide, ropinirole, and pramipexole are the most potent dopaminergic agents; other agents with dopaminergic activity include methylphenidate (Ritalin), amantadine (Symmetrel), and bupropion (Wellbutrin). Methylphenidate may be used specifically for treatment of apathy and can be started at 5 mg qam. It may be increased as tolerated up to 10 mg bid (morning and noon).
Parkinson’s Disease
59
Treatment of Psychosis Psychotic symptoms such as visual hallucinations and persecutory delusions in a patient with PD may be manifestations of delirium caused by anticholinergic agents, overmedication with dopaminergic agents, or underlying systemic disease such as urinary tract or respiratory system infection. Discontinuation of the offending agent or treatment of the underlying disease process usually resolves the psychotic symptoms, although they may persist for days or weeks. Psychotic symptoms are rare in the course of untreated PD; when psychotic symptoms occur prior to initiation of treatment, they may suggest the existence of Lewy body dementia. If a dementia is present, the patient should receive a trial of a cholinesterase inhibitor. Psychotic symptoms are commonly produced in a clear sensorium by dopaminergic agents, and these medications should be minimized as a first step in treating psychosis in PD. Traditional neuroleptics such as haloperidol (Haldol) and newer agents such as risperidone (Risperdal) frequently fail to ameliorate psychosis without producing significant extrapyramidal symptoms, but the atypical antipsychotics clozapine (Clozaril) and olanzapine (Zyprexa) have been shown to be both safe and effective in treating PD. These agents have relatively little impact on the nigrostriatal portion of the dopaminergic system, which may explain their lack of extrapyramidal effects. Hypotension is a concern, and clozapine should be started at 6.25 mg/day and increased as tolerated up to the lowest effective dose, usually under 100 mg/day in PD. Also, the risk of agranulocytosis increases with age, and patients must have weekly hematological monitoring. Olanzapine does not have these side effects.
Treatment of Depressive Mood Disorders Anti-PD medications have variable effects on depressive symptoms. Occasionally, an increase in L-dopa dosage or addition of an agonist may alleviate mild depressive symptoms. Amantadine and anticholinergics may also have a mild stimulatory effect. For moderate or severe depressions, tricyclic antidepressants or bupropion may be used. In the early stages of PD, imipramine (Tofranil) and desipra-
60
Psychiatric Management in Neurological Disease
mine (Norpramin) have been shown to improve rigidity and tremor, possibly as a result of these agents’ anticholinergic effects (Laitinen 1969; Strang 1965); in one study, 10 of 20 patients on bupropion experienced at least 30% improvement in their parkinsonism, possibly due to a dopaminergic effect (Goetz et al. 1984). Selegiline is not approved for treatment of depression in the United States, and the 10-mg dose does not appear to have an antidepressant effect in PD (Factor et al. 1995; Silver and Yudofsky 1992). Antidepressant medications have been used effectively in the treatment of depression in PD and should be tried after adjustments in anti-PD agents have failed or when the depression includes symptoms such as anhedonia, guilt, and suicidal ideation. Nortriptyline (Pamelor) and desipramine are relatively safe and effective, provided they are initiated at low doses (10–20 mg/day) to avoid potentiating the hypotensive effect of L-dopa. These agents can be titrated up to the usual therapeutic dosages over 1–2 weeks, although adequate blood levels (nortriptyline at 50–150 ng/mL, desipramine at >125 ng/mL; drawn 10–14 hours after last dose) can frequently be achieved in the elderly with doses as low as 50 mg/day. Nortriptyline and desipramine can also be effective for comorbid anxiety, especially panic disorder. Bupropion can be started at 75–100 mg/day and increased up to 100 mg tid. Other antidepressants have not been well studied in PD patients. Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine (Prozac) and sertraline (Zoloft), are free of hypotensive and anticholinergic effects, and serotonin systems theoretically may play a significant role in the pathophysiology of depression in PD. Paroxetine (Paxil), another SSRI with no hypotensive effect, might also be a good choice because of its antianxiety and mild anticholinergic effects. Although fluoxetine has been reported to cause extrapyramidal side effects in a few patients, a recent series of 13 patients experienced no worsening of their parkinsonism with this agent (Montastruc et al. 1995). In elderly patients, fluoxetine, sertraline, and paroxetine should be started at 10 mg, 25 mg, and 10 mg, respectively, and the dose may be doubled after 1 week. Selegiline must be discontinued at least 14 days prior to initiation of antidepressant therapy, because adverse reactions can occur at the 10-mg dose. Antidepressant medications that are nonselective
Parkinson’s Disease
61
inhibitors of MAO are contraindicated because of the potential for an adverse interaction with L-dopa. Lithium (Eskalith) can be used to augment antidepressant therapy and may potentiate both the effects and the side effects of L-dopa. In the elderly, lithium should be started at 150 mg/day and gradually titrated to a therapeutic dose because it has been reported to occasionally produce extrapyramidal symptoms (Cummings 1992; Koller and Megaffin 1994; Silver and Yudofsky 1992). Electroconvulsive therapy (ECT) remains the safest and most effective treatment for depression in all age groups. About half of PD patients treated with ECT will experience a significant but usually temporary reduction in their motor symptoms independently of the effect on their psychiatric symptoms (Faber and Trimble 1991). Individual and group psychotherapy can be very helpful and should address at least six goals. First, patients should be educated about the course of the illness in order to ameliorate the effect of unexpected deteriorations. Second, strategies must be developed to reduce disability in the face of worsening motor symptoms. Third, social support should be maximized. Fourth, patients should be helped to develop healthy strategies for coping with stress. Fifth, they may need to work through feelings of worthlessness and be helped to appreciate that the illness is not their fault. Finally, caretakers should always be adequately evaluated for psychiatric morbidity, as PD patients usually become emotionally and physically dependent on their caretakers.
Treatment of Anxiety Disorders Anxiety in the elderly may be caused by infections of the urinary or respiratory systems or by emphysema, heart disease, thyroid disorder, arthritic pain, constipation, or other systemic disorders. Medications that frequently produce anxiety include anti-PD agents, thyroid replacement, steroids, and sympathomimetics such as pseudoephedrine and beta-agonists. Withdrawal from alcohol or sedatives and side effects from neuroleptics may also produce anxiety. Underlying systemic conditions should be diagnosed and treated first and the doses of anti-PD agents then adjusted. If anxiety symptoms persist, pharmacological and psychological
62
Psychiatric Management in Neurological Disease
approaches should be employed. Most antidepressants are effective for panic disorder and are a logical choice because of the frequent comorbidity of panic disorder with depression, but benzodiazepines may be required to control the initial stimulatory effects that antidepressants can produce. Benzodiazepines must be administered with caution, because they frequently cause impairments in gait, balance, and cognition that may lead to falls in the elderly. Also, rebound anxiety can occur with short-acting agents such as lorazepam (Ativan) and may require tid or qid dosing. Clonazepam (Klonopin) at 0.5 mg bid is usually adequate to control anxiety in the elderly and has a gradual onset of action with a steady plasma level over 24 hours; however, strict vigilance for drug accumulation and attendant side effects is critical in the elderly. Although buspirone (BuSpar) at 5 mg tid may be helpful for some patients, it requires several weeks to become effective. Buspirone should be given in three divided doses daily; the dose may be increased up to 40 mg/day as tolerated. More data regarding the effectiveness of buspirone is needed, however, because the drug was found to be without effect on anxiety in a small sample of PD patients (Ludwig et al. 1986) The main goal of psychological intervention is to help patients cope with stressful social situations. This goal can be achieved through either individual or group therapy, including relaxation techniques, cognitive restructuring, situational behavioral analysis, and training in social skills, with interventions specifically adapted to the disease (Ellgring et al. 1993).
Treatment of Sexual Disorders Brown et al. (1990) concluded that there is no simple approach to managing sexual disorders in patients with PD. As detailed above, a variety of factors have been implicated in these disorders, including illness severity, autonomic dysfunction, depression, and treatmentrelated side effects. A range of disease, psychological, social, and marital variables were evident in the study of Brown et al. (1990), and the authors advocated a multimodal therapeutic approach. Additional treatment data in PD are lacking. Absent these data, sexual dysfunction may be managed in the same manner as in primary sexual disorders.
Parkinson’s Disease
63
Treatment of Medication-Induced Psychiatric Disorders Confusional states are best managed by treating underlying infections and minimizing all medications, especially anticholinergic agents. Mania or hypomania caused by dopaminergic therapy typically subsides when drug dosage is reduced; some patients may require management on small doses of L-dopa/carbidopa alone without other agents to minimize manic behavior. Lithium administration benefits some patients but not others (Van Woert et al. 1971). Hypersexuality caused by dopaminergic therapy usually decreases with dose reduction (Uitti et al. 1989). If dose reduction is not possible, low-potency neuroleptics or antitestosterone agents may be tried (Factor et al. 1995), although there are no guidelines for these treatments. Sleep disturbances require assessment for a confusional state, reduction of dopaminergic therapy, or treatment for depression. Persistent sleep disturbance may be treated with the triazolopyridine antidepressant trazodone (Desyrel) (50 mg qhs), with a short-acting benzodiazepine such as temazepam (Restoril), or with zolpidem (Ambien).
Treatment of Psychiatric Consequences of Surgical Therapy Subcortical surgical lesions may produce psychiatric symptoms, but there are few reports in the literature of postoperative psychiatric morbidity. Masterman and colleagues at UCLA (personal communication) examined 20 patients at 3-month follow-up postpallidotomy and found essentially no change in depression, anxiety, psychosis, or other psychiatric symptoms. In contrast, Rossitch et al. (1988) observed cognitive and speech changes in patients who had undergone thalamotomy. Similar problems may be encountered with chronic electrical stimulation of subcortical structures but can be reduced with adjustment of frequency intensity (Benabid et al. 1996). Human fetal mesencephalic tissue transplantation appears to have few long-term psychiatric sequelae (Price et al. 1995), although psychotic features are common in the early postoperative period. These procedures are currently receiving intense investigation, and their impact on psychiatric morbidity will be better understood as they are used more widely.
64
Psychiatric Management in Neurological Disease
Summary PD is a progressive and disabling illness of the brain that affects motor, cognitive, and emotional function. Degenerative changes occur in subcortical structures where parallel circuits that modulate these three brain activities are in close proximity. Dopaminergic agents may improve cognitive speed, and cholinergic therapy is effective for both Alzheimer’s disease and Lewy body dementia. Depression, anxiety disorders, and apathy are frequent in PD. These symptoms are independent of anti-PD treatment and appear to respond to pharmacotherapy and psychotherapy; however, very few treatment studies have been done. Psychosis is generally associated with dopaminergic or anticholinergic therapy but may herald the onset of dementia. If psychosis persists after dosage adjustment, it is very difficult to treat but may respond to low doses of clozapine or olanzapine. PD affects its victims over the course of many years and causes considerable psychiatric morbidity; therefore, psychiatric evaluation and treatment are critical elements to the proper care of patients with this relentless illness.
References Aarsland D, Tandberg E, Larsen JP, et al: Frequency of dementia in Parkinson disease. Arch Neurol 53:538–542, 1996 Adler CH, Sethi KD, Hauser RA, et al: Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49:393– 399, 1997 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Barbeau A: Parkinson’s disease: clinical features and etiopathology, in Handbook of Clinical Neurology, Vol 5 (49): Extrapyramidal Disorders. Edited by Vinken PJ, Bruyn GW, Klawans HL. New York, Elsevier Science Publishers, 1986, pp 87–152 Barinaga M: Researchers broaden the attack on Parkinson’s disease (news). Science 267:455–456, 1995 Beck BJ: Neuropsychiatric manifestations of diffuse Lewy body disease. J Geriatr Psychiatry Neurol 8:189–196, 1995
Parkinson’s Disease
65
Benabid AL, Pollak P, Gao D, et al: Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 84:203–214, 1996 Brown R, Jahanshahi M: Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 65:61–84, 1995 Brown RG, MacCarthy B, Gotham AM, et al: Depression and disability in Parkinson’s disease: a follow-up study of 132 cases. Psychol Med 18:49– 55, 1988 Brown RG, Jahanshahi M, Quinn N, et al: Sexual function in patients with Parkinson’s disease and their partners. J Neurol Neurosurg Psychiatry 53:480–486, 1990 Burchiel KJ: Thalamotomy for movement disorders. Neurosurg Clin N Am 6:55–71, 1995 Celesia CG, Wanamaker WM: Psychiatric disturbances in Parkinson’s disease. Diseases of the Nervous System 33:577–583, 1972 Cummings JL: Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc 39:708–716, 1991 Cummings JL: Depression and Parkinson’s disease: a review. Am J Psychiatry 149:443–454, 1992 Cummings JL, Benson DF: Dementia: A Clinical Approach, 2nd Edition. Boston, MA, Butterworth-Heinemann, 1992 Cummings JL, Trimble MR: Concise Guide to Neuropsychiatry and Behavioral Neurology. Washington, DC, American Psychiatric Press, 1995 DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281–285, 1990 de Smet Y, Ruberg M, Serdaru M, et al: Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161–1164, 1982 Di Rocco A, Molinari SP, Kollmeier B, et al: Parkinson’s disease: progression and mortality in the L-dopa era. Adv Neurol 69:3–11, 1996 Ellgring H, Seiler S, Perleth B, et al: Psychosocial aspects of Parkinson’s disease. Neurology 43 (12 suppl 6):S41–S44, 1993 Emser W, Brenner M, Stober T, et al: Changes in nocturnal sleep in Huntington’s and Parkinson’s diseases. J Neurol 235:177–179, 1988 Faber R, Trimble MR: Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov Disord 6:293–303, 1991 Factor SA, Molho ES, Podskalny GD, et al: Parkinson’s disease: druginduced psychiatric states. Adv Neurol 65:115–138, 1995 Fischer P, Danielczuk W, Simanyi M, et al: Dopaminergic psychosis in advanced Parkinson’s disease. Adv Neurol 53:391–397, 1990
66
Psychiatric Management in Neurological Disease
Gancher ST: Pharmacology of Parkinson’s disease, in Parkinson’s Disease: Neurobehavioral Aspects. Edited by Huber SJ, Cummings JL. New York, Oxford University Press, 1992, pp 273–287 Glantz RH, Bieliauskas L, Paleologos N: Behavioral indicators of hallucinosis in levodopa treated Parkinson’s disease. Adv Neurol 45:417–420, 1987 Goetz CG, Tanner CM, Klawans HL: Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 139:494–497, 1982 Goetz CG, Tanner CM, Klawans HL: Bupropion in Parkinson’s disease. Neurology 34:1092–1094, 1984 Goodwin FK: Psychiatric side effects of levodopa in man. JAMA 218: 1915–1920, 1971 Growdon JH, Corkin S, Rosen TJ: Distinctive aspects of cognitive dysfunction in Parkinson’s disease. Adv Neurol 53:365–376, 1990 Guttman M: Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology 49:1060–1065, 1997 Hagell P, Odin P, Vinge E: Pregnancy in Parkinson’s disease: a review of the literature and a case report. Mov Disord 13:34–38, 1998 Henderson R, Kurlan R, Kersun JM, et al: Preliminary examination of the co-morbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:257–264, 1992 Hofman A, Collette HJ, Bartelds AI: Incidence and risk factors of Parkinson’s disease in the Netherlands. Neuroepidemiology 8:296–299, 1989 Huber SJ, Shuttleworth EC, Paulson GW: Dementia in Parkinson’s disease. Arch Neurol 43:987–990, 1986 Hubble JP, Cao T, Hassanein RE, et al: Risk factors for Parkinson’s disease. Neurology 43:1693–1697, 1993 Jankovic J, McDermott M, Carter J, et al: Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40:1529–1534, 1990 Klawans HL: Levodopa-induced psychosis. Psychiatr Ann 8:447–451, 1978 Koller WC, Megaffin BB: Parkinson’s disease and parkinsonism, in The American Psychiatric Press Textbook of Geriatric Neuropsychiatry. Edited by Coffey CE, Cummings JL. Washington, DC, American Psychiatric Press, 1994, pp 433–456 Koller WC, Vetere-Overfield B, Williamson A, et al: Sexual dysfunction in Parkinson’s disease. Clin Neuropharmacol 13:461–463, 1990
Parkinson’s Disease
67
Korczyn AD, Brooks DJ, Brunt ER, et al: Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study (053 Study Group). Mov Disord 13:46–51, 1998 Laitinen L: Desipramine in treatment of Parkinson’s disease: a placebocontrolled study. Acta Neurol Scand 45:109–113, 1969 Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism (letter). Am J Psychiatry 148:274, 1991 Lauterbach EC, Duvoisin RC: The locus coeruleus and anxiety disorders in demented and nondemented familial parkinsonisms (letter). Am J Psychiatry 150:994, 1993 Lesser RP, Fahn S, Snider SR, et al: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29:1253–1260, 1979 Lipe H, Longstreth WT Jr, Bird TD, et al: Sexual function in married men with Parkinson’s disease compared to married men with arthritis. Neurology 40:1347–1349, 1990 Ludwig CL, Weinberger DR, Bruno G, et al: Buspirone, Parkinson’s disease and the locus ceruleus. Clin Neuropharmacol 9:373–378, 1986 MacCarthy B, Brown R: Psychosocial factors in Parkinson’s disease. Br J Clin Psychol 28:41–52, 1989 Maj J, Rogóz Z, Skuza G, et al: Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 104:525–533, 1997 Marder K, Tang MX, Mejia H, et al: Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology 47:155– 160, 1996 Marin RS, Fogel BS, Hawkins J, et al: Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 7:23–30, 1995 Martilla RJ: Epidemiology, in Handbook of Parkinson’s disease. Edited by Koller WC. New York, Marcel Dekker, 1987, pp 35–50 Mayberg HS, Soloman DH: Depression in Parkinson’s disease: a biochemical and organic viewpoint. Adv Neurol 65:49–60, 1995 Mayeux R, Stern Y, Rosen J, et al: Depression, intellectual impairment and Parkinson disease. Neurology 31:645–650, 1981 Mayeux R, Stern Y, Sano M, et al: Clinical and biochemical correlates of bradyphrenia in Parkinson’s disease. Neurology 37:1130–1134, 1987 Mayeux R, Stern Y, Sano M, et al: The relationship of serotonin to depression in Parkinson’s disease. Mov Disord 3:237–244, 1988 Menza MA, Robertson-Hoffman DE, Bonapace AS: Parkinson’s disease and anxiety: co-morbidity with depression. Biol Psychiatry 34:465–470, 1993
68
Psychiatric Management in Neurological Disease
Montastruc JL, Fabre N, Blin O, et al: Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 10:355–357, 1995 Olanow CW, Marsden CD, Lang AE, et al: The role of surgery in Parkinson’s disease management. Neurology 44 (3 suppl 1):S17–S20, 1994 Olanow CW, Hauser RA, Gauger L, et al: The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38:771– 777, 1995 Olichney JM, Galasko D, Corey-Bloom J, et al: The spectrum of diseases with diffuse Lewy bodies. Adv Neurol 65:159–170, 1995 Parent A, Hazrati LN: Functional anatomy of the basal ganglia, II: the place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 20:128–154, 1995 Parkinson’s Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183, 1993 Perry EK, McKeith I, Thompson P, et al: Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci 640: 197–202, 1991 Perry EK, Haroutunian V, Davis KL, et al: Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease. Neuroreport 5:747–749, 1994 Pollak P, Benabid AL, Limousin P, et al: Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. Adv Neurol 69:591–594, 1996 Price LH, Spencer DD, Marek KL, et al: Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson’s disease. Biol Psychiatry 38:498–505, 1995 Rogers D, Lees AJ, Smith E, et al: Bradyphrenia in Parkinson’s disease and psychomotor retardation in depressive illness: an experimental study. Brain 110:761–776, 1987 Rossitch E Jr, Zeidman SM, Nashold BS Jr, et al: Evaluation of memory and language function pre- and postthalamotomy with an attempt to define those patients at risk for postoperative dysfunction. Surg Neurol 29:11–16, 1988 Saint-Cyr JA, Taylor AE, Lang AE: Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology 43 (12 suppl 6):S47–S52, 1993 Saint-Cyr JA, Taylor AE, Nicholson K: Behavior and the basal ganglia. Adv Neurol 65:1–28, 1995
Parkinson’s Disease
69
Schiffer RB, Kurlan R, Rubin A, et al: Evidence for atypical depression in Parkinson’s disease. Am J Psychiatry 145:1020–1022, 1988 Shannon KM, Bennett JP, Friedman JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 49:724–728, 1997 Siegfried J, Lippitz B: Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 35:1126–1130, 1994 Silver JM, Yudofsky SC: Drug treatment of depression in Parkinson’s disease, in Parkinson’s Disease: Neurobehavioral Aspects. Edited by Huber SJ, Cummings JL. New York, Oxford University Press, 1992, pp 240–254 Snow BJ: Fluorodopa PET scanning in Parkinson’s disease. Adv Neurol 69:449–457, 1996 Starkstein SE, Rabins PV, Berthier ML, et al: Dementia of depression among patients with neurological disorders and functional depression. J Neuropsychiatry Clin Neurosci 1:263–268, 1989 Starkstein SE, Preziosi TJ, Bolduc PL, et al: Depression in Parkinson’s disease. J Nerv Ment Dis 178:27–31, 1990a Starkstein SE, Preziosi TJ, Forrester AW, et al: Specificity of affective and autonomic symptoms of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 53:869–873, 1990b Starkstein SE, Mayberg HS, Leiguarda R, et al: A prospective longitudinal study of depression, cognitive decline and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 55: 377–382, 1992a Starkstein SE, Mayberg HS, Preziosi TJ, et al: Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:134–139, 1992b Stein MB, Heuser IJ, Juncos JL, et al: Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry 147:217–220, 1990 Strang RR: Imipramine in treatment of parkinsonism: a double-blind placebo study. BMJ 2:33–34, 1965 Tandberg E, Larsen JP, Aarsland D, et al: The occurrence of depression in Parkinson’s disease: a community-based study. Arch Neurol 53:175– 179, 1996 Tanner CM, Goldman SM: Epidemiology of Parkinson’s disease. Neurol Clin 14:317–335, 1996
70
Psychiatric Management in Neurological Disease
Troster AI, Paolo AM, Lyons KE, et al: The influence of depression on cognition in Parkinson’s disease: a pattern of impairment distinguishable from Alzheimer’s disease. Neurology 45:672–676, 1995a Troster AI, Stalp MA, Paolo AM, et al: Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol 52: 1164–1169, 1995b Uitti RJ, Tanner CM, Rajput AH, et al: Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12:375–383, 1989 Van Woert MH, Ambani LM, Weintraub MI: Manic behavior and levodopa (letter). N Engl J Med 285:1326, 1971 Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, et al: “Panic attacks” in Parkinson’s disease: a long-term complication of levodopa therapy. Acta Neurol Scand 87:14–18, 1993 Waters CH, Kurth M, Bailey P, et al: Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 49:665–671, 1997
C H A P T E R
3
Huntington’s Disease Neal G. Ranen, M.D.
H
untington’s disease (HD) is an autosomal dominant inherited degenerative neuropsychiatric disorder caused by an expanded trinucleotide repeat (CAG) in a gene (IT15) on chromosome 4. The clinical features of HD can be thought of as a triad of motor, cognitive, and noncognitive psychiatric disturbances (McHugh and Folstein 1975). Although this triad is always present, there is considerable variability of clinical features among different patients. There is no currently available treatment that can halt or reverse the inexorable progression of HD. Furthermore, much of what is recommended with regard to the symptomatic treatment of HD has been arrived at by consensus of experts in the field rather than by controlled trials (Ranen et al. 1993). This is especially true for treatment of the psychiatric aspects of the disease. Nonetheless, rational treatment of specific psychiatric and motor symptoms can reduce unnecessary morbidity, which in turn can improve the quality of life of patients with HD.
Prevalence The prevalence of HD has been estimated to be in the range of 4.1–7.5 per 100,000 (Folstein et al. 1987). HD is seen throughout the world but is rare in Finland and Japan (Harper 1992). There are a few isolated populations of Western European origin that have a much higher prevalence of the disease, such as the much-studied HD population of Lake Maracaibo, Vene71
72
Psychiatric Management in Neurological Disease
zuela (Gusella et al. 1983; Penney et al. 1990; Wexler et al. 1987), where the prevalence of HD is estimated at 700 per 100,000.
Clinical Recognition and Neurological Presentation Clinical Course Symptoms begin insidiously (Penney et al. 1990), with onset typically between the ages of 35 and 50 years, but onset may occur anytime from childhood to old age (Folstein et al. 1987). The differential diagnosis of chorea is presented in Table 3–1. Adult-onset HD can be roughly divided into three stages. Early in the disease, manifestations include subtle changes in coordination, perhaps some minor involuntary movements, difficulty thinking through problems, and, often, a depressed or irritable mood. In the middle stage, chorea usually becomes prominent, and difficulty with voluntary motor activities will be more evident, with worsening dysarthria and dysphagia. As cognitive deficits increase, the paTable 3–1.
Differential diagnosis of chorea
Huntington’s disease Dentatorubro-pallidoluysian atrophy (DRPLA) Tardive dyskinesia Side effects of medications (e.g., L-dopa–induced dyskinesia) Neuroacanthocytosis Sydenham’s chorea Spinocerebellar ataxias Benign familial chorea Wilson’s disease (hepatolenticular degeneration) Paroxysmal choreoathetosis Senile chorea (diagnosis of exclusion) Stroke Thyrotoxicosis Closed head injury Infectious disease (AIDS/toxoplasmosis) Note.
AIDS = acquired immunodeficiency syndrome.
Huntington’s Disease
73
tient will be unable to hold a job or carry out most household responsibilities. Patients with late-stage disease may have severe chorea but are more often rigid and bradykinetic. They are largely nonverbal and bedridden, with a more global dementia, although they retain a significant degree of comprehension (Ranen et al. 1993). Psychiatric disorders may appear at any time during the course of the disease, even years before motor symptoms develop (Folstein et al. 1983). Death occurs an average of about 15 years after symptoms start, although some patients die early from falls or suicide, and others survive for 30–40 years, particularly if a feeding tube is placed (Folstein 1989).
The Movement Disorder The movement disorder in HD has two clinical components: a disturbance of involuntary movement and a disturbance of voluntary movement. In addition to chorea (or choreoathetosis), which consists of irregular jerky or writhing movements, other disturbances of involuntary movement consist of myoclonus and seizures. Myoclonus is more common in juvenile-onset HD and in the later stages of adult-onset HD, although it can be seen occasionally in less severely affected adult-onset patients. Epilepsy is also seen most commonly in juvenile-onset HD, but it is occasionally seen in adults with advanced disease. Disturbances of voluntary movement include abnormal eye movements (abnormal saccades and pursuit, among others); uncoordinated, arrhythmic, and slow fine motor movements; and dysphagia, dysarthria, bradykinesia, clumsiness, rigidity, and gait disturbance. In contrast to chorea, which often plateaus and even wanes in the later stages of the disease, disturbances in voluntary movement progress more steadily (Folstein 1989; Penney et al. 1990). The disturbance of voluntary movement is more highly correlated with functional disability than is the chorea (Brandt et al. 1984). The Quantified Neurologic Examination (QNE; Folstein et al. 1983) and the Unified Huntington’s Disease Rating Scale (Huntington Study Group 1996) have been developed as standardized measures of movement disorder in HD.
74
Psychiatric Management in Neurological Disease
Early patient complaints attributable to the motor disorder include clumsiness, difficulty with balance, and jerky movements or tremor. Patients may also note that they are dropping things, have difficulty typing, have noticed a change in their handwriting, have been tripping or stumbling more often, or have become aware that they are applying uneven pressure to the gas pedal in a car. In late-stage HD, patients are akinetic and largely nonverbal, with severe rigidity and joint contractures. At this point, they may have no involuntary movements except for occasional whole-body movements, resembling myoclonic jerks, when they are disturbed. Difficulties with swallowing commonly lead to death in HD, either directly from suffocation or aspiration or indirectly from starvation. HD that begins in childhood (i.e., juvenile-onset HD) often presents with a somewhat different set of signs and symptoms; for example, bradykinesia, rigidity, and dystonia (Van Dijk et al. 1986). Chorea may be completely absent. Involuntary movements may take the form of tremors, and seizures and myoclonus may occur. This rigid, akinetic form is termed the Westphal variant of HD.
Pathological Features Pathology The pathology of HD is restricted to the central nervous system, with selective neuronal vulnerability. Although the brains of patients with HD show some generalized atrophy, there is a particularly marked degeneration within the striatum (caudate and putamen) and in the deep layers of the cerebral cortex. Within the striatum, there is highly selective neuronal loss, with near-complete loss of medium spiny neurons and preservation of several classes of large interneurons. These striatal medium spiny neurons, which are GABAergic, project to the globus pallidus and receive glutamatergic inputs from the cerebral cortex and dopaminergic inputs from the substantia nigra (Albin et al. 1989). Severity of Huntington’s disease is rated with the Vonsattel score, which ranges from 0 to 4, with 4 representing the most severe degree of atrophy as determined by gross and microscopic examination (Vonsattel et al. 1985).
Huntington’s Disease
75
Much of the clinical presentation of HD can be appreciated in terms of the multiple frontal–subcortical circuits that unite specific regions of the frontal cortex with the basal ganglia and the thalamus and mediate motor activity, eye movements, and behavior (Alexander et al. 1986; Mega and Cummings 1994). Chorea can be appreciated as arising from a disturbance of the motor circuit, which has as its target the supplementary motor area; abnormal eye movements from a disturbance of the oculomotor circuit, which has as its target the frontal eye fields; dementia from a disturbance of the dorsolateral prefrontal cortex circuit, which is important in executive cognitive functions; irritability, disinhibition, and perhaps mania from a disturbance of the lateral orbitofrontal cortex circuit, which is tied to aspects of personality; and apathy from a disturbance of the anterior cingulate circuit, which is important in motivation.
Genetics and Theories of Pathogenesis HD demonstrates autosomal dominant transmission; homozygotes (i.e., individuals who have two copies of the mutated gene—an uncommon occurrence in HD) have no more severe disease than do heterozygotes (i.e., those who have one copy of the mutated gene) (Wexler et al. 1987). In 1983, the gene for HD was localized to the short arm of chromosome 4 (Gusella et al. 1983); 10 years later, the gene was isolated (Huntington’s Disease Collaborative Research Group 1993). The mutation causing HD is an expanded repeating sequence of three nucleotide base pairs, CAG, known as a trinucleotide or triplet repeat. Repeats in the range of 10–29 are normal, repeats of 30–36 are intermediate, and repeats of 37 and above are causative of HD (Duyao et al. 1993; Kremer et al. 1994). An expanded CAG repeat on IT15 is 100% specific and 98.8% sensitive for HD (Kremer et al. 1994). Some cases with signs and symptoms similar to HD but without the IT15 CAG expansion are thought to arise from as-yet-undefined genes (Andrew et al. 1994). Other such cases have been attributed to hysterical symptomatology (e.g., conversion reactions) (Ranen et al. 1997). The length of the trinucleotide repeat is highly correlated with age at onset of the disease (Duyao et al. 1993). Most of the correlation is accounted for by very long repeats. However, for fewer than 55 re-
76
Psychiatric Management in Neurological Disease
peats, which are most common, repeat length is a poor predictor of age at onset. Therefore, the utility of this correlation for individuals seeking presymptomatic genetic testing is limited. As with other triplet-repeat disorders, HD exhibits anticipation. Anticipation is the earlier onset of disease in successive generations within a pedigree. In HD, anticipation is a phenomenon of paternal transmission (Ranen et al. 1995; Ridley et al. 1988) and is associated with further expansion of the trinucleotide repeat when passed from father to child (Ranen et al. 1995). Study results vary as to whether the length of the repeat is associated with rate of progression, with some studies finding more rapid progression with longer repeats (Brandt et al. 1996) and others finding no such relationship (Kieburtz et al. 1994). The process by which the expanded trinucleotide repeat causes HD is unknown. It is known that the expanded CAG repeat is translated into the protein, named huntingtin, as a glutamine repeat (CAG codes for glutamine). The function of huntingtin is not known. Evidence to date suggests that the mutation results in a gain, rather than a loss, of function of the protein. This gain of function may be due to intensified or novel interactions with other proteins (Li et al. 1995). Basal ganglia pathophysiology in HD is depicted in Figure 1–2 in Chapter 1.
Neuroimaging The most striking finding from anatomic neuroimaging (computed tomography [CT] and magnetic resonance imaging [MRI]) of HD patients is striatal degeneration. However, this finding is often not seen early in the disease. With disease progression, ventricular dilatation (“boxcarring”) suggestive of caudate atrophy is seen on MRI. Using volumetric MRI measurements, Aylward et al. (1994) have demonstrated reduced basal ganglia size in presymptomatic, genepositive individuals. Mayberg et al. (1992) found that depression in HD is associated with frontal hypometabolism on positron-emission tomography (PET) scan.
Huntington’s Disease
77
Laboratory Investigation and Predictive Testing Results of controlled screening programs have been encouraging, with most individuals stating that they were relieved to know the results even if they were adverse (Brandt et al. 1989; Wiggins et al. 1992). A sense of relief regardless of whether the results revealed the presence or absence of the mutation may be due to reduced uncertainty. There have been a few case reports of dramatic adverse consequences of both positive and negative results (Wexler 1992). The International Huntington Association (IHA) and World Federation of Neurology (WFN) Research Group on Huntington’s Chorea have jointly developed guidelines for predictive testing (IHA–WFA Research Group on Huntington’s Chorea 1994). The guidelines include the concepts of full informed consent, presymptomatic counseling, face-to-face disclosure of results, and posttest counseling. A blood sample from the subject is all that is needed to test for the HD gene. The cost is usually about $400, and the test is available at several commercial and university laboratories. Predictive testing should be carried out at an approved center where patient and family anxiety can be best addressed, and where procedures are in place that follow the IHA recommendations. Family members’ questions about their genetic risk should be answered directly—a child of an affected parent has a 50% chance of inheriting the gene, and a grandchild has a 25% chance. It is helpful to express cautious optimism about the possibility that research developments will lead to specific treatments in the future. Despite the presence of guidelines, ethical questions will still arise. For example, should an individual whose grandparent was affected be tested if the parent, who is as yet unaffected, does not want to know his or her gene status? If that individual tests positive for the mutated gene, the parent will probably know that he or she has the mutated gene. A positive gene test does not indicate disease onset, only the likelihood that the disease will occur. Onset of disease remains a clinical diagnosis.
78
Psychiatric Management in Neurological Disease
Psychiatric Manifestations Although the cognitive disorder is well known, in his original manuscript in 1872 George Huntington noted that “the tendency to insanity, and sometimes that form of insanity which leads to suicide, is marked.” The most common noncognitive psychiatric disturbances in HD are mood disorders (depressive and bipolar disorders), irritability, and apathy (Folstein et al. 1987). Psychotic symptoms occur less frequently. Mood disorders have a variety of behavioral manifestations, including aggressive outbursts, impulsiveness, social withdrawal, and suicidal behavior.
Cognitive Impairment and Dementia The cognitive disorder in HD has less-striking aphasia and agnosia than in “cortical dementias” (e.g., Alzheimer’s disease), consistent with the features of “subcortical dementia” (McHugh and Folstein 1975). This is coded in DSM-IV (American Psychiatric Association 1994) as dementia due to HD. Initial cognitive changes involve loss of cognitive speed and flexibility (Mayeux et al. 1986). Patients may have trouble changing from one task to another or keeping track of serial tasks, and thus may need more time to think through a problem. Such cognitive inefficiency may result in patients having difficulty maintaining an accurate checkbook or accounts, trouble in keeping up with assigned work or school load, diminished concentration, and decreased quality of work. Such early HD patients usually perform within the normal range on IQ tests and may be impaired only on neuropsychological testing that requires speed, concentration, mental flexibility, and new verbal learning (Brandt 1994). On the Mini-Mental State Exam (MMSE; Folstein et al. 1975), the Serial Sevens Task (serially subtracting 7, starting from 100) is typically the first task affected (Brandt et al. 1988). Compared with Alzheimer’s disease patients, patients with HD appear to have a disturbance of retrieval rather than of storage of memories, and therefore they are more apt to recognize words from a list they were asked to remember or to respond to cues to help them remember (Brandt et al. 1992; Butters et al. 1986). Cognitive losses accumulate progressively. Deficits in memory,
Huntington’s Disease
79
visuospatial abilities, and judgment appear. Further along in the course, the dementia becomes more global. Advanced patients become nonverbal, and their cognitive state is more difficult to assess. The patient who presents with an unexpected rapid deterioration of cognition should be evaluated for causes of delirium. In HD, common causes of delirium include alcohol use, illicit substance abuse, dehydration, medications (especially those with anticholinergic effects), subdural hematoma, and infections. Patients taking lithium who become dehydrated may become delirious on dosages that were previously appropriate.
Irritability and Aggressiveness Severe irritability has been found to be present in about one-third of patients with HD (Folstein et al. 1987). In terms of DSM-IV, irritability can be coded as a personality change due to a general medical condition. Alternatively, episodic aggressive behavior can be coded as intermittent explosive disorder. In contrast to the more diffuse catastrophic reactions seen in Alzheimer’s disease, irritability in HD tends to be more specifically directed and to be associated with irritable traits premorbidly (Burns et al. 1990). Violent behavior—including assault, arson, and homicide attempts—in HD patients has been reported in the literature (Dewhurst et al. 1970; Rosenbaum 1941). Baxter et al. (1992) found that “anger/hostility” was higher in subjects at high risk for HD as determined by genetic markers and PET scans. Irritability can take different forms. One form is an overall increase in the patient’s baseline level of irritability punctuated by episodes of explosiveness. Irritable responses become exaggerated in intensity and duration. Patients develop a “short fuse” and are unable to tolerate a high degree of frustration. In another form, patients are not necessarily irritable in general, but they become agitated when they are unable to have their requests met immediately, no matter how inappropriate. These patients often perseverate relentlessly on a single desire or idea and become progressively more irritable when it is not indulged. Patients often will not report irritability in the clinic and when confronted will deny that they are irritable. Furthermore, spouses may be reluctant to report irritability in front of the patient out of fear. For this reason, informants should be interviewed separately.
80
Psychiatric Management in Neurological Disease
Apathy Patients can develop apathy at any time during the course of illness. Once present, it tends to persist or worsen. Performance at work or school becomes sluggish and can result in disciplinary actions. Like irritability, apathy can be thought of as a DSM-IV personality change due to a general medical condition. Apathy may coexist with irritability. Patients can sit around with little motivation to do anything except watch television but then become angry when someone tries to change the channel or asks them to take a bath or eat. Apathy can be a source of conflict when caregivers know that the patient is physically capable of activities but “won’t” do them. Consequently, the patient’s apathy may be inappropriately labeled as willful “laziness” rather than being seen as a symptom of a disease. The most important differential diagnosis for apathy is depression, especially in patients with alexithymia. Even though they appear to be experiencing intense emotional pain, alexithymic patients are unable to identify their emotional state and therefore do not complain that they are depressed. The apathetic patient should be asked not only about mood but also about other features of depression.
Psychosis Schizophrenia occurs in about 4% of patients with HD (Folstein et al. 1987). Patients presenting with hallucinations and delusions usually have coexisting depression, even if the delusions seem bizarre and mood incongruent. Patients who are delirious may also be hallucinating or delusional (see “Cognitive Impairment and Dementia” subsection above).
Mood Disorders Mood disorder is found in about 40% of patients with HD (Folstein et al. 1987). Although most of these patients suffer from major depression, about one-quarter of them (10% of HD patients overall) have bipolar disorder (manic-depressive illness). Depression, when present, frequently begins prior to the onset of the movement disorder (Folstein et al. 1987).
Huntington’s Disease
81
As with non-HD patients, depressed mood in HD patients can sometimes develop as an understandable reaction to life events such as diagnosis of HD, demoralization due to loss of self-esteem, loss of roles within and outside the family, loss of ability to work or care for one’s family, cessation of driving, or loss of bodily functions. However, these situational mood disturbances are usually short lived, do not meet diagnostic criteria for major affective disorder, and often respond to psychotherapeutic interventions. Patients with HD who have secondary major depression tend to have the same patterns of symptoms as those with idiopathic major depression, such as changes in self-attitude, feelings of worthlessness or guilt, self-blame, and changes in neurovegetative symptoms such as sleep and appetite. Delusions and hallucinations may occur and tend to be mood congruent (Ranen et al. 1993). The diagnosis of major depression may be difficult in patients with advanced disease. It helps to determine whether there has been a change in baseline mood, attitude, or level of functioning. For example, a patient with HD who suffers from moderate apathy and dementia may become completely withdrawn or unable to answer simple questions in the context of a superimposed depression. The suicide rate in patients with HD has been reported to be as high as 12.7% (Schoenfeld et al. 1984).
Anxiety Disorders The presentation of anxiety may range from generalized anxiety to panic disorder. There are many anxiety-provoking issues of concern to both at-risk and affected individuals; for example, engaging in “symptom searching” (i.e., constant concern over whether episodes of clumsiness are normal or actually represent disease onset). From early on in the illness, HD patients are prone to become anxious even about minor issues. Patients may worry for several days about what to wear to an event. Many HD patients are anxious about how their disease will progress, particularly if they remember their parent as having a difficult course. Panic disorder, although uncommon in HD, can be seen. The prevalence of anxiety disorders in HD has not been well studied.
82
Psychiatric Management in Neurological Disease
Obsessive-compulsive disorder. True obsessive-compulsive disorder (OCD) is uncommon in HD but has been reported (Cummings and Cunningham 1992). The exact prevalence is not known. The most common obsessions in HD patients are similar to those in other patients with OCD and relate to cleanliness or whether specific tasks have been carried out, such as having turned off the stove. Although not systematically studied, OCD appears to aggregate in certain HD families. More common than OCD is an obsessive preoccupation with particular ideas or requests (see “Irritability and Aggressiveness” subsection above). This latter behavior is more consistent with DSM-IV personality change due to a general medical condition than with OCD.
Sexual Disorders George Huntington, in his initial manuscript, wrote of two men with advancing disease who were “constantly making love to some young lady” and who, despite marked chorea, “never let an opportunity to flirt with a girl go past unimproved. The effect is ridiculous in the extreme” (Huntington 1872). Although most patients become uninterested in sexual contact (i.e., DSM-IV hypoactive sexual desire disorder due to a general medical condition) and male patients usually become impotent (i.e., male erectile dysfunction disorder due to a general medical condition), hypersexuality and paraphilias have been described by many investigators (Bolt 1970; Dewhurst et al. 1970; Watt and Seller 1993). Men may become aggressive toward their partners if their sexual demands are not met. The prevalence of sexual disorders in HD has not been well studied.
Neurological Management Treatment of Underlying Disease Progression Treatments aimed at retarding the underlying progression of HD have been largely unsuccessful in controlled clinical trials. Medications tested have included baclofen (Shoulson et al. 1989), an agent that attenuates glutamate neurotransmission, in part by inhibiting glutamate release, and idebenone (Ranen et al. 1996a), a benzo-
Huntington’s Disease
83
quinone antioxidant. d-alpha-Tocopherol (vitamin E) at 3,000 IU/day demonstrated no clear-cut benefit overall, although a post hoc analysis suggested a possible slowing of progression for early-stage HD patients (Peyser et al. 1995). Limitations of these clinical trials included small sample sizes that provided insufficient power to detect modest effects. Investigations into the utility of tissue transplantation are also under way. A protective effect of implanted encapsulated cells producing a neurotrophic factor (CNTF) in a monkey model of HD has been reported (Emerich et al. 1997).
Treatment of the Movement Disorder Neuroleptic medications such as haloperidol and fluphenazine are often used to treat chorea. However, these medications may exacerbate the disturbance of voluntary movement. Neuroleptics may contribute to increased morbidity by making patients more rigid, sedated, and apathetic. Therefore, nonpharmacological interventions should be considered first; for example, having the patient wear wrist weights while eating, thereby decreasing the amplitude of chorea. If pharmacological treatment is attempted, starting doses of neuroleptics, such as haloperidol and fluphenazine, should be low; for example, starting at 0.5–1.0 mg/day. Barr et al. (1988) found that haloperidol doses greater than 10 mg/day yielded little or no increased benefit over lower doses. Neuroleptic medication often has little or no effect on chorea in the later stages of the disease. A variety of medications have been used to manage rigidity, spasticity, and dystonia, but none with much success. An exception is botulinum toxin injections, which have been used with a fair degree of success for cervical dystonia in juvenile-onset HD.
Psychiatric Management Treatment of Cognitive Impairment and Dementia There are no specific treatments for the cognitive disorder in HD. Predictability, reduction of complexity of the environment, reduc-
84
Psychiatric Management in Neurological Disease
tion of the need for decision making, retirement, and providing cues can all be helpful. It is also important to reevaluate the medication regimen and stop all unnecessary medications, particularly those with sedating and/or anticholinergic properties.
Treatment of Irritability and Aggressiveness Underlying causes or triggers of the behavior should be identified if possible. Such factors include hunger, pain, inability to communicate, frustration with failing capabilities, boredom, difficult interpersonal relationships, and, in particular, minor unexpected changes in routine. Improvement in irritability can usually be seen if the patient is relieved of responsibilities, although this may be difficult to accomplish diplomatically and with preservation of the patient’s self-esteem. Often, symptoms of irritability will improve dramatically with retirement. Confrontations and ultimatums should be avoided as much as possible unless the issue is critical. Coping with an irritable patient can be difficult, and often family members will gain support from talking about these issues with other caregivers and family members. Lay organizations, such as the Huntington’s Disease Society of America (1-800-345-HDSA), coordinate local support groups. Other lay organizations include the Huntington Society of Canada (519-622-1002) and the International Huntington Association (315-733-1595). Where no Huntington’sspecific support group exists, caregivers for HD patients can still benefit from support groups for more prevalent dementing illnesses such as Alzheimer’s disease. Nonpharmacological interventions are not always effective in completely eliminating irritability, particularly in severe cases. Several medications have been used successfully. Selective serotonin reuptake inhibitors (SSRIs), particularly sertraline, have been demonstrated to be effective for irritability and severe, physically violent behavior (Ranen et al. 1996b). Prior to the use of the SSRIs, carbamazepine was the first-line agent for irritability. Both carbamazepine and divalproex sodium can be very helpful in the management of these patients. Clomipramine has been used in cases in which irritability seems to be tied to obsessions and perseveration on a particular topic. Clonazepam is occasionally effective at dosages
Huntington’s Disease
85
ranging from 0.5 mg to 4.0 mg/day (given in divided doses) in late-stage irritable and aggressive patients. Caution must be taken not to oversedate patients, which can predispose to aspiration. Benzodiazepines, including clonazepam, may also cause paradoxical disinhibition, but this seems to be uncommon in patients with HD. Some clinicians have found low-dose neuroleptics useful, although the same precautions regarding worsening of dysphagia and gait in treating patients with neuroleptics for chorea hold true for irritability (see “Treatment of the Movement Disorder” subsection above). Therefore, when antipsychotic agents are used to manage irritability, the newer atypical agents are preferable.
Treatment of Apathy Apathy not associated with depression tends to be unresponsive to medication therapy, even psychostimulant treatment. Although HD patients have difficulty initiating activities, they are often willing to help or participate if someone else suggests a project and works along with them to sustain energy and attention. Neuroleptics can cause or contribute to apathy and should be tapered if possible.
Treatment of Psychosis Psychoses presenting early in the course of disease tend to be more difficult to treat than late-onset psychotic features. Also, anecdotally, delusions tend to respond better than hallucinations to neuroleptic therapy (Ranen et al. 1993). Clozapine, because of its reduced extrapyramidal side effects, may be especially useful in HD (Bonucelli et al. 1994; Sajatovic et al. 1990). Risperidone and olanzapine may also be useful for this purpose. In cases of delirium presenting with psychotic features, lowdose, high-potency neuroleptics may be helpful in managing behavior while the underlying cause is being treated more definitively.
Treatment of Mood Disorders Treatment of bipolar disorder. HD patients may not need pharmacological treatment for their spells of elevated mood if these are brief and not associated with dangerous behavior. For those who re-
86
Psychiatric Management in Neurological Disease
quire treatment, lithium has been effective only rarely (Ranen et al. 1993). Furthermore, because patients with HD are vulnerable to dehydration, there is a greater risk for lithium toxicity. Carbamazepine has been the initial treatment of choice, but valproate has also been used for bipolar disorder. Again, neuroleptic medication or a benzodiazepine may be added to control disorganization or agitation in mania. Although there is less experience with electroconvulsive therapy (ECT) for mania than for depression in HD, it should nonetheless remain an option in refractory cases. Treatment of depression. Despite its high prevalence, depression in HD historically has been undertreated (Korenyi and Whittier 1967; Ringel et al. 1973). Major depression in HD responds to the same treatments used in idiopathic depression. Tricyclic antidepressants, particularly nortriptyline, and the SSRIs have traditionally represented the standard first-line agents for treatment of depression in patients with HD (Caine and Shoulson 1983; Ranen et al. 1993; Whittier et al. 1961). Sertraline has the added benefit of having been reported to successfully treat the irritability that often accompanies depression in HD patients (Ranen et al. 1996b). Although the greatest amount of clinical experience in HD patients has been with nortriptyline and the SSRIs, all of the marketed antidepressants are used, although, again, there are no systematic studies supporting their use. Some patients will respond to a monoamine oxidase inhibitor who have not responded to other agents (Ford 1986). Antipsychotic medication added to antidepressant medication is indicated for depression accompanied by delusions, hallucinations, or a high degree of agitation. If the goal is to also diminish chorea, a low-dose traditional antipsychotic agent could be used; otherwise, one of the newer atypical agents is preferable. Benzodiazepines such as clonazepam, or lorazepam if an intramuscular route is necessary, can be used in addition to or instead of neuroleptics, thus avoiding the risks of extrapyramidal reactions in patients who are very agitated. Neuroleptics and benzodiazepines should be tapered as soon as the clinical picture allows (Ranen et al. 1993). ECT is indicated for depressed patients who are refractory to treatment with medication, particularly patients who have delu-
Huntington’s Disease
87
sions, who are not eating or drinking because of their depression, or who are such a danger to themselves that immediate treatment is necessary. ECT is administered in the same way for depression in HD as it is for idiopathic affective disorder. As with idiopathic affective disorder, the presence of delusions seems to predict a favorable response (Ranen et al. 1994).
Treatment of Anxiety In addressing anxiety, as in addressing irritability, attempts should be made to decrease the complexity of the patient’s environment. Stopping a job that has become too difficult will usually result in a decline in symptoms. Assisting the caregiver in establishing a predictable routine for the patient is also helpful. Some caregivers find it useful to refrain from discussing any special events until the day before they occur. Patients should be assured that their symptoms will be followed carefully and that if any new ones arise, such as depression, they will be treated aggressively. Treatment of obsessive-compulsive disorder. Both clomipramine and the SSRIs have been effective in managing OCD in HD at doses similar to those used in idiopathic OCD.
Treatment of Sexual Disorders Successful treatments for sexual disorders have included oral medroxyprogesterone (Provera), parenteral medroxyprogesterone (Depo-Provera), and depot leuprolide (Lupron) (Rich and Ovsiew 1994).
Summary Patients with HD present with a triad of cognitive, noncognitive psychiatric, and movement disturbances. Although there are currently no treatments for the underlying course of HD, good symptomatic treatments are available, particularly for the psychiatric aspects of the disease.
88
Psychiatric Management in Neurological Disease
References Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366–375, 1989 Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381, 1986 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Andrew SE, Goldberg YP, Kremer B, et al: Huntington disease without CAG expansion: phenocopies or errors in assignment? Am J Hum Genet 54:852–863, 1994 Aylward EH, Brandt J, Codori AM, et al: Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology 44:823–828, 1994 Barr AN, Fischer JH, Koller WC, et al: Serum haloperidol concentration and choreiform movements in Huntington’s disease. Neurology 38:84–88, 1988 Baxter LR, Mazziotta JC, Pahl JJ, et al: Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington’s disease. Arch Gen Psychiatry 49:148–154, 1992 Bolt JMW: Huntington’s chorea in the west of Scotland. Br J Psychiatry 116:259–270, 1970 Bonucelli U, Ceravolo R, Maremmani C, et al: Clozapine in Huntington’s chorea. Neurology 44:821–823, 1994 Brandt J: Cognitive investigations in Huntington’s disease, in Neuropsychological Explorations of Memory and Cognition: Essays in Honor of Nelson Butters. Edited by Cermak LS. New York, Plenum, 1994, pp 4135–4146 Brandt J, Strauss ME, Larus J, et al: Clinical correlates of dementia and disability in Huntington’s disease. J Clin Neuropsychol 6:401–412, 1984 Brandt J, Folstein SE, Folstein MF: Differential cognitive impairment in Alzheimer’s disease and Huntington’s disease. Ann Neurol 23:555–561, 1988 Brandt J, Quaid KA, Folstein SE, et al: Presymptomatic diagnosis of delayed onset disease with linked DNA markers: the experience in Huntington’s disease. JAMA 261:3108–3114, 1989 Brandt J, Corwin J, Krafft L: Is verbal recognition memory really different in Huntington’s and Alzheimer’s disease? J Clin Exp Neuropsychol 14: 773–784, 1992
Huntington’s Disease
89
Brandt J, Bylsma FW, Gross R, et al: Trinucleotide repeat length and clinical progression in Huntington’s disease. Neurology 46:527–531, 1996 Burns A, Folstein SE, Brandt J, et al: Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 178:20–26, 1990 Butters N, Wolfe J, Granholm E, et al: An assessment of verbal recall, recognition and fluency abilities in patients with Huntington’s disease. Cortex 22:11–32, 1986 Caine ED, Shoulson I: Psychiatric syndromes in Huntington’s disease. Am J Psychiatry 140:728–733, 1983 Cummings JL, Cunningham K: Obsessive-compulsive disorder in Huntington’s disease. Biol Psychiatry 31:263–270, 1992 Dewhurst K, Oliver JE, McKnight AL: Socio-psychiatric consequences of Huntington’s disease. Br J Psychiatry 116:255–258, 1970 Duyao M, Ambrose C, Myers R, et al: Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 4:387–392, 1993 Emerich DF, Winn SR, Hantraye PM, et al: Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s disease. Nature 386:395–399, 1997 Folstein MF, Folstein SE, McHugh PR: “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198, 1975 Folstein SE: Huntington’s Disease: A Disorder of Families. Baltimore, MD, Johns Hopkins University Press, 1989 Folstein SE, Jensen B, Leigh RJ, et al: The measurement of abnormal movement: methods developed for Huntington’s disease. Neurobehav Toxicol Teratol 5:605–609, 1983 Folstein SE, Chase GA, Wahl WE, et al: Huntington disease in Maryland: clinical aspects of racial variation. Am J Hum Genet 41:168–179, 1987 Ford MF: Treatment of depression in Huntington’s disease with monoamine oxidase inhibitors. Br J Psychiatry 149:654–656, 1986 Gusella JF, Wexler NS, Conneally PM, et al: A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306:234–238, 1983 Harper PS: The epidemiology of Huntington’s disease. Hum Genet 89: 365–376, 1992 Huntington G: On chorea. Med Surg Rep 26:317–321, 1872 Huntington’s Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:917–983, 1993
90
Psychiatric Management in Neurological Disease
Huntington Study Group: The Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 4:136–142, 1996 International Huntington Association and World Federation of Neurology Research Group on Huntington’s Chorea: Guidelines for the molecular genetics predictive test in Huntington’s disease. Neurology 44:1533– 1536, 1994 Kieburtz K, MacDonald M, Shih C, et al: Trinucleotide repeat length and progression of illness in Huntington’s disease. J Med Genet 31:872–874, 1994 Korenyi C, Whittier JR: Drug treatment in 117 cases of Huntington’s disease with special reference to fluphenazine (Prolixin). Psychiatr Q 41:203– 210, 1967 Kremer B, Goldberg P, Andrew SE, et al: A worldwide study of the Huntington’s disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 330:1401–1406, 1994 Li X-J, Li S-H, Sharp AH, et al: A Huntington-associated protein enriched in brain with implications for pathology. Nature 378:398–402, 1995 Mayberg HS, Starkstein SE, Peyser CE, et al: Paralimbic frontal lobe hypometabolism in depression associated with Huntington’s disease. Neurology 42:1791–1797, 1992 Mayeux R, Stern Y, Herman A, et al: Correlates of early disability in Huntington’s disease. Ann Neurol 20:727–731, 1986 McHugh PR, Folstein MF: Psychiatric syndromes of Huntington’s chorea: a clinical and phenomenological study, in Psychiatric Aspects of Neurologic Disease. Edited by Benson DF, Blumer D. New York, Grune & Stratton, 1975, pp 267–286 Mega MS, Cummings JL: Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 6:358–370, 1994 Penney JB Jr, Young AB, Shoulson I, et al: Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5:93–99, 1990 Peyser CE, Folstein M, Chase GA, et al: Trial of d-alpha-tocopherol in Huntington’s disease. Am J Psychiatry 152:1771–1775, 1995 Ranen NG, Peyser CE, Folstein SE: A Physician’s Guide to the Management of Huntington’s Disease: Pharmacologic and Non-Pharmacologic Interventions. New York, Huntington’s Disease Society of America, 1993 Ranen NG, Peyser CE, Folstein SE: ECT as a treatment for depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci 6:154–159, 1994
Huntington’s Disease
91
Ranen NG, Stine OC, Abbott MH, et al: Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet 57:593–602, 1995 Ranen NG, Peyser CE, Coyle JT, et al: A controlled trial of idebenone in Huntington’s disease. Mov Disord 11:549–554, 1996a Ranen NG, Lipsey JR, Treisman G, et al: Sertraline in the treatment of severe aggressiveness in Huntington’s disease. J Neuropsychiatry Clin Neurosci 8:338–340, 1996b Ranen NG, Rosenblatt A, Ross CA: Differential diagnosis of Huntington’s disease. Poster abstract presented at the American Association of Geriatric Psychiatry 10th Annual Meeting, Orlando, FL, March 1997 Rich SS, Ovsiew F: Leuprolide acetate for exhibitionism in Huntington’s disease. Mov Disord 9:353–357, 1994 Ridley RM, Frith CD, Crow TJ, et al: Anticipation in Huntington’s disease is inherited through the male line but may originate in the female. J Med Genet 25:589–595, 1988 Ringel SP, Guthrie M, Klawans HL: Current treatment of Huntington’s chorea. Adv Neurol 1:797–801, 1973 Rosenbaum D: Psychosis with Huntington’s chorea. Psychiatr Q 15:93–99, 1941 Sajatovic M, Verbanac P, Ramirez LF, et al: Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington’s chorea. Neurology 41:156, 1990 Schoenfeld M, Myers RH, Cupples LA, et al: Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 47:1283–1287, 1984 Shoulson I, Odoroff C, Oakes D, et al: A controlled trial of baclofen as protective therapy in early Huntington’s disease. Ann Neurol 25:252–259, 1989 Van Dijk JG, Van der Velde EA, Roos RA, et al: Juvenile Huntington disease. Hum Genet 73:235–293, 1986 Vonsattel JP, Myers RH, Stevens TJ, et al: Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577, 1985 Watt DC, Seller A: A clinico-genetic study of psychiatric disorder in Huntington’s chorea. Psychol Med Suppl 23:1–46, 1993 Wexler NS: The Tiresias complex: Huntington’s disease as a paradigm for testing for late-onset disorders. FASEB J 6:2820–2825, 1992 Wexler NS, Young AB, Tranzi RE, et al: Homozygotes for Huntington’s disease. Nature 326:194–197, 1987
92
Psychiatric Management in Neurological Disease
Whittier J, Haydu G, Crawford J: Effect of imipramine (Tofranil) on depression and hyperkinesia in Huntington’s disease. Am J Psychiatry 118:79, 1961 Wiggins S, Whyte P, Huggins M, et al: The psychological consequences of predictive testing for Huntington’s disease. N Engl J Med 327:1401– 1405, 1992
C H A P T E R
4
Wilson’s Disease (Progressive Hepatolenticular Degeneration) Edward C. Lauterbach, M.D.
W
ilson’s disease (WD), an autosomal recessive disorder, is caused by copper deposition in the brain, liver, cornea, skeletal system, and, occasionally, other organs, such as the heart. The tendency toward cuprification of the liver and brain lenticular nucleus (putamen and globus pallidus) leads to the disorder’s alternative name, hepatolenticular degeneration. Specific treatments for WD exist in the form of decoppering agents. Although various aspects of the disease were described earlier, Wilson (1912) first linked liver cirrhosis with basal ganglia movement disorders, forming the modern conceptualization of this disease. Today, WD responds well to decoppering agents if detected early enough.
Prevalence WD occurs at a rate of approximately 1 per 40,000 births. The incidence is 12–30 cases per million population (mean of 20 per million) across the world. The somewhat higher prevalence of WD in Japan has been linked to greater consanguinity. The carrier frequency of the gene is about 1%. 93
94
Psychiatric Management in Neurological Disease
Clinical Recognition and Neurological Presentation While the potential manifestations of WD are legion, a rule of thirds applies, with approximately one-third of WD patients initially presenting with hepatic (hepatic WD), neurological (neurological WD), or psychiatric (psychiatric WD) symptomatology. The mean age at onset is 17 years (range: 5–35 years), and phenotypic presentations such as age at onset and initial manifestations sometimes vary between families. Disease progression varies but generally involves the liver initially (i.e., in childhood and adolescence) and the brain later (in the second to third decade of life). WD is divided into three stages: asymptomatic, early symptomatic (hepatic), and late symptomatic (extrahepatic). Prognosis depends on clinical manifestations once effective treatment is undertaken. Without treatment, patients can die within 5 years, but with treatment, they can live 20 years or longer. If left untreated, patients can die within 6 months after the onset of neurological signs. Liver manifestations are quite variable (Table 4–1). If hepatic WD is not treated, cirrhosis develops. Neurological manifestations (Tables 4–1 and 4–2) develop as the liver loses its ability to store copper. The frequency of neurological signs in 48 WD patients studied by Oder et al. (1991) is shown in Table 4–2. Symptoms begin with subtle abnormalities, including mild tremor, speech problems, and micrographia (small handwriting), that are usually accompanied by Kayser-Fleischer rings (see next paragraph), hypoceruloplasminemia, or thrombocytopenia (Brewer and Yuzbasiyan-Gurkan 1992). In one study that assessed 19 WD patients more than 10 years after the illness was first diagnosed, 17 (89%) of the patients had basal ganglia signs and 2 (11%) had oculomotor or cerebellar signs (Arendt et al. 1994). Dystonia and chorea are especially common in childhood-onset and end-stage WD (Walshe 1995). Seizures occur in 6% of WD patients, but remit with WD treatment in over 60% (Dening et al. 1988). Visual and sensory systems are curiously spared, despite observations of high copper concentrations in the sensory cortex. Without WD treatment, patients become dysarthric, bedridden, and unable to perform activities of daily living; develop flexion contractures; and die. Greater detail on liver manifestations
Wilson’s Disease
Table 4–1.
95
Hepatic and neurological manifestations in Wilson’s disease
Hepatic manifestations Primary Abnormal liver tests Hepatomegaly Acute hepatitis Chronic active hepatitis Chronic cirrhosis Secondary Portal hypertension Esophageal varices Hypersplenism Hepatorenal syndrome Jaundice Spider angiomata Palmar erythema Asterixis Hypoalbuminemia Ascites Hyperammonemia Hemolysis of cirrhosis Hepatic encephalopathy Reduced clotting factor synthesis Bleeding diatheses Gallstones Delayed puberty Amenorrhea Gonadal insufficiency Hyperpigmented skin
Neurological manifestations Oculomotor signs Cerebellar signs Ataxia Dysdiadochokinesia Other Dysarthria (dystonic, cerebellar, parkinsonian, or spastic types) Drooling Movement disorders Bradykinesia Parkinsonism Dystonia Dystonic arm posturing Risus sardonicus Chorea Tics Tremors Postural tremor Wing beating tremor Other Pyramidal tract signs Dysautonomia Seizures Pathological emotionality
Source. Brewer and Yuzbasiyan-Gurkan 1992a (hepatic manifestations); Arendt et al. 1994 and Oder et al. 1991 (neurological manifestations).
has been provided elsewhere (Hoogenraad 1996). Greenish-brown, muddy brown (Figure 4–1), or golden KayserFleischer (KF) rings resulting from copper deposition are best seen on slit-lamp ophthalmological exam but, when prominent, can also
96
Psychiatric Management in Neurological Disease
Table 4–2.
Frequency of neurological signs in Wilson’s disease patients (n = 45) No. Frequency, %
Neurological signs Dysdiadochokinesia Dysarthria Bradykinesia (in isolation) Postural tremor Parkinsonism Chorea/dystonia Ataxia Source.
27 25 23 17 14 8 3 1
60 56 51 38 31 18 7 2
Oder et al. 1991.
Figure 4–1. Kayser-Fleischer ring, most apparent at corneal junction with sclera. Source. Reproduced from Yanoff M, Fine BS: Ocular Pathology: A Color Atlas. Philadelphia, PA, JB Lippincott, 1988, p. 105. Copyright © 1988, Mosby International. Used with permission.
Wilson’s Disease
97
be seen with an ophthalmoscope near the junction of the cornea and the sclera. The rings initially appear superiorly and may be less apparent medially and laterally. In one study, 85% of patients with neurological WD manifested KF rings, in contrast to fewer than 15% of patients with hepatic WD (Oder et al. 1991). Sunflower cataracts can occur, and progressive lens and retinal changes vary with treatment. Some of the other less-prominent features of WD are listed in Table 4–3. Aside from the characteristics detailed in this table and the considerations mentioned below, no other clinically important interactions between WD and patient gender have been reported.
Pathological Features Pathology The physiological importance of copper is immense. Studies in rats indicate that copper is a potent releaser of catecholamines (Wang 1999) and a potent inhibitor of GABA-A receptors (Sharonova et al. 1998), possibly contributing to neuropathological or pathophysiological processes in WD. Copper is integral to cytochrome-c oxidase in the mitochondrial electron transport chain, catecholamine metabolism (tyrosine metabolism, dopamine beta-hydroxylase, and monoamine oxidase), melanin formation, collagen and elastin cross-linkage, and free radical deactivation (superoxide dismutase). Excessive copper accumulation can lead to cellular demise through a number of potential mechanisms. These include free radical–induced cellular oxidation, inhibited protein synthesis, inactivation of enzymes (in mitochondria, cytosol, and cell membrane), intracellular failure (of mitochondria, peroxisomes, microtubules, plasma membranes, enzymes, and DNA cross-linking), and induction of cellular injury, inflammation, and cell death due to unbound ionic copper (Hoogenraad and Van den Hamer 1996; Walshe 1995). Mitochondrial copper accumulation can produce premature oxidative aging and mitochondrial DNA mutations, further impairing cell function (Mansouri et al. 1997). A thorough review of normal copper metabolism can be found elsewhere (Hoogenraad and Van den Hamer 1996). Early hepatic intracellular fatty accumulations proceed to stea-
98
Table 4–3.
Psychiatric Management in Neurological Disease
Other nonpsychiatric features of Wilson’s disease
Renal Urolithiasis Hematuria Renal tubular dysfunction Hypokalemia Aminoaciduria Proteinuria Uricosuria Hypercalciuria Abnormal glucose tolerance Defective urinary acidification Fanconi syndrome Nephrolithiasis Hepatorenal syndrome Immunoglobulin A (IgA) glomerulonephritis Penicillamine immunoglobulin G (IgG) glomerulonephritis Musculoskeletal Osteoarthritis Osteomalacia Hypertrophic osteoarthropathy Chondrocalcinosis Arthralgias Stiffness of back, knee, hip, and wrist Rhabdomyolysis Muscle weakness of hypokalemia
Cardiac Cardiac interstitial fibrosis Myocarditis Cardiac arrhythmia Electrocardiogram (ECG) abnormalities Endocrinological Oligomenorrhea Amenorrhea Hyperglycemia Hypertestosteronemia Hyperestradiolemia Hypogonadism of cirrhosis Pancreatic disease Hypoparathyroidism Miscellaneous Orthostatic hypotension Skin abnormalities Cholelithiasis Dermatopathies Ruptured spleen Hemolysis
tosis in hepatic WD. Subsequently, inflammatory cellular infiltration (lymphocytes and histiocytes), collagen deposition, fibrosis, and necrosis ensue. Fibrosis progresses to nodular cirrhosis with cholestasis. Nodules can measure as large as 2 cm, and individual liver lobules vary in color (yellow, red, green, brown). Brain pathology in WD can include widespread copper deposi-
Wilson’s Disease
99
tion, gliosis, and astrocytic proliferation, especially in gray matter. Spongy necrosis, demyelination, and denervation may be evident in frontal, parietal, and occipital cortical areas. Macroscopically, ventricular dilatation, lenticular atrophy, yellowish or reddish-brown discoloration, softening, and spongy degeneration are seen. Cavitation is especially apparent in rapidly progressive juvenile dystonic forms of WD, whereas atrophy is more common in more slowly progressive adult forms. The pathology of hepatic encephalopathy is similar to WD pathology and is occasionally superimposed (Hoogenraad 1996). Liver failure can increase pallidal manganese concentrations.
Etiology and Genetics The ATP7B gene responsible for WD is located on band 14.1–21.1 of chromosome 13q14 (Nanji et al. 1997). The gene product is a copper-containing P-type adenosine triphosphatase (ATPase), important to the process of binding copper to apoceruloplasmin to form holoceruloplasmin. Holoceruloplasmin is integral to hepatobiliary copper excretion. In WD, however, apoceruloplasmin fails to bind copper (Kojimahara et al. 1995). Mutant forms of the ATPase in WD have difficulty migrating from the trans-Golgi network to cytoplasmic vesicles, where they would normally assist in binding excess copper to form holoceruloplasmin (Schaefer et al. 1999). Although WD patients have holoceruloplasmin in the liver, holoceruloplasmin is lacking in the biliary system (Chowrimootoo et al. 1997), reflecting impaired copper transport from hepatocytes to the biliary system. Biliary excretion normally accounts for 10% of daily copper loss (Hoogenraad and Van den Hamer 1996), and impaired biliary excretion soon leads to copper accumulation. WD differs from the other major abnormal P-type ATPase copper disease, X-linked Menkes’ disease. Menkes’ disease is caused by copper deficiency secondary to intestinal copper malabsorption resulting from mutations in the ATP7A gene. It leads to death in childhood (Walshe 1995). More than 100 mutations of the WD gene have been documented, some of which are associated with ethnicity, severity, age at onset, or presentation (Forbes and Cox 1998; Nanji et al. 1997; Walshe 1995). Highly dysfunctional mutations lead to early-onset,
100
Psychiatric Management in Neurological Disease
severe hepatic WD, whereas milder mutations lead to late-onset neurological WD (Houwen et al. 1995). A cytosine-to-adenine transversion may be responsible for 30% of North American WD cases (Hoogenraad and Houwen 1996). Animal models include the Bedlington terrier and the Long Evans Cinnamon rat. Recently, a strain of mice has been developed with a mutation of the ATP7B gene, resulting in the development of WD features in these mice (Buiakova et al. 1999).
Neuroimaging Increased putaminal signal (hyperintensity) due to copper deposition is usually present on magnetic resonance imaging (MRI) scan T2-weighted images (Figure 4–2). Increased T2 signal can also sometimes be seen in the thalamus, globus pallidus, caudate, cerebellum, subcortical white matter, midbrain, and pons. Although reduced T1 signal is common, increased pallidal T1 signal sometimes occurs and may correlate with hepatic demise (Saatci et al. 1997). MRI abnormalities occurred most frequently in the putamen and pons (present in 80%–90% of subjects) in two studies (King et al. 1996; Saatci et al. 1997), whereas pallidal abnormalities occurred in WD patients with portosystemic shunting in another study (van Wassenaer– van Hall et al. 1996). On computed tomography (CT), the most common findings are ventricular dilatation, basal ganglia hyperdensities, and atrophy of the cerebral cortex, brain stem, or cerebellum. Similar findings in other brain regions are sometimes seen. Basal ganglia MRI hypointensity and CT hypodensity are consistent with cavitation in more aggressive WD. On positron emission tomography (PET), glucose metabolism may be reduced in the cerebellum and striatum as well as in cortical and thalamic regions (Kuwert et al. 1992); reduced striatal glucose metabolism has been correlated with neurological severity (Schlaug et al. 1996). Dopamine D2 receptor binding on single-photon emission computed tomography (SPECT) imaging has correlated negatively with neurological severity (Oder et al. 1996; Schlaug et al. 1996).
Wilson’s Disease
101
Figure 4–2. Appearance of Wilson’s disease at two adjacent levels on T2-weighted magnetic resonance imaging (MRI). Note variegated increased signal in putamen and caudate heads due to copper deposition and reduced signal in globus pallidus. Source. Reproduced from Martin WRW, Snow B, Ashforth R: “Abnormalities of Movement and Posture Due to Disease of the Extrapyramidal Motor Systems,” in Neuroimaging: A Companion to Adams and Victor’s Principles of Neurology. Edited by Greenberg JO. New York, McGraw-Hill, 1995, pp. 5–24. Copyright © 1988, The McGraw-Hill Companies. Used with permission.
Clinical and Laboratory Investigation: Diagnosis Clinical suspicion is critical to diagnosing WD. The disease must be actively considered in the neuropsychiatric differential diagnosis in order to avoid missing the diagnosis. In a retrospective review of 136 cases of neurological WD, the diagnosis was missed in two-thirds of WD initial presentations, resulting in a 13-month delay in diagnosis (Walshe and Yealland 1992). In another series, two-thirds of patients with neurological WD exhibited psychiatric symptoms, but psychiatrists missed the diagnosis despite the uniform presence of KF rings (Brewer and Yuzbasiyan-Gurkan 1992). Clinicians must
102
Psychiatric Management in Neurological Disease
therefore remain vigilant for signs of WD, particularly because prompt detection is critical for successful treatment. Initial presentation with hepatic, neurological, or psychiatric symptoms, especially when accompanied by KF rings or a family history of WD, cirrhosis, or neurological disorder, warrants a diagnostic workup to exclude WD. Psychiatric features precede other symptoms in at least 20% of WD patients. In the remaining 80%, liver disease usually precedes other WD manifestations (Walshe 1995). Manifestations such as renal, endocrinological, hematological, cardiac, or joint disease may also elicit clinical suspicion. The diagnosis of WD is made by measuring blood ceruloplasmin and 24-hour urine copper levels. WD is confirmed by liver biopsy. Ceruloplasmin is reduced in 95% of cases, but it can also be normal or elevated, especially in early WD. Although urinary copper is usually elevated, 40% of presymptomatic homozygotes (i.e., future WD patients) have values lower than the 100 µg/day observed in typical WD patients (Lindahl and Sharp 1982). Hepatic needle biopsy disclosing copper is diagnostically definitive (although liver biopsy copper concentrations can vary in children) in early and end-stage WD (Hoogenraad 1996), and in different liver nodules (Faa et al. 1995). Although the finding of KF rings on slit-lamp exam supports the diagnosis, rings are usually absent when WD is confined to the liver (Akil and Brewer 1995). Serum copper levels are not of diagnostic utility. Once the diagnosis is established in a patient, definitive diagnoses in siblings can be made by DNA analysis (Roberts and Cox 1998) (see “Family Considerations and Genetic Testing” under “Neurological and Psychiatric Management” section later in chapter). Laboratory test values are summarized in Table 4–4 and are reviewed in detail elsewhere (Brewer and Yuzbasiyan-Gurkan 1992). Values vary somewhat among laboratories. Presymptomatic WD homozygotes generally exhibit low concentrations of ceruloplasmin, normal to high concentrations of urinary copper, and high concentrations of liver copper. The differential diagnosis of WD as it relates to disease signs and laboratory manifestations is summarized in Table 4–5. Although other diseases are associated with excessive copper accumulation, only WD results in copper deposition in the brain (Walshe 1995). False negatives and false positives can occur, as with all tests.
Laboratory investigation of Wilson’s disease
Test
Normal
Wilson’s disease
Heterozygous carriers
Ceruloplasmin 24-hour urinary copper Hepatic copper
20–35 mg/d 20–50 µg/d 20–50 µg/g
0–10 mg/d 100 µg/d 200 µg/g
0–35 mg/d 20–75 µg/d 20–150 µg/g
Wilson’s Disease
Table 4–4.
Note. Values for normal control subjects, homozygous Wilson’s disease patients, and asymptomatic carriers. mg/d = milligrams per day; µg/d = micrograms per day; µg/g = micrograms per gram of dry liver tissue.
103
104
Psychiatric Management in Neurological Disease
Table 4–5.
Differential diagnosis of Wilson’s disease
Heritable liver disorders Wilson’s disease Hemochromatosis Alpha-1 antiprotease (antitrypsin) deficiency Cystic fibrosis Excessive copper accumulation Wilson’s disease Primary biliary cirrhosis Indian childhood cirrhosis Non-Indian childhood cirrhosis Severe familial intrahepatic cholestasis Prolonged biliary obstruction Hypoceruloplasminemia Wilson’s disease homozygotes (patients) 10% of heterozygous Wilson’s disease carriers Normal infants up to age 6 years 1% of normal adults Menkes’ syndrome Hereditary hypoceruloplasminemias Copper deficiency High urinary copper levels Wilson’s disease Copper storage diseases other than Wilson’s Severe proteinuria Obstructive liver disease Primary biliary cirrhosis Cholestasis Indian childhood cirrhosis Non-Indian childhood cirrhosis High hepatic copper levels and high urinary copper levels Wilson’s disease Obstructive liver disease (see “High urinary copper levels” above for details) Kayser-Fleischer rings Wilson’s disease Obstructive liver disease (see “High urinary copper levels” above for details) Source.
Hoogenraad 1996; Kumar and Riely 1995; Walshe 1995.
Wilson’s Disease
105
Moreover, in hepatic WD, one-third of patients lack KF rings, abnormal ceruloplasmin, and urinary copper (Steindl et al. 1997). In ambiguous cases, DNA marker analysis can be helpful (see “Family Considerations and Genetic Testing” under “Neurological and Psychiatric Management” section later in chapter). DNA analysis can distinguish between homozygous WD patients and heterozygous WD carriers (Gaffney et al. 1992). Western blot analysis of ceruloplasmin has successfully distinguished WD homozygotes, WD heterozygotes, and non-WD hypoceruloplasminemic patients (Chowrimootoo et al. 1997). Although prenatal diagnosis is now possible, there is no reason to undertake this, given the excellent prognosis of well-treated presymptomatic homozygotes (Hoogenraad 1996). Although the biliary isoform of ceruloplasmin is reduced in neonates, reductions in the plasma isoform of ceruloplasmin in cord blood can assist in the neonatal diagnosis of WD (Chowrimootoo et al. 1998). Other tests are supportive but not diagnostic of WD. Putaminal abnormalities on MRI T2 images can suggest WD (see “Neuroimaging” section above). Although the neurological exam is more diagnostically sensitive than CT imaging (Roach et al. 1985), basal ganglia hypodensities on CT can also suggest the diagnosis of WD. Additional tests of suggestive or supportive diagnostic value include elevated serum transaminases, reduced serum alkaline phosphatase, slowing or epileptiform activity on electroencephalogram (EEG), abnormal auditory evoked responses (peaks I–IV), reduced striatal D2 receptor binding or basal ganglia hypometabolism on SPECT, and reductions in striatal, cerebellar, cortical, or thalamic glucose metabolism on PET (Kuwert et al. 1992). An abnormal 65Cu test (see Lyon et al. 1995 for a description of this test) at 72 hours is also supportive of a diagnosis of WD (Merli et al. 1998).
Psychiatric Manifestations Psychiatric symptoms are evident at initial presentation in between one-third and two-thirds of patients (including those with neurological WD), and psychiatric symptoms occur in isolation in about 20% (Akil and Brewer 1995; Dening and Berrios 1989a; Schwartz et al. 1993). Half of patients undergo psychiatric hospitalization before
106
Psychiatric Management of Neurological Diseases
WD is recognized (Akil et al. 1991; Rathbun 1996). Because improvement in WD depends on treatment within the first 5 years of disease onset, clinical vigilance and early diagnosis is critical. Cognitive, mood, and personality disturbances dominate psychiatric presentations (Table 4–6). Wilson observed prominent psychiatric symptoms in his patients, including silliness, euphoria, sexual preoccupation, hebephrenia, catatonia, occasional hallucinations, “hysterical” behavior, and “narrowing of mental horizons.” He concluded that “facility, docility, childishness, and emotional overaction form the chief features of the more chronic cases” (Wilson 1912). Among 129 WD patients examined in one study, the most common psychiatric symptoms were incongruous behavior, irritability, depression, and cognitive impairment (Dening and Berrios 1990). Akil and Brewer (1995) observed that personality disturbances, depression, and academic or employment failure were the most common psychiatric presentations. Thus, WD can profoundly affect intellectual, emotional, and behavioral aspects of the patient’s life. Table 4–6.
Frequency of psychiatric manifestations in Wilson’s disease Frequency, %
Psychiatric presentation frequencies across studies Pure psychiatric initial presentation Predominantly psychiatric initial presentation Psychiatric features present on initial presentation Psychiatric features present during illness course
20 33 33–67 50–100
Psychiatric feature frequencies across studies Any psychiatric features Depression Suicidality Irritability/aggression Elation Cognitive impairment Delusions Hepatocerebral syndrome and catatonia
65 27 4 46 13 <24 1–7 Rare
Source. Data approximated from Akil and Brewer 1995; Akil et al. 1991; Brewer and Yuzbasiyan-Gurkan 1992a; Dening and Berrios 1989a, 1989b; Oder et al. 1991; Scheinberg and Sternlieb 1984; Schwartz et al. 1993; Walshe 1995.
Wilson’s Disease
107
Two-thirds of Wilson’s original 12 patients had “psychical” abnormalities (Wilson 1912). Point prevalences of psychiatric disorders in WD range as high as 100%, but 50% may represent a better estimate (Dening and Berrios 1989a). Lifetime prevalences of cognitive impairment, psychosis, mood and anxiety disorders, impulsivity, and personality disturbances may, together, approach 100% (Scheinberg and Sternlieb 1984). In a retrospective review of 42 WD patients undergoing zinc treatment, irritable and aggressive personality disturbances occurred in 17 (45.9%) of the 37 symptomatic patients, whereas cognitive changes, anxiety, psychosis, and catatonia were less common (Akil et al. 1991). Of 24 neurological WD patients assessed in one study, 17 (71%) had various personality changes, 10 (42%) depression, 4 (17%) cognitive changes, 3 (13%) anxiety, 2 (8%) psychosis, 2 (8%) catatonia, and 5 (21%) other psychiatric presentations (Brewer and Yuzbasiyan-Gurkan 1992). Specific psychiatric disturbances are discussed in the following subsections. Psychiatric manifestations (Akil and Brewer 1995; Dening and Berrios 1989a) and neuropsychological impairment (Lang et al. 1990) usually occur with neurological rather than hepatic disease.
Cognitive Impairment Patients should be scrutinized for DSM-IV (American Psychiatric Association 1994) amnestic disorder due to Wilson’s disease and for cognitive disorder not otherwise specified. The rate of cognitive impairment varies, but overall, such impairment occurs in less than 25% of WD patients (Lauterbach et al. 1998). Impairment increases with disease duration (Knehr and Bearn 1956). In a study of 19 patients with neurological WD (Medalia et al. 1988), patients scored lower on the Full Scale IQ, Dementia Rating Scale, and Wechsler Memory Scale than did either 15 normal control subjects or 12 WD patients without neurological WD. Slowing on time-dependent psychometric tests increases with neurological WD severity (Arendt et al. 1994), but this may result from slowed motor speed rather than from reduced information-processing speed (Littman et al. 1995). Cognitive impairment also attends occasional hepatic encephalopathies (Tarter et al. 1987). Cognitive function, memory, and IQ can improve with treatment (references cited in Lauterbach et al. 1998).
108
Psychiatric Management in Neurological Disease
Pathological Affect Emotional lability with forced laughter and crying may occur in WD (see Chapter 1 for treatment approaches).
Behavioral and Personality Changes Among WD patients with significant psychiatric disturbances, the majority have antisocial or impulse-control features. Nearly half of WD patients manifest personality changes, including impulsivity, aggression, disinhibition, recklessness, emotionality, irritability, anger, bizarre and odd behavior, and other less easily definable presentations (references cited in Lauterbach et al. 1998). These presentations correspond to DSM-IV personality change due to Wilson’s disease, including disinhibited, labile, and aggressive types. In 42 patients treated with zinc, Akil et al. (1991) found that 37 were symptomatic; of these, 17 (45.9%) had irritable or aggressive personality disturbances. These personality features can lead to marital troubles and occasional criminality. Irritability, incongruous behavior, and personality disturbances are associated with brain-stem signs and dystonia but not with tremor (Dening and Berrios 1989a). Personality syndromes also correlate with dyskinesia, dysarthria, and putaminal and pallidal lesions (Oder et al. 1993). Psychopathic personality features, in particular, correlate with dysarthria (Dening and Berrios 1989b). Incongruous, disinhibited, aggressive, hyperactive, and hypersexual behaviors have improved with treatment of WD, but irritability has not (Akil and Brewer 1995; Dening and Berrios 1990).
Functional Decline A common problem in WD is deterioration in work or academic performance (Akil and Brewer 1995). Such deterioration can lead patients to drop out of school or to quit or be fired from their jobs, more as a result of attentional deficits than of intellectual impairments or personality disturbances (Akil and Brewer 1995). Diminished functional capacity correlates with ataxia, tremor, and focal thalamic lesions (Oder et al. 1993). Occasionally, WD is mistaken for a psychiatric diagnosis.
Wilson’s Disease
109
Walshe and Munro (1995) reported the case of a 17-year-old with intractable vomiting who was misdiagnosed with anorexia nervosa for 9 years. In reality, the patient was suffering from gastrointestinal manifestations of WD.
Psychosis Psychosis can be the presenting sign of WD—hence the clinical admonition to exclude WD in first-onset psychosis. Although early studies suggested an association of psychosis and WD related to basal ganglia pathology (Slater and Cowie 1971), later studies indicated that schizophreniform disorders, catatonia, and hallucinations are not increased in WD (Dening and Berrios 1989a; Oder et al. 1991). Delusions occurred in 3 (7%) of 45 WD patients in a prospective study by Oder et al. (1991). In a study of 24 patients with neurological WD, psychosis and catatonia each occurred in 2 (8%) (Brewer and Yuzbasiyan-Gurkan 1992). Psychotic features occasionally reverse with WD treatment, and incongruous behavior can improve over the disease course (Dening and Berrios 1990). Great care is necessary when using antipsychotics in patients with neurological WD (see “Psychotropic Treatment” under “Neurological and Psychiatric Management” section later in chapter). Occasionally, reversible psychosis is precipitated after commencing WD treatment (McDonald and Lake 1995). Although this treatment complication would likely be diagnosed in DSM-IV as a psychotic disorder due to a general medical condition, the exact diagnoses corresponding to psychotic features observed in WD have not yet been determined.
Mood Disorders Mania WD affects brain structures associated with mania, including the striatum, thalamus, and cerebellum (see Chapter 7 in this volume). Elation occurs in about 13% of WD patients across studies (Akil et al. 1991; Dening and Berrios 1989a; Oder et al. 1991). Although manic presentations have been observed ever since Wilson’s original report (1912), the prevalences of such presentations have yet to be determined. In conducting future epidemiological studies, it will be im-
110
Psychiatric Management in Neurological Disease
portant to distinguish the various DSM-IV bipolar disorders and mood disorder due to Wilson’s disease with manic features, because WD personality changes can also resemble mania (see “Behavioral and Personality Changes” subsection above). Whereas irritability tends not to respond to WD treatment (Dening and Berrios 1990), hypersexuality, hyperactivity, and aggression occasionally improve with such intervention (Akil and Brewer 1995). Depression Depressive illness occurs in about 30% (Akil et al. 1991; Dening and Berrios 1989a, 1989b; Oder et al. 1991) or more of WD patients (Akil and Brewer 1995). In a prospective study of 45 patients with WD, 12 (27%) had mood disorders consistent with major depression; in all of these subjects, the major depression was attended by the features of neurological WD (Oder et al. 1991). Some depressive symptoms correlate with hepatic dysfunction (Dening and Berrios 1989b). Depression may evolve over the disease course, eventually occurring in perhaps all WD patients (Arendt et al. 1994) and coexisting with (Oder et al. 1993) or without (Arendt et al. 1994) cognitive impairment. In a follow-up study of 129 WD patients, neither depression nor irritability improved with WD treatment, especially in patients with neurological and hepatic WD (Dening and Berrios 1990). Nevertheless, some case reports indicate that depression can improve with treatment. Major depression in WD can be associated with delusions, suicide attempts, and personality disturbances. Across studies, suicidal behavior is observed in 4%–16% of patients (references cited in Lauterbach et al. 1998). Disinhibited, impulsive, and aggressive WD personality changes may compound the risk of suicide. Consequently, depressed WD patients should be thoroughly evaluated for suicide potential. Mild depression correlates with cognitive impairment, parkinsonian rigidity, bradykinesia, and third-ventricle dilatation (Oder et al. 1993) as well as with gait disorders (Dening and Berrios 1989b). Mood disturbances have not been found to correlate with evoked potential abnormalities (Arendt et al. 1994). Whether depression is a psychological reaction to illness or a biological event is unresolved
Wilson’s Disease
111
(Akil and Brewer 1995), but both mechanisms probably apply to varying degrees in individual patients. Consequently, as for psychoses and mania, it is unclear what percentage of depressive disorders in WD represent DSM-IV mood disorders due to WD. Future studies using diagnostic criteria will be useful in separating out adjustment disorders from major depression and dysthymia.
Anxiety Disorders Although several reports have identified anxiety in WD subjects (Akil and Brewer 1995; Akil et al. 1991; Loiseau and Demangeat 1956), the prevalence, clinical and pathological correlates, psychosocial determinants, and treatment of specific anxiety disorders in WD remain to be determined.
Impulse Control Disorders In one study of 124 WD patients, 6 (4.8%) displayed increased sexual preoccupation and reduced sexual inhibition (Akil and Brewer 1995). Sexual behaviors included exhibitionism and promiscuity. Hypersexual, disinhibited, aggressive, and hyperactive behavior can improve with treatment of WD (Akil and Brewer 1995; Dening and Berrios 1990). Impulsive behavior was discussed earlier in this chapter (see “Behavioral and Personality Changes” subsection above). The types, prevalences, clinical and pathological correlates, psychosocial determinants, and treatment of impulse control disorders in WD need elucidation.
Substance Abuse Disorders Reports of substance abuse in WD patients have been published (Akil et al. 1991; Hawkins et al. 1987; Lhermitte and Muncie 1980). Personality disturbances and mood disorders may pose special risk, but prevalences, correlates, determinants, and special treatment issues associated with substance abuse in WD are unknown. Further work is needed to delineate substance abuse disorders in WD patients.
112
Psychiatric Management in Neurological Disease
Neurological and Psychiatric Management Three aspects of treatment merit discussion: 1) psychotherapeutic considerations, 2) treatment of the underlying neurological disease, and 3) treatment of psychiatric manifestations.
Psychotherapeutic Considerations Clinicians should attempt to provide psychological support to patients, and help them to grieve and adapt to the illness. Patients should be assisted in the process of working through the issues of disease acceptance. They should be encouraged to maintain their daily routines to the extent possible. Denial of illness and noncompliance with treatment may be particular problems in younger patients or those with behavioral disinhibition. Poor insight into both the illness and its consequences is another issue that complicates treatment. Practical aspects of coping with the disease and with the limitations of lifestyle imposed by its attendant disabilities and its treatment should be addressed. Hope can be offered with treatment, but it is important to guard against unrealistic expectations. Enlisting the patient’s support system may be helpful for adaptation and adjustment to the illness, as well as for monitoring compliance to the treatment regimen. Vigilance for suicide is important in those who are depressed. Evaluation of depression is particularly indicated for those with parkinsonism or gait disturbance. Conventional psychotherapeutic strategies should be employed as indicated for the specific psychiatric disorders identified in the individual patient. Support groups can also be very helpful, providing camaraderie and education for the patient and family. Such groups reduce fear of the unknown about the disease, provide practical tactics useful for coping with WD, and can also help patients gain a sense of mastery over the illness by allowing them to actively do something about the disease rather than feel like its passive victim. Support groups provide a forum wherein the patient can confront the illness, grieve it, and come to terms with it. Some patients derive added benefit from organizing these groups or serving in leadership positions. Although WD is an uncommon illness, referral can be made to support groups for Parkinson’s disease, dystonia, or stroke, depending on the patient’s neurological features. Further information on support
Wilson’s Disease
113
groups and informational resources for patients and their families can be obtained by contacting the Wilson’s Disease Association (P.O. Box 75324, Washington, DC 20012-5324) or the National Center for the Study of Wilson’s Disease (432 West 58th Street, Suite 614, New York, NY 10019, phone 212-523-8717, fax 212-523-8708).
Treatment of the Underlying Neurological Disease First-Line Treatments The introduction of functional ATP7B protein by recombinant adenovirus-mediated gene delivery holds promise as a future treatment of Wilson’s disease (Terada et al. 1998). However, at present, treatment options are limited to agents that reduce the level of toxic copper in the body. First-line agents for treating WD include Dpenicillamine, zinc, trientine, and tetrathiomolybdate. Early recognition and treatment of WD is paramount, because improvement with treatment is usually limited to the first 5 years of symptomatic illness and the first 2 years of treatment (Akil and Brewer 1995; Dening and Berrios 1990). Improvement generally occurs only after the first 6 months of treatment. Both psychiatric and other manifestations can improve with WD treatment. Gastroenterological, neurological, or other consultation is advisable, depending on disease manifestations. WD treatments include copper chelating agents that increase urinary copper excretion (e.g., penicillamine and trientine) and copper depleting agents (zinc and thiomolybdate). Specific indications for the various drugs are controversial (e.g., LeWitt 1999). Some experts recommend using penicillamine and switching to trientine followed by dimercaprol in the event of side effects or lack of efficacy. Brewer (1995a) has outlined indications for the use of these agents. A combination of trientine and zinc is advised for patients with mild liver failure. Zinc is recommended for maintenance therapy, presymptomatic treatment, and treatment during pregnancy. Tetrathiomolybdate may be the treatment of choice for neurological disease because it infrequently causes neurological exacerbations (Brewer and Yuzbasiyan-Gurkan 1992). Zinc monotherapy is suboptimal for the initial treatment of neurological WD, because improvement occurs too slowly.
114
Psychiatric Management in Neurological Disease
Recent reports suggest the utility of plasma exchange and peritoneal dialysis in fulminant WD and hemolytic anemia, but these are rarely necessary and may foster neurological exacerbations. Penicillamine. Walshe introduced D-penicillamine (Cuprimine, Depen) in 1956, and for many years it remained the drug of first choice for the treatment of WD. Because of its many side effects, the drug is gradually titrated upward to 8.3 mg/kg tid (250 mg qid to 500 mg tid in adults) over several weeks. It is given at least 30 minutes before meals and no sooner than 2 hours after meals. Pyridoxine 25 mg/day is coadministered to prevent penicillamine-induced deficiency. Copper–penicillamine complexes are excreted in the urine, resulting in an initially large cupruresis of several milligrams per day that declines to 0.5 mg/day after several months (Brewer and Yuzbasiyan-Gurkan 1992). Baseline complete blood counts and renal function tests should be obtained before commencing treatment, because both WD and penicillamine can produce leukopenia and thrombocytopenia. If either of these conditions is present, the initial dose should be smaller and more gradually titrated. The majority of WD patients treated with penicillamine make an excellent recovery in hepatic, neurological, and psychiatric function and can return to gainful employment (Walshe 1986a). Of 137 WD patients undergoing chelation in one study, 57 (42%) became asymptomatic, another 36 (26%) experienced significant neurological improvement, and only 24 (18%) failed to recover function (Walshe and Yealland 1993). Penicillamine treatment leads to regression of copper depositions in the brain seen on T2-weighted MRI imaging and improvement in D2 dopamine receptor binding (Schwarz et al. 1994). Improved motor function after penicillamine therapy correlates with increased cerebral glucose metabolism and dopamine receptor binding (Schlaug et al. 1994). Adverse side effects occur in 10%–30% of patients, and 10% of patients are unable to tolerate long-term penicillamine therapy (Saito et al. 1991). Major side effects are summarized in Table 4–7. Gastrointestinal upset is common. Switching to zinc (Barbosa et al. 1992), dimercaprol, or trientine (Castellano et al. 1992) has been useful in the event of D-penicillamine–induced renal exacerbations. The two most important side effects of penicillamine therapy are
Wilson’s Disease
Table 4–7.
115
Side effects of penicillamine
Gastrointestinal conditions Anorexia Nausea Vomiting Pyridoxine deficiency Lysyl oxidase inhibition Dermatological conditions Collagen-elastin damage Cutis laxa Dermal atrophy, wrinkling, and bleeding Elastosis performans serpiginosa Aphthous stomatitis Gingival hyperplasia Conjunctival inflammation Follicular conjunctivitis Penicillamine dermatopathy Pemphigus Lichen planus Pseudoxanthoma elasticum Abnormal collagen development Abnormal wound healing Pleural effusion Fever Lymphadenopathy Rash
Immunologically induced conditions Goodpasture’s syndrome Systemic lupus erythematosus Rash Immune complex nephritis Fatality Polyarthritis Myasthenia gravis Optic neuritis Nephrotic syndrome Proteinuria Hypersensitivity Urticaria Urticaria with hematuria Immunoglobulin A (IgA) deficiency Endocrinological conditions Hirsutism Mastodynia Hematological conditions Pancytopenia Bone marrow depression Aplastic anemia Retinal hemorrhages Acute polyarthritis
Source. Brewer and Yuzbasiyan-Gurkan 1992; Hoogenraad 1996; Karkos 1996; Katz 1967; Walshe 1986a.
hypersensitivities (in 30% of patients) and neurological exacerbations (Brewer and Yuzbasiyan-Gurkan 1992). Both can lead to death. Among immune reactions, urticaria is the most common, and only immune nephritis responds to drug withdrawal. Therefore, brief courses of an antihistamine or prednisolone are sometimes necessary before resuming a lower dose of penicillamine, with more gradual dose titration (Walshe 1986a).
116
Psychiatric Management in Neurological Disease
Even with gradual titration, a serious concern with this drug is initial exacerbation of neurological symptoms in up to 21% of WD patients (Walshe and Yealland 1993) and in about 50% of patients with neurological WD (Brewer and Yuzbasiyan-Gurkan 1992). Neurological exacerbations have included seizures, movement disorders, neuropsychiatric disturbances, and, sometimes, irreversible neurological disability (Brewer et al. 1994c). Neurological exacerbations can occur in patients free of neurological manifestations. Possible psychiatric exacerbations (new onset of psychosis) may also occur (McDonald and Lake 1995). Switching to zinc (Huang and Chu 1996) or continuing treatment with penicillamine (McDonald and Lake 1995) has sometimes led to resolution. In the latter case, the established procedure is to discontinue penicillamine for 1 week and then resume treatment at a lower dose. To monitor penicillamine treatment, some authorities recommend following serial plasma free copper (see “Zinc,” below), maintaining levels below 10 µg/dL and measuring ceruloplasmin levels every 6 weeks for the first year and annually thereafter. Zinc. Indications for zinc include maintenance therapy, initial treatment in presymptomatic patients, and treatment of pregnant patients (Brewer 1995b). Zinc is administered as zinc acetate (50 mg po tid) or zinc sulfate (300 mg po tid) as far between meals as possible (at least 1 hour before or after meals) (Brewer et al. 1990; Hoogenraad 1996). Lower doses are insufficient for effective treatment of WD (Brewer 1995b), and higher doses may be required in some patients. Zinc induces the production of intestinal and hepatic metallothionein (Sturniolo et al. 1999), thereby reducing intestinal absorption of copper and binding circulating copper to a nontoxic pool in the liver (Brewer 1995b; Brewer et al. 1994b). Side effects of zinc include nausea, epigastric pain, occasional vomiting, and the potential for sideroblastic anemia (Walshe 1995). Zinc acetate (Galzin) is better tolerated by the stomach than is zinc sulfate (Brewer et al. 1990). Tolerance to gastrointestinal irritation develops within a few weeks of commencing treatment, and morning nausea can be avoided by giving the first dose of the day between breakfast and lunch. If food must be taken with zinc to reduce irritation, meat is associated with the least reduction in zinc absorp-
Wilson’s Disease
117
tion (Brewer et al. 1990). Hemolysis, dermatitis, mild serum amylase elevation, and reductions in high-density lipoprotein cholesterol have been reported with zinc therapy (Hoogenraad 1996). Although some authorities recommend zinc as the initial treatment in neurological WD (Bona et al. 1993), fatal neurological deterioration can occur (Lang et al. 1993). Improvement in the neurological exam as well as on MRI has been documented with zinc treatment (Heckmann et al. 1994). Neurological exacerbations occurring during zinc therapy have been effectively treated by combining penicillamine with dimercaprol and a zero-copper diet (Walshe and Munro 1995). Zinc’s effect on copper balance takes at least 3 weeks to become evident on laboratory testing. Treatment compliance is critical, because patients who discontinue therapy develop serious medical conditions or can even die within several months (Brewer 1995b). Compliance and copper balance can be monitored by means of the oral 64Cu uptake test, urinary copper and zinc levels, and plasma free copper concentrations. In patients who are compliant with their zinc regimens, the peak blood concentration 1–2 hours after 64Cu ingestion is reduced to an average of 1.2% of the administered dose; in patients who are noncompliant, however, the peak blood concentration increases back up toward 6% of the administered dose (as in untreated WD) and reduces when they again become compliant. The desired values are ≤125 µg/24 hours for urinary copper and ≥2 mg/24 hours for urinary zinc in WD patients taking zinc (Brewer et al. 1990). Plasma free copper should be kept at ≤25 µg/dL. Plasma free copper (i.e., copper not bound to ceruloplasmin) can be determined by measuring plasma copper and ceruloplasmin levels and subtracting 3 µg of copper for each milligram of ceruloplasmin from the total plasma copper value. An increase suggests noncompliance. Percutaneous liver biopsies may reveal increased copper over the first 3 years of zinc treatment, but liver copper levels eventually return to normal with continued treatment (Brewer et al. 1990). Trientine. Trientine (triethylene tetramine dihydrochloride; Syprine) is usually given as 600 mg tid between meals (not sooner than 30 minutes before meals and 2 hours after meals), with reduction in dose to 600 mg/day once evidence of treatment response is seen
118
Psychiatric Management in Neurological Disease
(Brewer and Yuzbasiyan-Gurkan 1992; Walshe 1986a). Trientine reduces gastrointestinal copper absorption and increases urinary copper excretion (Siegemund et al. 1991). Both transient (Saito et al. 1991) and irreversible (Dahlman et al. 1995) neurological exacerbations have occurred with trientine therapy, suggesting that dosages should be titrated upward very gradually. Although side effects are minimal, iron deficiency, sideroblastic anemia, hepatic adenocarcinoma, colitis, and duodenitis have been associated with trientine (Dahlman et al. 1995), and it is expensive (Walshe 1995). Tetrathiomolybdate. Tetrathiomolybdate combines with copper to form a tripartite complex with protein, reducing intestinal copper absorption and inactivating circulating copper (Brewer 1995b). Ammonium tetrathiomolybdate is used as an initial treatment in neurological presentations because it infrequently causes neurological exacerbations and produces more rapid improvement than does zinc (Brewer 1995b). Most patients make good to excellent neurological recovery (Brewer et al. 1996). Tetrathiomolybdate is given both with meals (to prevent absorption) and between meals (to complex plasma copper). The drug is begun at 20 mg tid with meals, with the between-meal dose escalated over 1 week (usually to 20–60 mg tid between meals) until all non– ceruloplasmin-bound plasma free copper is complexed (see “Zinc,” above, for explanation of plasma free copper). After 8 weeks of treatment, maintenance zinc therapy is begun, and tetrathiomolybdate is discontinued 2 weeks later (Brewer 1995b). Alternatively, the drug can be chronically administered at 40 mg bid, although it is no more effective than zinc when given this way and is not considered useful in hepatic WD (Hoogenraad 1996). However, long-term maintenance therapy is useful in patients refractory to other treatments (Walshe 1995). Because tetrathiomolybdate can cause epiphyseal plate destruction, its use is generally contraindicated in children (Walshe 1995); if absolutely necessary, however, the total daily dose is usually ≥2.9 mg/kg (Brewer and Yuzbasiyan- Gurkan 1992). In addition to requiring special synthesis for clinical use in individual patients, tetrathiomolybdate is unstable, requiring storage under argon gas to prevent deterioration (Brewer et al. 1994a). Other
Wilson’s Disease
119
drawbacks include bone marrow suppression and intestinal lesions, which have been reported in a few patients (Harper and Walshe 1986; Hoogenraad 1996). The drug is not yet available in the United States and is currently under U.S. Food and Drug Administration (FDA) review. Other Treatments Dimercaprol. In 1951, Cumings proposed dimercaprol (British anti-Lewisite, or BAL) as the first WD treatment. When used alone, dimercaprol is administered in painful daily intramuscular injections (300 mg in oil) for 20 consecutive days every 4 weeks for up to 4 courses (Hoogenraad 1996). As supplemental therapy, the dosage is 200 mg bid with D-penicillamine 500 mg tid (Walshe and Munro 1995). Although dimercaprol is initially effective, tachyphylaxis usually soon leads to inefficacy, and penicillamine provides a more sustained response (Brewer and Yuzbasiyan-Gurkan 1992; Saito et al. 1991). Other side effects include headache, fever, nausea, vomiting, salivation, and lacrimation; hallucinosis, delirium, coma, and death have also been reported (Walshe 1995). Other drugs. Drugs of yet-unproven value include potassium disulfide, ascorbic acid (vitamin C), and d-alpha-tocopherol (vitamin E). The chelating agent sodium 2,3-dimercaptopropane sulfonate is used in Russia and China (Hoogenraad 1996). Combination strategies. Some investigators recommend commencing treatment with D-penicillamine or trientine and switching to zinc after the first several months (Brewer and YuzbasiyanGurkan 1992). Regardless of the agent used, once therapy is initiated, it should be continued without interruption throughout life (Brewer and Yuzbasiyan-Gurkan 1992; McIntyre 1991). If neurological exacerbation or side effects require a switch from penicillamine, that agent can be stopped and zinc (acetate 40 mg tid or sulfate 200 mg tid) can be started the same day (Hoogenraad 1996). Simultaneous administration of chelators with zinc does not increase effectiveness and is theoretically counterproductive (Brewer et al. 1993), although this combination has sometimes been used in severely ill patients.
120
Psychiatric Management in Neurological Disease
Drinking water and diet. Deionized or distilled water may be helpful in communities with high levels of copper in the drinking water (Brewer and Yuzbasiyan-Gurkan 1992). A “low copper diet” is ineffective in preventing WD and is not usually necessary in patients undergoing decoppering therapy (Scheinberg and Sternlieb 1996). Most patients absorb no more than 1 mg/day of copper, an amount that poses no problem for decoppering therapy. However, some authorities recommend that WD patients limit their consumption of shellfish to no more often than once a week and of liver to no more than half an ounce each month (Brewer and Yuzbasiyan-Gurkan 1992). There is some evidence that a vegetarian diet may be sufficient for adequate maintenance therapy (Hoogenraad 1996). Liver transplantation. When liver disease is irreversible, transplantation should be considered. Acute hepatic failure, complications of cirrhosis, and a factor V reduction of greater than 25% are considered indications for transplantation (Cuthbert 1995; Hoogenraad 1996; Khanna et al. 1999; Walshe 1995). Graft survival rate in WD exceeds 73%, and patient survival rate exceeds 80%. Survival is better with chronic advanced liver disease (90%) than with fulminant hepatic failure (73% survival rate) (Bellary et al. 1995). Liver transplantation provides a phenotypic cure, sometimes reversing brain abnormalities (Bax et al. 1998; Bellary et al. 1995). Neurological improvement may be evident as early as 4–6 weeks after transplantation (Schumacher et al. 1997). Psychiatric improvement following liver transplantation has not been systematically studied. Specific Patient Populations Patients with liver disease. Penicillamine or trientine is recommended in hepatic WD, sometimes in combination with each other or with zinc (Brewer 1995b; Schilsky 1996). Patients with portal hypertension should not be switched from penicillamine to zinc (Hoogenraad 1996). Of course, management of ascites, edema, coagulopathy, and other complications of liver disease is necessary. Secondary manifestations of hepatic disease can reverse with WD treatment (Schilsky et al. 1991; Santos Silva et al. 1996). Plasmapheresis (Milovanovic et al. 1998) and peritoneal dialysis (Kuno et al. 1998) have been employed to treat acute hepatic complications in WD.
Wilson’s Disease
121
Neurological patients. Tetrathiomolybdate produces good to excellent recovery, usually without any functional deterioration in neurological or psychiatric WD, and it is preferred by some authorities (Brewer 1995b; Brewer et al. 1994a). Although zinc may act too slowly to be given as the sole treatment to the neurological patient (Brewer and Yuzbasiyan-Gurkan 1992), it may be useful during exacerbations (Barbosa et al. 1992). Among 137 neurological WD patients treated with chelators, 57 (42%) became symptom free, 36 (26%) improved substantially, 24 (17%) were disabled, and 20 (15%) died; across groups, 30 (22%) suffered initial neurological exacerbations (Walshe and Yealland 1993). Psychiatric patients. Although research is needed, psychiatric WD should probably be treated in the same manner as neurological WD. In a study of WD patients with psychiatric initial presentations treated with thiomolybdate, exacerbations did not occur and most made a good recovery over a 1-year treatment course (Brewer 1995b). Incongruous behavior and cognitive impairment improve more than do irritability and depression with WD treatment (Dening and Berrios 1990). Psychiatric symptoms may resolve more often in patients lacking dysarthria, incongruous behavior, and hepatic symptoms. Other features resolving with WD treatment have included amnestic disorder, dementia, hypersexuality, aggression, hyperactivity, and disinhibition. In evaluating treatment responses, clinicians should remember that patients experience “good” days and “bad” days (as a function of stress, fatigue, etc.) in terms of neuropsychiatric symptom severity. Pregnant patients. A review of contraceptive options and their effects on hepatic function is provided elsewhere (Haimov-Kochman et al. 1997). Lack of WD treatment can lead to amenorrhea and infertility in female patients and can result in miscarriage in pregnant patients (Schagen van Leeuwen et al. 1991). WD is one disease in which the pregnant patient should be treated. Successful pregnancies have been documented in patients receiving D-penicillamine (Berghella et al. 1997), zinc acetate, and trientine (Walshe 1986b). Zinc is preferred, because penicillamine is associated with teratogenic birth defects, including cutis laxa, micrognathia, low-set ears, inguinal hernias, hy-
122
Psychiatric Management in Neurological Disease
drocephalus, and cerebral palsy. Assuming that the mother received adequate decoppering prior to conception, the dose can be reduced to 25 mg tid during pregnancy and re-increased to 50 mg tid after lactation (Brewer 1995b; Brewer and Yuzbasiyan-Gurkan 1992). Zinc may actually protect against some forms of birth defects (Nunns et al. 1995). Trientine is also considered useful in pregnancy. Obviously, consultation with an obstetrician is indicated, especially in the presence of severe liver disease. Presymptomatic patients. Zinc is recommended for initial treatment in presymptomatic patients, starting with half the usual dose (in children, one-quarter of the usual adult dose) and adjusting the dose according to plasma copper levels (Hoogenraad 1996). Penicillamine can induce neurological symptoms and other side effects and is not recommended (Hoogenraad 1996). Monitoring Disease Progression and Treatment Efficacy Clinical methods of following WD include videotaped quantitative neurological exam, audiotaped speech examination, T2 MRI (Schwarz et al. 1994; Thuomas et al. 1993), photographed KF rings, and liver function tests (Brewer et al. 1990). Auditory and somatosensory evoked potentials detect treatment-related neurological improvement but may not correlate with psychiatric improvement (references cited in Lauterbach et al. 1998). Glucose metabolism and dopamine receptor binding have correlated with improved motor function (Schlaug et al. 1994), but metabolic improvements may precede clinical improvements (Cordato et al. 1998). A reduction in KF rings may occur within several years after commencing treatment. Monitoring a reduction in positive copper balance can be useful, and a negative copper balance can signify deterioration (Hoogenraad 1996). Plasma free copper concentration can be monitored, maintaining the level at 10 µg/dL (for other measures, see “Zinc” under “Treatment of Underlying Disease” subsection earlier in chapter). Measurement of urinary copper is not useful in patients treated with chelating agents, because urinary copper is complexed with the chelator. Serial liver biopsies have been used to follow WD, but their results can be quite variable (Faa et al. 1995).
Wilson’s Disease
123
Family Considerations and Genetic Testing When WD is detected, siblings should also be screened, because one in four will have presymptomatic WD (Brewer 1995b). The risk of WD is approximately 1 in 200 in the patient’s children, 1 in 800 in cousins, and 1 in 600 in nieces and nephews (Bachmann et al. 1991). Presymptomatic molecular genetic diagnosis is useful in studying siblings (Maier-Dobersberger et al. 1995). For example, the 5-year-old sister of a WD patient was asymptomatic and had normal ceruloplasmin, serum copper, and 24-hour urinary copper excretion. Nevertheless, restriction fragment length polymorphisms and polymerase chain reaction–based analysis with microsatellite markers disclosed her to be homozygous for disease-associated markers. A liver biopsy revealed a 20-fold increased liver copper content, confirming WD and allowing diagnosis before irreparable liver damage occurred. Genetic polymorphic satellite markers identified a heterozygous asymptomatic patient who had previously been assumed to be homozygous, allowing discontinuation of lifetime treatment with penicillamine (Vidaud et al. 1996). Unfortunately, the applicability of DNA analysis is limited to siblings of patients with established diagnoses of WD. Genetic diagnosis in the absence of a relative affected with WD is unlikely, because there are so many different mutations that can cause the illness.
Treatment of Psychiatric Manifestations Psychotropic Treatment Controlled studies of psychotropic treatment in psychiatric WD have not been reported (Rummans et al. 1999). Thus, the usual pharmacological armamentarium would seem to apply in WD, with the added consideration of potential copper deposition in the brain, liver, kidney, heart, and bone marrow (see Chapter 1 in this volume for a discussion of management principles in the context of specific organ system disease). Basal ganglia cuprification may lead to a heightened susceptibility to dystonia brought on by neuroleptics or selective serotonin reuptake inhibitors (SSRIs). Neuroleptic malignant syndrome and parkinsonism are more likely in WD patients, and atypical antipsychotics may be safer in this regard. Psycho-
124
Psychiatric Management in Neurological Disease
tropics that lower the seizure threshold may increase the likelihood of seizures in WD, especially in patients receiving WD treatment (Dening et al. 1988). Patients on anticonvulsants are at risk for the many drug interactions that can occur between these agents and psychotropics (Stoudemire and Fogel 1987; Stoudemire et al. 1995). Liver disease may affect the metabolism of psychotropics and prolong the functional half-life of the drug, leading to dose accumulation and toxic blood levels. Use of shorter-half-life drugs, lower doses, and drugs that are minimally metabolized before elimination may circumvent this problem. There is some evidence that the benzodiazepine antagonist flumazenil may have utility in treating the delirium of hepatic encephalopathy (Bostwick and Masterson 1998). Renal dysfunction in WD may lead to elevated lithium concentrations. Cardiac copper deposition can affect conduction pathways, leading to dysrhythmias, including tachycardia or bradycardia, with reduced cardiac efficiency (Hilz et al. 1990). Electrocardiogram abnormalities occur in about 30% of patients with WD, and orthostatic hypotension and sudden death have been reported. Therefore, use of psychotropics with low dysrhythmogenic and hypotensive potentials will be critical in some cases (Stoudemire and Fogel 1987; Stoudemire et al. 1995) (see “Heart disease” under “General Pharmacological Concerns” subsection in Chapter 1). Bone marrow suppression can occur with certain psychotropics as well as in WD. Attention must also be given to the effects of psychotropics on nonpsychotropic drugs that the medically ill patient is taking. For example, SSRIs can inhibit the metabolism of many drugs, leading to toxic elevations of plasma levels, which then can act upon already-diseased organs such as the heart or brain. Identifying targets of treatment. Absent specific empirical data regarding psychotropic use in psychiatric WD, several considerations germane to subcortical disease are of potential importance. These include the potential for delayed evolution, forme fruste presentations, compound syndromes, differential responsivity, and atypical responsivity of psychiatric disorders. Both neurological and psychiatric manifestations of a subcortical lesion can develop after a delay of months or years (Lauterbach et al. 1994, 1997a), and greater scrutiny of patients is therefore needed over a longer follow-up period than
Wilson’s Disease
125
usual. Psychiatric forme fruste syndromes (limited-symptom presentations) can develop after subcortical lesions (Lauterbach et al. 1997b), requiring thorough evaluation for detection. Compound forms of illness may also exist, such as several different types of depression simultaneously coexisting after thalamic lesions. Moreover, different simultaneously coexisting depressions may selectively respond to different serotonergic and noradrenergic antidepressants (Lauterbach et al. 1994). Thus, the clinician should be alert to compound syndromes with differential or atypical responses. In addition, certain psychotropics may be ineffective in certain lesions, necessitating alternative treatment approaches. For example, lithium may be useful in cases of neuroleptic-refractory psychosis in basal ganglia disease (Munir 1986). A novel and creative pharmacological approach may therefore be necessary. Treatment should commence with lower doses, and doses should be titrated upward more gradually than in disease-free patients. It should be borne in mind that no controlled trials regarding psychotropic treatment of psychiatric manifestations of WD have been carried out. Antipsychotics. Because of the danger of severe extrapyramidal syndromes with neuroleptic use in WD (Hoogenraad 1996), quetiapine, clozapine, olanzapine, or risperidone might be preferable. Furthermore, these 5-HT2A receptor antagonists, which may act in part at the cortex, may be useful when subcortical dopaminergic systems are unresponsive. Moreover, clozapine can attenuate parkinsonian and dystonic features, although bone marrow suppression, seizure risk, and exacerbation of impaired liver function should be considered. In light of the paucity of data for these agents and mixed findings in Parkinson’s disease, however, patients treated with these agents deserve intensive monitoring (see Chapter 1 in this volume). Vigilance for cognitive impairment, cardiac dysrhythmia, and hypotension is necessary with the more anticholinergic agents (e.g., lowpotency neuroleptics, clozapine). Chlorpromazine has multiple metabolites, some with very long half-lives. These may accumulate in the context of hepatic failure. High-potency neuroleptics can either exacerbate or improve the various types of dystonia (see Chapter 6 in this volume), but there are no good predictors of effect. In one case report, neuroleptic malignant syndrome in WD responded to dan-
126
Psychiatric Management in Neurological Disease
trolene and bromocriptine (Kontaxakis et al. 1988). Given the potentially lethal impact of antipsychotic treatment in WD, a thorough discussion of benefits, risks, and side effects should be undertaken as part of informed consent, as with any drug treatment in WD. Mood stabilizers. For mania, disinhibited behavior, aggression, neuroleptic-refractory psychosis, and irritability, lithium may be of value if there is no renal impairment, seizure proclivity, or exacerbation of a tremor or a gait disorder. Anticonvulsants and benzodiazepines may be useful if gait, cognitive, liver, and bone marrow status do not contraindicate. Patients with the psychiatric manifestations of mania, disinhibited behavior, or irritability coupled with dystonia may benefit from lithium or anticonvulsants (see Chapter 6 in this volume). Similarly, WD patients with tremor and aggression may benefit from propranolol if cardiovascular status does not contraindicate. Of course, patients should be screened for the usual contraindications to beta-blockers before enlisting these agents in the treatment regimen. Antidepressants. SSRIs (see below) and antidepressants may be of value for mood disorders, obsessive-compulsive disorder, and panic disorder. Because of the possibility of unmasking subclinical cognitive impairment, sedating and strongly anticholinergic tricyclic antidepressants should be reserved for later trials. The same caveats listed for low-potency neuroleptics should be regarded for tricyclics, particularly those with tertiary amine structures. Amoxapine should be used cautiously, because it metabolizes to loxapine and can provoke extrapyramidal reactions (dystonia, parkinsonism, neuroleptic malignant syndrome). Bupropion may prove useful in dysautonomia or sexual dysfunction, but the risk of seizures should be considered. Buspirone and selective serotonin reuptake inhibitors. Patients with impulse control disorders, aggression, irritability, anxiety, or substance abuse may also benefit from serotonergic agents such as SSRIs or buspirone. However, these agents occasionally worsen akathisia, parkinsonism, dystonia, and other movement disorders such as myoclonus (see Chapters 1 and 6 in this volume). Cyto-
Wilson’s Disease
127
chrome P450 drug interactions are another consideration in SSRI administration (see Chapter 1). Benzodiazepines. Benzodiazepines that have short half-lives (e.g., oxazepam, triazolam) or that are glucuronidated but not oxidized (e.g., lorazepam) may be of value in patients with liver disease. The possibility of precipitating or worsening cognitive impairment, disinhibition, reaction-time delays, ataxia, or substance abuse should be considered when using benzodiazepines. Nevertheless, benzodiazepines may have utility in treating catatonia (Davis and Borde 1993), anxiety, aggression, mania, postural tremor, and dystonia in selected patients. The long half-life of clonazepam, which can result in toxic dose accumulation, calls for frequent blood-level monitoring, especially in the presence of hepatic disease. Electroconvulsive Therapy Although experience is limited, electroconvulsive therapy (ECT) can be risky in WD. Negro Junior and Lousa Neto (1995) described a case in which a 46-year-old man with WD and major depression with mood-incongruent psychotic symptoms was treated with ECT after 2 years of treatment with penicillamine. He also exhibited disorganized behavior, disorientation, negativism, loose associations, persecutory and control delusions, and evidence of dementia. CT showed cortical atrophy but no enlargement of the lateral ventricles, and the EEG was normal. The patient was given one bilateral briefpulse ECT (12.4 J of charge), leading to a 3-minute motor seizure. He switched to mania the next day. When the depression recurred several days later, the patient was successfully treated with imipramine 150 mg/day and haloperidol 10 mg/day. The authors of the case report caution that ECT should be used with care, especially in untreated WD patients, who may have higher brain copper levels. They suggest that such patients may be more sensitive to ECT. The protracted 3-minute seizure in this case is consistent with the increased risk of seizures in this disease.
Summary Clinicians must remain vigilant for signs of hepatic and neurological disease. If WD is suspected, appropriate laboratory investigation and
128
Psychiatric Management in Neurological Disease
consultation should be obtained. If WD is diagnosed, siblings and family members of patients should be evaluated for WD. Early recognition and treatment is crucial for optimal outcome. WD is an illness presenting a panoply of psychiatric conditions that can be treated with a variety of modalities, including interventions targeting both the underlying neurological disease and the psychiatric manifestations of the disease. In the patient with WD, the clinician is confronted with an intriguing array of psychiatric manifestations with the potential for novel presentations, illness courses, and treatments. The co-occurrence of neurological and other WD manifestations can challenge the clinician’s pharmacological and therapeutic skills. Certain psychiatric conditions in WD may improve with decoppering treatments. WD can be a devastating disease, and improvement after psychiatric intervention is rewarding to both the clinician and the patient.
References Akil M, Brewer GJ: Psychiatric and behavioral abnormalities in Wilson’s disease. Adv Neurol 65:171–178, 1995 Akil M, Schwartz JA, Dutchak D, et al: The psychiatric presentations of Wilson’s disease. J Neuropsychiatry Clin Neurosci 3:377–382, 1991 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Arendt G, Hefter H, Stremmel W, et al: The diagnostic value of multimodality evoked potentials in Wilson’s disease. Electromyogr Clin Neurophysiol 34:137–148, 1994 Bachmann H, Lössner J, Kühn HJ, et al: Diagnostic strategies in Wilson’s disease, in Proceedings of the 5th Symposium on Wilson’s Disease. Edited by Czlonkowska A, Van den Hamer CJA. Delft, Netherlands, University Press, 1991, pp 79–86 Barbosa ER, Burdmann E de A, Cancado ER, et al: Zinc in the treatment of hepatolenticular degeneration: report of 3 cases. Arq Neuropsiquiatr 50:99–103, 1992 Bax RT, Hassler A, Luck W, et al: Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology 51:863–865, 1998
Wilson’s Disease
129
Bellary S, Hassanein T, Van Thiel DH: Liver transplantation for Wilson’s disease. J Hepatol 23:373–381, 1995 Berghella V, Steele D, Spector T, et al: Successful pregnancy in a neurologically impaired woman with Wilson’s disease. Am J Obstet Gynecol 176:712–714, 1997 Bona I, Broussolle E, Neuschwander P, et al: Treatment of Wilson’s disease with zinc: 5 cases. Rev Neurol (Paris) 149:393–397, 1993 Bostwick JM, Masterson BJ: Psychopharmacological treatment of delirium to restore mental capacity. Psychosomatics 39:112–117, 1998 Brewer GJ: Practical recommendations and new therapies for Wilson’s disease. Drugs 50:240–249, 1995a Brewer GJ: Interactions of zinc and molybdenum with copper in therapy of Wilson’s disease. Nutrition 11 (1 suppl):114–116, 1995b Brewer GJ, Yuzbasiyan-Gurkan V: Wilson disease. Medicine (Baltimore) 71:139–164, 1992 Brewer GJ, Yuzbasiyan-Gurkan V, Lee DY: Use of zinc-copper metabolic interactions in the treatment of Wilson’s disease. J Am Coll Nutr 9: 487–491, 1990 Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, et al: Treatment of Wilson’s disease with zinc, XI: interaction with other anticopper agents. J Am Coll Nutr 12:26–30, 1993 Brewer GJ, Dick RD, Johnson V, et al: Treatment of Wilson’s disease with ammonium tetrathiomolybdate, I: initial therapy in 17 neurologically affected patients. Arch Neurol 51:545–554, 1994a Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al: Treatment of Wilson’s disease with zinc, XIII: therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 123:849–858, 1994b Brewer GJ, Turkey A, Yuzbaziyan-Gurkan V: Development of neurologic symptoms in a patient with asymptomatic Wilson’s disease treated with penicillamine. Arch Neurol 51:304–305, 1994c Brewer GJ, Johnson V, Dick RD, et al: Treatment of Wilson disease with ammonium tetrathiomolybdate, II: initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53:1017– 1025, 1996 Buiakova OI, Xu J, Lutsenko S, et al: Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet 8:1665– 1671, 1999 Castellano G, Blasco A, Ballesta F, et al: Wilson’s disease: a retrospective analysis of 12 cases [in Spanish]. Rev Clin Esp 190:223–228, 1992
130
Psychiatric Management in Neurological Disease
Chowrimootoo GF, Andoh J, Seymour CA: Western blot analysis in patients with hypocaeruloplasminaemia. Q J Med 90:197–202, 1997 Chowrimootoo GF, Scowcroft H, Seymour CA: Caeruloplasmin isoforms in Wilson’s disease in neonates. Arch Dis Child Fetal Neonatal Ed 79: F198–F201, 1998 Cordato DJ, Fulham MJ, Yiannikas C: Pretreatment and posttreatment positron emission tomographic scan imaging in a 20-year-old patient with Wilson’s disease. Mov Disord 13:162–166, 1998 Cuthbert JA: Wilson’s disease: a new gene and an animal model for an old disease. J Investig Med 43:323–336, 1995 Dahlman T, Hartvig P, Lofholm M, et al: Long-term treatment of Wilson’s disease with triethylene tetramine dihydrochloride (trientine). Q J Med 88:609–616, 1995 Davis EJ, Borde M: Wilson’s disease and catatonia. Br J Psychiatry 162: 256–259, 1993 Dening TR, Berrios GE: Wilson’s disease: psychiatric symptoms in 195 cases. Arch Gen Psychiatry 46:1126–1134, 1989a Dening TR, Berrios GE: Wilson’s disease: a prospective study of psychopathology in 31 cases. Br J Psychiatry 155:206–213, 1989b Dening TR, Berrios GE: Wilson’s disease: a longitudinal study of psychiatric symptoms. Biol Psychiatry 28:255–265, 1990 Dening TR, Berrios GE, Walshe JM: Wilson’s disease and epilepsy. Brain 111:1139–1155, 1988 Faa G, Nurchi V, Demelia L, et al: Uneven hepatic copper distribution in Wilson’s disease. J Hepatol 22:303–308, 1995 Forbes JR, Cox DW: Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet 63:1663–1674, 1998 Gaffney D, Walker JL, O’Donnell JG, et al: DNA-based presymptomatic diagnosis of Wilson disease. J Inherit Metab Dis 15:161–170, 1992 Haimov-Kochman R, Ackerman Z, Anteby EY: The contraceptive choice for a Wilson’s disease patient with chronic liver disease. Contraception 56:241–244, 1997 Harper PL, Walshe JM: Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 64:851–853, 1986 Hawkins RA, Mazziotta JC, Phelps ME: Wilson’s disease studied with FDG and positron emission tomography. Neurology 37:1707–1711, 1987 Heckmann JM, Eastman RW, De Villiers JC, et al: Wilson’s disease: neurological and magnetic resonance imaging improvement on zinc treatment (letter). J Neurol Neurosurg Psychiatry 57:1273–1274, 1994
Wilson’s Disease
131
Hilz MJ, Druschky KF, Bauer J, et al: Wilson’s disease—critical deterioration under high-dose parenteral penicillamine therapy [in German]. Dtsch Med Wochenschr 115:93–97, 1990 Hoogenraad TU: Wilson’s Disease. London, WB Saunders, 1996 Hoogenraad TU, Houwen RHJ: Prevalence and genetics, in Wilson’s Disease. Edited by Hoogenraad TU. London, WB Saunders, 1996, pp 14–24 Hoogenraad TU, Van den Hamer CJA: Copper metabolism, copper toxicity and pathogenesis of Wilson’s disease, in Wilson’s Disease. Edited by Hoogenraad TU. London, WB Saunders, 1996, pp 25–44 Houwen RH, Juyn J, Hoogenraad TU, et al: H714Q mutation in Wilson disease is associated with late, neurological presentation. J Med Genet 32: 480–482, 1995 Huang CC, Chu NS: Wilson’s disease: resolution of MRI lesions following long-term oral zinc therapy. Acta Neurol Scand 93:215–218, 1996 Karkos C, Moore A, Manche A, et al: Pleural effusion associated with D-penicillamine therapy: a case report. J Clin Pharm Ther 21:15–17, 1996 Katz R: Penicillamine-induced skin lesions: a possible example of human lathyrism. Arch Dermatol 95:196–198, 1967 Khanna A, Jain A, Eghtesad B, et al: Liver transplantation for metabolic liver diseases. Surg Clin North Am 79:153–162, 1999 King AD, Walshe JM, Kendall BE, et al: Cranial MR imaging in Wilson’s disease. AJR Am J Roentgenol 167:1579–1584, 1996 Knehr CA, Bearn AG: Psychological impairment in Wilson’s disease. J Nerv Ment Dis 124:251–255, 1956 Kojimahara N, Nakabayashi H, Shikata T, et al: Defective copper binding to apo-ceruloplasmin in a rat model and patients with Wilson’s disease. Liver 15:135–142, 1995 Kontaxakis V, Stefanis C, Markidis M, et al: Neuroleptic malignant syndrome in a patient with Wilson’s disease (letter). J Neurol Neurosurg Psychiatry 51:1001–1002, 1988 Kumar A, Riely CA: Inherited liver diseases in adults. West J Med 163: 382–386, 1995 Kuno T, Hitomi T, Zaitu M, et al: Severely decompensated abdominal Wilson disease treated with peritoneal dialysis: a case report. Acta Paediatr Jpn 40:85–87, 1998 Kuwert T, Hefter H, Scholz D, et al: Regional cerebral glucose consumption measured by positron emission tomography in patients with Wilson’s disease. Eur J Nucl Med 19:96–101, 1992 Lang C, Muller D, Claus D, et al: Neuropsychological findings in treated Wilson’s disease. Acta Neurol Scand 81:75–81, 1990
132
Psychiatric Management in Neurological Disease
Lang CJ, Rabas-Kolominsky P, Engelhardt A, et al: Fatal deterioration of Wilson’s disease after institution of oral zinc therapy. Arch Neurol 50:1007–1008, 1993 Lauterbach EC, Price ST, Spears TE, et al: Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm. Biol Psychiatry 35:488–490, 1994 Lauterbach EC, Jackson JG, Wilson AN, et al: Major depression after left posterior globus pallidus lesions. Neuropsychiatry Neuropsychol Behav Neurol 10:9–16, 1997a Lauterbach EC, Jackson JG, Price ST, et al: Clinical, motor, and biological correlates of depressive disorders after focal subcortical lesions. J Neuropsychiatry Clin Neurosci 9:259–266, 1997b Lauterbach EC, Cummings JL, Duffy J, et al: Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. J Neuropsychiatry Clin Neurosci 10:249–266, 1998 LeWitt PA: Penicillamine as a controversial treatment for Wilson’s disease. Mov Disord 14:555–556, 1999 Lhermitte J, Muncie WS: Hepatolenticular degeneration: a report of three unusual cases. Arch Neurol Psychiatry 23:750–760, 1980 Lindahl JA, Sharp HL: Screening asymptomatic family members for Wilson’s disease. Minn Med 65:473–475, 1982 Littman E, Medalia A, Senior G, et al: Rate of information processing in patients with Wilson’s disease. J Neuropsychiatry Clin Neurosci 7:68–71, 1995 Loiseau P, Demangeat M: Syndrome Wilsonien atypique avec troubles mentaux d’allure schizophrenique: remission spectaculaire des troubles mentaux au stade pre-agonique. Ann Med Psychol (Paris) 114: 413–420, 1956 Lyon TD, Fell GS, Gaffney D, et al: Use of a stable copper isotope (65Cu) in the differential diagnosis of Wilson’s disease. Clin Sci (Colch) 88: 727–732, 1995 Maier-Dobersberger T, Mannhalter C, Rack S, et al: Diagnosis of Wilson’s disease in an asymptomatic sibling by DNA linkage analysis. Gastroenterology 109:2015–2018, 1995 Mansouri A, Gaou I, Fromenty B, et al: Premature oxidative aging of hepatic mitochondrial DNA in Wilson’s disease. Gastroenterology 113:599– 605, 1997
Wilson’s Disease
133
Martin WRW, Snow B, Ashforth R: Abnormalities of movement and posture due to disease of the extrapyramidal motor systems, in Neuroimaging: A Companion to Adams and Victor’s Principles of Neurology. Edited by Greenberg JO. New York, McGraw-Hill, 1995, pp 5–24 McDonald LV, Lake CR: Psychosis in an adolescent patient with Wilson’s disease: effects of chelation therapy. Psychosom Med 57:202–204, 1995 McIntyre N: Wilson’s disease. Kayser and Fleischer’s sign and Walshe’s treatment. Br J Clin Pract 45:135–140, 1991 Medalia A, Isaacs-Glaberman K, Scheinberg IH: Neuropsychological impairment in Wilson’s disease. Arch Neurol 45:502–504, 1988 Merli M, Patriarca M, Loudianos G, et al: Use of the stable isotope 65Cu test for the screening of Wilson’s disease in a family with two affected members. Ital J Gastroenterol Hepatol 30:270–275, 1998 Milovanovic DD, Tomasevic R, Bogdanovic G: Treatment of chronic Wilson’s disease in 2 patients using plasmapheresis: clinico-biochemical observations [in Serbo-Croatian (Cyrillic)]. Srp Arh Celok Lek 126(9–10):327–334, 1998 Munir KM: The treatment of psychotic symptoms in Fahr’s disease with lithium carbonate. J Clin Psychopharmacol 6:36–38, 1986 Nanji MS, Nguyen VT, Kawasoe JH, et al: Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 60:1423– 1429, 1997 Negro Junior PJ, Louza Neto MR: Results of ECT for a case of depression in Wilson’s disease (letter). J Neuropsychiatry Clin Neurosci 7:384, 1995 Nunns D, Hawthorne B, Goulding P, et al: Wilson’s disease in pregnancy. Eur J Obstet Gynecol Reprod Biol 62:141–143, 1995 Oder W, Grimm G, Kollegger H, et al: Neurological and neuropsychiatric spectrum of Wilson’s disease: a prospective study of 45 cases. J Neurol 238:281–287, 1991 Oder W, Prayer L, Grimm G, et al: Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 43:120–124, 1993 Oder W, Brucke T, Kolleger H, et al: Dopamine D2 receptor binding is reduced in Wilson’s disease: correlation of neurological deficits with striatal 123I–iodobenzamide binding. J Neural Transm 103:1093–1103, 1996 Rathbun JK: Neuropsychological aspects of Wilson’s disease. Int J Neurosci 85:221–229, 1996 Roach ES, Ford CS, Spudis EV, et al: Wilson’s disease: evoked potentials and computed tomography. J Neurol 232:20–23, 1985
134
Psychiatric Management in Neurological Disease
Roberts EA, Cox DW: Wilson disease. Baillieres Clin Gastroenterol 12: 237–256, 1998 Rummans TA, Lauterbach EC, Coffey CE, et al: Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 11:176–189, 1999 Saatci I, Topcu M, Baltaoglu FF, et al: Cranial MR findings in Wilson’s disease. Acta Radiol 38:250–258, 1997 Saito H, Watanabe K, Sahara M, et al: Triethylene–tetramine (trien) therapy for Wilson’s disease. Tohoku J Exp Med 164:29–35, 1991 Santos Silva EE, Sarles J, Buts JP, et al: Successful medical treatment of severely decompensated Wilson disease. J Pediatr 128:285–287, 1996 Schaefer M, Hopkins RG, Failla ML, et al: Hepatocyte-specific localization and copper-dependent trafficking of the Wilson’s disease protein in the liver. Am J Physiol 276(3 pt 1):G639–G646, 1999 Schagen van Leeuwen JH, Christiaens GC, et al: Recurrent abortion and the diagnosis of Wilson disease. Obstet Gynecol 78:547–549, 1991 Scheinberg IH, Sternlieb I: Wilson’s disease, in Major Problems in Internal Medicine, Vol 23. Edited by Smith LH Jr. Philadelphia, PA, WB Saunders, 1984 Scheinberg IH, Sternlieb I: Wilson disease and idiopathic copper toxicosis. Am J Clin Nutr 63:842S–845S, 1996 Schilsky ML: Wilson disease: genetic basis of copper toxicity and natural history. Semin Liver Dis 16:83–95, 1996 Schilsky ML, Scheinberg IH, Sternlieb I: Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 100:762–767, 1991 Schlaug G, Hefter H, Nebeling B, et al: Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine therapy in Wilson’s disease. J Neurol 241:577–584, 1994 Schlaug G, Hefter H, Engelbrecht V, et al: Neurological impairment and recovery in Wilson’s disease: evidence from PET and MRI. J Neurol Sci 136:129–139, 1996 Schumacher G, Platz KP, Mueller AR, et al: Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson’s disease. Clin Transplant 11:217–224, 1997 Schwartz M, Fuchs S, Polak H, et al: Psychiatric manifestation in Wilson’s disease [in Hebrew]. Harefuah 124:75–77, 1993 Schwarz J, Antonini A, Kraft E, et al: Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson’s disease. Neurology 44:1079–1082, 1994
Wilson’s Disease
135
Sharonova IN, Vorobjev VS, Haas HL: High-affinity copper block of GABA(A) receptor-mediated currents in acutely isolated cerebellar Purkinje cells of the rat. Eur J Neurosci 10:522–528, 1998 Siegemund R, Lossner J, Gunther K, et al: Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson’s disease. Acta Neurol Scand 83:364–366, 1991 Slater E, Cowie V: The Genetics of Mental Disorders. London, Oxford University Press, 1971 Steindl P, Ferenci P, Dienes HP, et al: Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 113: 212–218, 1997 Stoudemire A, Fogel BS: Psychopharmacology in the medically ill, in Principles of Medical Psychiatry. Edited by Stoudemire A, Fogel BS. Orlando, FL, Grune & Stratton, 1987, pp 79–112 Stoudemire A, Moran MG, Fogel BS: Psychopharmacology in the medically ill patient, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 783–801 Sturniolo GC, Mestriner C, Irato P, et al: Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson’s disease patients. Am J Gastroenterol 94:334–338, 1999 Tarter RE, Switala J, Carra J, et al: Neuropsychological impairment associated with hepatolenticular degeneration (Wilson’s disease) in the absence of overt encephalopathy. Int J Neurosci 37:67–71, 1987 Terada K, Schilsky ML, Miura N, et al: ATP7B (WND) protein. Int J Biochem Cell Biol 30:1063–1067, 1998 Thuomas KA, Aquilonius SM, Bergstrom K, et al: Magnetic resonance imaging of the brain in Wilson’s disease. Neuroradiology 35:134–141, 1993 van Wassenaer–van Hall HN, van den Heuvel AG, Algra A, et al: Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 198:531–536, 1996 Vidaud D, Assouline B, Lecoz P, et al: Misdiagnosis revealed by genetic linkage analysis in a family with Wilson disease. Neurology 46:1485–1486, 1996 Walshe JM: Wilson’s disease, in Handbook of Clinical Neurology, Vol 5 (49): Extrapyramidal Disorders. Edited by Vinken PJ, Bruyn GW, Klawans HL. Amsterdam, Elsevier Science BV, 1986a, pp 223–238 Walshe JM: The management of pregnancy in Wilson’s disease treated with trientine. Q J Med 58:81–87, 1986b
136
Psychiatric Management in Neurological Disease
Walshe JM: Copper: not too little, not too much, but just right. Based on the triennial Pewterers Lecture delivered at the National Hospital for Neurology, London, on 23 March 1995. J R Coll Physicians Lond 19:280–288, 1995 Walshe JM, Munro NA: Zinc-induced deterioration in Wilson’s disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet (letter). Arch Neurol 52:10–11, 1995 Walshe JM, Yealland M: Wilson’s disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 55:692–696, 1992 Walshe JM, Yealland M: Chelation treatment of neurological Wilson’s disease. Q J Med 86:197–204, 1993 Wang JK: Cu2+ induces Ca2+-dependent neurotransmitter release from brain catecholaminergic nerve terminals. Eur J Pharmacol 373(2–3): 163–169, 1999 Wilson SAK: Progressive lenticular degeneration, a familial nervous disease associated with cirrhosis of the liver. Brain 34:295–507, 1912 Yanoff M, Fine BS: Ocular Pathology: A Color Atlas. Philadelphia, PA, JB Lippincott, 1988
C H A P T E R
5
Fahr’s Syndrome Edward C. Lauterbach, M.D.
C
alcification of the basal ganglia has been variably referred to as Fahr’s disease, Fahr’s syndrome (FS), striopallidodentate calcification, striatopallidodentate calcification, and calcinosis nucleorum cerebri, among other terms. The course of FS is progressive. In adult FS, calcium deposition generally begins in the third decade of life, with neurological deterioration developing two decades later. FS has also been reported to occur in pediatric populations. The condition has been known since the middle 1800s, and Fahr (1931) actually was not the first to describe the illness. Ostertag (1922), Spatz (1922), and Weimann (1922) had previously published extensive reviews (Lowenthal 1986).
Prevalence A number of studies have determined the frequency of basal ganglia calcification (BGC) on computed tomography (CT) in patients undergoing radiological neuroimaging. Averaging these frequencies yields a BGC rate of 0.93% (274 BGC cases from a combined sample of 29,484 scans) (references cited in Lauterbach et al. 1998). The radiological prevalence of calcification is higher in children (15%) than in adults (Kendall and Cavanagh 1986). As discussed in the following section, the prevalence of FS depends on how the syndrome is defined. To avoid confusion with incidental BGC, it is advisable to require the presence of clinical findings ascribable to the calcification. Viewed from this perspec137
138
Psychiatric Management in Neurological Disease
tive, the prevalence of FS is probably somewhat less than 50 patients per 10,000 population, or 0.5%. In a review of 6,348 subjects’ CT scans, 62 (0.98%) had BGCs, but only 31 (0.49%) actually had FS (Konig 1989). There is some variance in this estimate of FS prevalence, because clinical findings vary widely among CT studies of FS. For example, in a study of 33 patients with calcification, none had clinical signs (Vles et al. 1981). In another study of 72 patients with calcification, extrapyramidal manifestations occurred in 15 (20.8%) and seizures in 13 (18.1%) (Kazis 1985). Psychiatric and neurological findings are inconsistently reported in prevalence studies of BGC ascertained by CT. The prevalences of specific etiological types of FS, including idiopathic Fahr’s disease, remain to be clarified.
Clinical Recognition and Neurological Presentation FS can be distinguished from other brain calcifications (e.g., calcified angiomas, infections, encephalitides, Addison’s disease lesions) by its greater severity and characteristic distribution (see “Neuroimaging” section later in chapter). FS should not be confused with normal calcification of cerebral structures such as the